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Abstract  
 
The work in this thesis reports studies directed to developing a calpain cysteine protease 
inhibitor that could be of value in slowing cataract development in humans. The work 
focuses on the development of macrocyclic compounds which can have advantages over 
acyclic compounds due to their resistance to proteolytic hydrolysis, improved selectivity, 
bioavailability and membrane permeability. A review of X-ray crystal structures of 
natural and synthetic calpain inhibitors complexed with the cysteine protease calpain 
show the inhibitors generally bind in the enzyme active site in an extended β-strand 
conformation.  
  
The calpain inhibitor SJA-6017 has been identified as a suitable lead compound. The 
importance of the para-fluoro group in SJA-6017 has been investigated. Modifications 
have been made to constrain this basic structure within a macrocycle and restrict the 
peptide chain as a β-strand conformation. Macrocycle CAT811 is a potent calpain 1 and 
2 inhibitor and shows promise in slowing the progression of cortical cataract in trials with 
sheep having a hereditary propensity towards the development of cataract.  
  
In this thesis I report studies directed to improve the yield of the key RCM 
macrocyclisation step in the synthesis of aldehyde CAT811 and of three ester analogues 
(2.1, 2.3 and 2.4). 
  
I also report the development of a more commercial route to CAT811 not involving 
RCM but using intramolecular nucleophilic cyclisation.  
  
This intramolecular nucleophilic cyclisation strategy was attempted for the preparation of 
a histidine containing macrocyclic ester (4.1a) but was unsuccessful. An alternate 
strategy involving intramolecular lactamization proved successful for the synthesis of 
histidine-based macrocyclic esters (4.1a-4.3a). Reduction to the corresponding alcohols 
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(4.1b-4.3b) was successful and oxidation of (4.1b and 4.3b) afforded the corresponding 
aldehydes (4.1c and 4.3c) for biological assay against ovine calpain 2.  
 
Aldehyde 4.3c has an IC50 of 1 µM and the corresponding alcohol 4.3b shows no activity 
(IC50 > 50 µM) consistent with the modelling which indicated that these two compounds 
did not adopt a β-strand conformation in the docking studies. Aldehyde 4.1c, on the other 
hand, shows significant inhibitory activity with an IC50 of 238 nM but as expected the 
corresponding alcohol 4.1b shows little activity (IC50 = 29 µM). Modelling studies 
showed that both the aldehyde 4.1c and the alcohol 4.1b on docking can form a β-strand 
with appropriate H-bonding interactions. The aldehyde is more active than the alcohol 
due to the reactivity of the aldehyde warhead allowing for the reversible formation of a 
hemiacetal. A similar difference in reactivity is observed for CAT811 (30 nM) and its 
alcohol analogue (700 nM). 
 
These results demonstrate the value of molecular modelling as a screening mechanism 
before unproductive synthetic work is considered. 
 
Work in this thesis has been published in the following papers: 
 
Abell, A. D.; Alexander, N. A.; Aitken, S. G.; Chen, H.; Coxon, J. M.; Jones, M. A.; 
McNabb, S. B.; Muscroft-Taylor, A. J. Org. Chem., 2009, 74, 4354–4356.  
 
Jones, M. A.; Coxon, J. M.; McNabb, S. B.; Mehrtens, J. M.; Alexander, N. A.; Jones, S.; 
Chen, H.; Buisan, C.; Abell, A. D. Aust. J. Chem., 2009, 62, 671–675. 
 
Zaman, S.; Chen, H.; Abell, A. D. Tetrahedron Lett., 2011, 52, 878–880. 
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 1          Chapter 1: Introduction 
Chapter 1: Introduction 
 
Calpains are Ca2+-dependent cysteine proteases that selectively cleave specific proteins in 
response to calcium signals.1 There are at least fifteen different calpain isoforms that have 
been identified from a variety of organisms and mammals and each isoform is encoded 
by an independent gene (Table 1.1).2 Some of these isoforms are expressed ubiquitously 
(calpains 1, 2, 4, 5, 7, 10, 12 and 13), while others are tissue-specific (calpains 3, 6, 8, 9 
and 11). For example, calpain 3 is a skeletal muscle-specific enzyme3 and calpain 8 is 
stomach-specific.4 Calpain 9 is tissue-specific with an express pattern restricted to the 
digestive track.5 Calpain 12 is highly expressed in mouse hair follicles.6 Calpains 11 and 
13 are mainly detected in testes.7 
 
Calpains are involved in the regulation of many biological processes and their 
physiological functions define important pathological roles in human diseases (Table 1.1). 
For example, deregulation of calpain activity is involved in neurological disorders, such 
as Alzheimer’s, Huntington’s and Parkinson’s diseases and in multiple sclerosis.8,9 An 
increased Ca2+ level in muscles leads to calpain over activation and is associated with 
muscular dystrophy.10 The proteolytic action of calpain 2 on lens crystallin proteins is 
thought to be a cause of cataracts in humans.11 The ageing process or an insult to the eye 
can result in elevated levels of Ca2+ in the lens tissue which leads to calpain over 
activation with associated deregulative proteolysis of soluble crystallins and cataract 
formation. This process is the topic of this thesis. 
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Table 1.1. The calpain family12 
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Two calpains isoforms, calpain 1 (µ-calpain) and calpain 2 (m-calpain), have been 
extensively studied.1 Calpain 1 and 2 each consist of an 80kDa catalytic subunit (the 
large subunit), containing four domains (DI-DIV), and a 28kDa regulatory subunit (the 
small subunit), containing two domains (DV and DVI). Domain I is a short helix. 
Domain II is a ubiquitous catalytic domain in which calpain activity is located. Domain 
III is a C2-like domain that is involved in membrane targeting. Domains IV and VI are 
calcium bonding segments with five EF hand motifs and these two domains are linked 
through the pairing of their fifth- EF hand (Figure 1.1).  
 
 
Figure 1.1: A comparison of calcium-free (left) and calcium-bound (right) calpain 
structures (Ca2+ ions are shown as teal spheres).13 
 
Calpain 1 and calpain 2 require micromolar and millimolar concentrations of calcium 
ions (Ca2+) respectively for in vitro activation. The binding of calcium ions induces a 
change in the relative positions of the domains of calpain, leading to its active 
conformation. The protease core contains two calcium ions, one in each of DI and DII 
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domains, and these are responsible for the cooperative assembly of the catalytic cleft. 
Four calcium ions are bound in both EF-hands of DIV and DVI and result in a shift in the 
EF hands, exposing a hydrophobic site allowing for substrate or inhibitor binding.  
 
1.1: Calpastatin, an endogenous calpain inhibitor 
 
1.1.1: Overview of calpastatin  
 
The activity of calpains 1 and 2 is tightly controlled by the endogenous inhibitor 
calpastatin, which exhibits IC50 values of 0.50-1.57 nM and 0.83-1.34 nM respectively. 
Calpastatin, a 120kDa protein widely distributed in most mammal tissues, comprises four 
inhibitory domains with each domain containing subdomains (A, B and C), and an N-
terminal region L (Figure 1.2).14 All four repeat units have similar inhibitory activity 
against calpains 1 and 2, but domain L is devoid of such activity.  
 
 
 
Figure 1.2. Repeat domain structure of human calpastatin. Regions A (20 residues), B 
(26 residues) and C (20 residues) are highly conserved among the four internally repeated 
domains 1–4. 
 
There are difficulties associated with the co-crystallization of the native calpain in the 
presence of calcium ions because the activated calpain hydrolyzes itself into inactive 
fragments.15 An inactive mutant of calpain 2 (C105S) has been co-crystallized with 
calpastatin’s inhibitory domain IV in the presence of calcium (Figure 1.3). Calpastatin 
domain IV (black) binds as an extended polypeptide over the surface of calpain, making 
contact with each domain of enzyme. The regions A and C of calpastatin domain IV bind 
to the hydrophobic calpain domain DIV and DVI and fold as a α-helix respectively. The 
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B subdomain of calpastatin binds to the calpain domains I and II in an extended 
orientation and blocks the active site of calpain.  
 
 
 
Figure 1.3. Complex between calpastatin domain IV and Ca2+-bound calpain 2.1,13 
 
1.1.2: Calpain-calpastatin interactions proximate to the active site of calpain  
 
Calpain presents a reaction surface to which its substrate peptide binds as defined by 
standard nomenclature developed by Berger and Schechter (Figure 1.4).16 Subsites that 
bind residues on the N terminal side of the substrate (or non-primed sites) are numbered 
as S1 – Sn and those toward the C terminus (primed sites) S1’– Sn’, beginning from the 
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sites on each side of the scissile bond. The corresponding substrate residues are numbered 
P1–Pn and P1’–Pn’ respectively as shown in Figure 1.4.  
 
 
 
Figure 1.4. Schechter and Berger nomenclature for substrate residues bound with the 
active site of protease as reported by Turk. 17  
 
The active site of calpains consists of a catalytic triad of amino acids, namely cysteine, 
histidine and asparagine that directly participate in the hydrolysis of the peptide substrate. 
The nucleophilic thiol (SH) of cysteine (for calpain 2, Cys 105) is positioned to react with 
a substrate to form an intermediate with a low-energy transition state thereby facilitating 
an increase in the rate of hydrolysis. The imidazole side chain of the histidine (for calpain 
2, His262) functions by accepting and donating a proton during the reaction. The 
aspartate side chain (for calpain 2, Asn286) interacts by way of a hydrogen bond to orient 
the histidine appropriately to remove the acidic proton from the thiol group of cysteine 
(see Figure 1.5). This deprotonation is the first step in peptide bond hydrolysis. The next 
step involves nucleophilic attack by the activated cysteine's anionic sulfur on the 
substrate carbonyl carbon to form a thioester intermediate. Donation of a proton by 
histidine to the peptide amide nitrogen forms a protonated amine which facilitates amide 
bond cleavage to release a fragment of the substrate having an amine terminus. 
Deprotonation of a water molecule by the histidine base is followed by nucleophilic 
attack at the carbonyl carbon to generate a tetrahedral intermediate which collapses to a 
carboxylic acid and release of free enzyme.  
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Figure 1.5. The proposed mechanism of action of cysteine protease.18  
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The binding of calpastatin to the active site Cys(Ser)105 of a mutant of calpain 2 disrupts 
this mechanism and is shown in Figure 1.6a. This crystal structure shows the B 
subdomain of the calpastatin binds with calpain domain DI-DIII and thereby obstructs the 
active site.1 The region on the N-terminal side (domain L) of the inhibitor forms 
hydrophobic and electrostatic interactions with residues in a shallow trough in calpain’s 
domain III. By contrast, the region C-terminal to the loop of subdomain B forms a two-
turn amphipathic α- helix that binds to domain I (also see Figure 1.3).  
 
 
 
                              (a)                                                                        (b) 
 
Figure 1.6. a) Central region of subdomain B of calpastatin’s domain IV (black) looping 
around the active site cysteine (serine) of calpain 2. b) Close-up views of calpastatin at 
the active site. 
 
The close-up view of calpastatin binding to the active site of calpain 2 shows that Leu612 
occupies the hydrophobic S2 subsite (Figure 1.6b). A type II β-turn conformation in 
calpastatin twists the P1 Gly613 of calpastatin away from the active site and holds the 
potentially scissile amide bond between P1 Gly613 and P1’ E614 of calpastatin about 2 Å 
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removed from the cysteine thiol, thereby preventing hydrolysis as a result of the looping 
of calpastatin away from the active site cysteine.19 
 
The 27-residue peptide Ac-DPMSSTYIEELGKREVTIPPKYRELLA-NH2, consisting of 
a repeat sequence of domain I of human calpastatin, has been synthesized and tested for 
inhibitory potential.20 This polypeptide is a highly potent and selective inhibitor of 
calpain 1 and 2 in a nanomolar range, but it does not however inhibit either papain or 
trypsin.21  
 
1.2: A survey of other natural and selected synthetic calpain inhibitors  
 
A number of naturally occurring calpain inhibitors have been reported as shown in Figure 
1.7.22 For example Leupeptin (Ac-Leu-Leu-Arg-H) and Strepin P-1 (N-i-valeryl-Tyr-Val-
Arg-H), isolated from Streptomyces species, inactivate calpain by reacting reversibly with 
the active site thiol of the enzyme. The peptidylepoxysuccinate inhibitor E-64, isolated 
from Aspergillus japonicas, acts as a non-selective calpain inhibitor with the epoxide 
reacting with an active site thiolate group to form a covalent bond. Inhibitor SC488, 
isolated from Streptomyces griseus, has an IC50 value of 1.2 µM against calpain.23 
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Figure 1.7. Representative calpain inhibitors derived from natural sources. 
 
These natural calpain inhibitors tend to have undesirable properties; for example a lack of 
selectivity and poor membrane cell permeability, absorption, and metabolic stability. A 
number of synthetic peptide- and nonpeptide-based calpain inhibitors have also been 
reported.24 These inhibitors have the scissile amide bond of a calpain substrate replaced 
with a functional group (warhead) that reacts with the active site thiolate cysteine either 
reversibly or irreversibly. Such inhibitors are classified into three groups according to the 
nature of the warhead. These include epoxysuccinate derivatives, aldehydes, aldehyde 
prodrugs (hemiacetals), and α-keto carbonyl compounds.  
 
While the epoxysuccinate derivative E-64 (Figure 1.8) functions as a cysteine protease 
inhibitor, it has the disadvantage that it is not permeable to cells because the ionizable 
carboxylic acid and guanidinium functional groups prevent it crossing cell membranes. 
The cellular penetration of E-64 has been improved by esterification of its carboxylic 
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acid and replacing the guanidinium group with an alkyl group as in E-64D.25 This 
inhibitor has been shown to provide significant neuroprotection after spinal cord injury in 
rat.26 The ester group in E-64D undergoes in vivo hydrolysis to give the active inhibitor 
E-64C. Both cell permeability and inhibitory activity of E-64 are improved by 
incorporation of a lipophilic N-terminal capping such as benzyloxycarbonyl (Ep-460). 
 
 
 
Figure 1.8. Examples of irreversible epoxysuccinate calpain inhibitors. 
 
Peptide aldehydes represent the largest class of known calpain inhibitors. These inhibitors 
function by reversibly reacting with the active site cysteine thiol. For example, Leupeptin 
(Figure 1.7) inactivates both calpain 1 and calpain 2 with IC50 values of 0.27 µM and 
0.38 µM, respectively. However its poor cell permeability results in this compound being 
unattractive as an in vivo agent. Modification of leupeptin with a NH2-terminal protected 
by a benzyloxycarbonyl group and removal of the guanidinium group results in a 
derivative [Calpeptin, Z-Leu-Nle-H] with improved cell permeability (Figure 1.9).27  
 
Peptide aldehydes MDL-28170, SJA-6017, ALLN and ALLM (Figure 1.9) all function 
as effective inhibitors of both calpain 1 and calpain 2. Administration of MDL-28170 
reduces the neuronal loss and improved locomotive functions in a rat model of 
Parkinson’s disease.28 The dipeptide aldehyde SJA-6017 is a potent calpain 2 inhibitor 
that is effective against selenite-induced cataract in rat.29 The tripeptide aldehyde ALLN 
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has been used to reduce neuronal damage in a rat model of focal ischaemia and as a 
chemotherapeutic agent to overcome acquired resistance in cancer therapy.30 Calpain 
inhibitor ALLM is reported to provide effective neuroprotection  in vitro and in vivo 
models of spinal cord injury and cerebral ischemia.31 
 
 
 
Figure 1.9. Examples of peptide aldehydes as reversible calpain inhibitors. 
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1.3: Evaluation of calpain inhibitors for the treatment of cataract 
 
Cataract is a disease of the eye. It results in the lens becoming opaque with a decrease in 
the quality of vision and ultimately blindness. The lens of the human eye is a highly 
specialized non-vascular tissue that focuses an image onto the retina of the eye, triggering 
electrical impulses that are interpreted by the brain as vision (Figure 1.10).32 
 
 
 
Figure 1.10. The difference in focusing of lighting between normal and lens with a 
cataract. 
 
There is increasing evidence that the over activation of calpain is implicated in some 
forms of cortical cataract.33,34 Calpain 2 is the major calpain isoform found in the 
epithelial cell of the human eye lens and is thought to be important in cortical cataract.35 
Cataract formation results from a variety of insults such as genotype, selenite and damage 
from ultraviolet light (Figure 1.11). Recent work has shown that as the human lens ages, 
the intensity of light scattered backwards out of the pupil can often increase 
exponentially.36  
 
It has been proposed that the ageing process results in elevated levels of Ca2+ in lens 
tissue and hence calpain over activation with associated deregulated proteolysis of 
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soluble crystallins giving rise to precipitation and aggregation. This compromises the 
function of crystallins in maintaining lens transparency and results in the reduced lens 
performance associated with cataract (Figure 1.11). 37 , 38 , 39  Development of calpain 
inhibitors that could slow cataract progression is considered of scientific and commercial 
interest. 
 
 
 
Figure 1.11. The origin of cataract. 
 
Currently the only treatment for cataract is surgery to replace the damaged lens with an 
artificial intraocular lens. It is one of the safest and most successful procedures in all of 
medicine. Surgical treatment is now a significant health cost and there are often long 
waiting lists; furthermore fear of surgery especially for the elderly remains an 
impediment to such treatment. Medical treatment of cataract is therefore a highly desired 
alternative.40 
 
A number of calpain inhibitors have been used in studies to demonstrate the role of 
calpain in cataract. Leupeptin has been used in this context but it has low cell penetration 
due to the presence of positively charged arginine. E-64, another widely used calpain 
inhibitor, has been reported to retard the development of nuclear cataract in in vitro 
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experiments. However the effect is poor in an in vivo animal model.41 SJA-6017 has been 
developed by Senju Pharmaceuticals Ltd and has been proved to be effective in 
preventing calcium-induced cortical cataract in rats.42 Inhibitor CAT811 has also been 
reported by our research group to protect sheep lens from calcium-induced cataract 
formation (see 1.5.2, Chapter 1).43 
 
SJA-6017 has a higher potency toward calpain 1 (7.5 nM) and calpain 2 (78 nM) than 
other known calpain inhibitors such as E-64, leupeptin and AK275 (Table 1.2).  
 
Table 1.2. Potency of SJA-6017 compared to other known calpain inhibitors. 
Compounds                                IC50(nM)  
 Calpain 1 Calpain 2 
SJA-6017 7.5 78 
E-64 570 570 
Leupeptin  410 720 
AK275 260 430 
 
SJA-6017 is therefore a suitable lead compound with structure activity relationship 
studies42 (Table 1.3) showing that inhibitory activity is reduced by replacing its valine 
with norvaline in 1.1 and norleucine in 1.2 at the P2 position. The incorporation of 
alanine as in 1.3, tryptophan as in 1.4, and phenylalanine as in 1.5 at the P1 position 
reduces inhibitory activity against calpain 1. This suggests that the size of hydrophobic 
groups at P1 and P2 is important, with Val and Leu being preferred at P1/P2 position 
respectively. Replacement of the aromatic ring in P3 with a methyl group (1.6) reduces 
potency. Methylation of the P2 N-H group as in 1.7 significantly reduces the inhibitory 
activity suggesting that the P2 N-H group is most likely required for hydrogen-bonding 
interactions with calpain. 
 
 
 16          Chapter 1: Introduction 
 
 
Table 1.3. Structure-activity relationship studies of lead compound SJA-6017 and its 
analogues.42  
     
Compound P3 R P2 P1 
IC50 (nM) 
Calpain 1 
SJA-6017 4-F-Ph H L-Val L-Leu-H 7.5 
1.1 4-F-Ph H L-Nval L-Leu-H 130 
1.2 4-F-Ph H L-Nle L-Leu-H 260 
1.3 4-F-Ph H L-Val L-Ala-H 630 
1.4 4-F-Ph H L-Val L-Trp-H 23 
1.5 4-F-Ph H L-Val L-Phe-H 27 
1.6 Me H L-Val L-Leu-H 830 
1.7 4-F-Ph Me L-Val L-Leu-H 21000 
 
Computer docking studies have been carried out in our research group, in an attempt to 
rationalize the inhibitory activity of a series of SJA-6017 analogues and to demonstrate 
the validity or otherwise, of in silico calpain model.44 Molecular modeling studies require 
knowledge of an active site and this was obtained from the recently published X-ray 
crystal structure of protease core of calpain 1 (1KXR)45 and calpain 2 (1MDW)46. Both 
the 1KXR and 1MDW constructs consists of domain I and II of calpain 1 and 2 
respectively.  
 
The protease core of calpain 1 (1KXR) was crystallized in the presence of calcium and 
this construct has the active site cysteine mutated to serine preventing autolysis during 
crystallization. The protease core of calpain 2 (1MDW) in the presence of calcium has 
also been crystallized however this construct did not show activity in an in vitro assay 
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because a tryptophan is positioned over the active site.46  Therefore the coordinates of the 
1KXR construct were chosen to obtain coordinates for the active site for the molecular 
modelling study (Figure 1.12). To perform the docking studies, the active site serine115 
was first mutated in silico to cysteine115, and the Cys115 deprotonated and His272 
protonated to mimic the physiological conditions of action mechanism of cysteine 
protease. 
 
  
                                      (a)                                                                     (b) 
 
Figure 1.12. a) Surface diagram of 1KXR showing the active site cleft (black line) with 
the active site Cys 115 in yellow. Above the Cys 115 is the non-prime side and below is 
the prime side. The active site is a deep valley with high sides. b) Active site of the 
calpain Glide model based on the PDB structure 1KXR showing the residues surrounding 
the non-prime region. 
 
The effect of varying P1, P2 and P3 residues on calpain inhibitory activity was 
investigated by docking studies carried out by Dr Blair G Stuart on SJA-6017 and its 
analogues with the calpain construct model (Figure 1.13). 
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                      (a)                                               (b)                                                  (c) 
 
Figure 1.13. (a) Best docked pose of SJA-6017 (blue), compounds 1.3 (pink), 1.4 (green) 
and 1.5 (red). (b) Best docked poses of compounds 1.1 (blue) and 1.2 (red). (c) Best 
docked poses of compound 1.7 (blue).  
 
Dockings of SJA-6017 (7.5 nM), 1.4 (23 nM) and 1.5 (27 nM) show three essential 
hydrogen bonds are formed with Gly271 and Gly208 (Figure 1.13a). The three hydrogen 
bonds are considered to be crucial for appropriate binding in the active site as a β-strand 
conformation. This β-strand conformation is universally recognized by proteolytic 
enzymes (see Section 1.4). 47 The best fit pose of compound 1.3 also shows these three 
hydrogen bonds, however compound 1.3 has one ‘ugly’ internal contact (see Table 1.4) 
reflected by an reduced inhibitory activity (630 nM) compared with SJA-6017, 1.4 and 
1.5. An ‘ugly’ internal contact reflects the molecule being forced to fit into the active 
site. The Glide docking program keeps the enzyme rigid and not able to move to 
accommodate such a ligand without unfavourable internal contacts.  
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Table 1.4. Docking data for best pose and inhibitory concentrations (IC50) of compound 
SJA-6017 and its analogues 1.1-1.7 with their structures shown in Table 1.3.  
 Glide Emodel Essential Warhead Internal contacts 
Compound Score Score H bonds Distance Å Good Bad Ugly 
IC50 (nM)  
µ-calpain 
SJA-6017 -5.8 -49.4 3 4.2 203 9 0 7.5 
1.1 -4.6 -49.2 2 4.0 188 20 3 130 
1.2 -4.0 -52.7 2 3.6 212 15 0 260 
1.3 -4.8 -49.9 3 4.1 139 10 1 630 
1.4 -4.6 -59.3 3 3.6 195 7 0 23 
1.5 -5.9 -54.7 3 4.0 205 14 0 27 
1.6 -5.9 -48.2 3 3.7 188 9 2 830 
1.7 -2.4 -45.9 1 4.4 217 15 0 21000 
a War head distance (WHD) is the distance between the carbonyl carbon of the aldehyde and the active site 
cysteine sulfur in Å.b Hydrogen bonds from the carbonyl group of Gly208, the NH group of Gly208, and the 
carbonyl group of Gly271 of the o-CAPN1 homology model. 
 
The best pose of 1.1 and 1.2 (Figure 1.13b) show that only two of three essential 
hydrogen bonds are formed, moreover compound 1.1 has a three ‘ugly’ internal contacts 
(see Table 1.4). As such this rationalises 1.1 and 1.2 exhibiting higher IC50 values namely 
130 nM and 260 nM, respectively. Compound 1.7 (Figure 1.13c) has an only one of the 
three essential hydrogen bonds resulting in a poor IC50 of 21000 nM.  
 
The carbonyl carbon of the warhead of all these compounds is less than 4.5 Å from the 
active site cysteine sulfur, a warhead distance allowing for nucleophilic attack by the 
sulfur of cysteine required for a reversible covalent inhibitor (Table 1.4). All these 
inhibitors have low negative Glide Scores and Emodel Scores suggesting tight binding 
(Table 1.4). Glide Score is a scoring function based on ChemScore and designed to 
estimate the free energy of binding for the protein–ligand complex. The function uses 
simple contact terms to estimate lipophilic and, where relevant, metal–ligand binding 
contributions, a simple explicit form for hydrogen bonds and a term which penalises 
flexibility. The Emodel is a model energy score that combines energy grid score, binding 
affinity predicted by GlideScore, and for flexible docking the internal strain energy.48 
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1.4: The universal importance of a β-strand conformation in protease 
inhibitor design 
 
The X-ray crystal structure of leupeptin in a complex with calpain 1 construct (1TL9) 
(Figure 1.14a) shows that the inhibitor is covalently bound between the carbon of the 
aldehyde and the sulfur of Cys115. Two key hydrogen bonds formed between the NH 
and carbonyl groups of leucine (P2) and an additional hydrogen bond between the NH 
and Gly271. SNJ-1715 complexed with calpain 1 (µI-II) also shows identical hydrogen 
bond interactions between the peptidyl backbone of SNJ-1715 and residues Gly271 and 
Gly208 in the active site binding pocket (Figure 1.14b).  
 
 
                              (a)                                                                       (b) 
 
Figure 1.14. X-ray structure of (a) leupeptin in a complex with calpain 1 construct 
(1TL9).49 (b) SNJ-1715 in the binding pocket of calpain 1 construct (2G8E).50 
 
These three hydrogen bonds are also observed in the X-ray crystal structure of E-64 in a 
complex with calpain 1 construct (1TL0), and AK-295-D2 with calpain 1 construct 
(2R9C).51  In all cases the result is binding of the ligand in a β-strand conformation. 
 21          Chapter 1: Introduction 
 
 
It turns out that this β-strand conformation is universally recognized by proteolytic 
enzymes. Over fifteen hundred X-ray crystal structures of protease-bound substrates, 
products and inhibitors have been reviewed in the active sites of the five protease classes; 
aspartic, serine, metallo, cysteine and threonine endopeptidases.47  Peptidic and non-
peptidic ligands all bind in an extended β-strand conformation, with very few exceptions.  
 
Cysteine proteases are known to have fairly shallow, solvent exposed active sites that can 
accommodate a 2-4 amino acid sequence in a β-strand conformation. A total of twelve 
inhibitors have been shown to bind the active site of cathepsin, a cysteine protease, in a β-
strand conformation (Figure 1.15a).47 Figure 1.15b shows the overlap of the β-strand 
conformation of inhibitors bound to the human cytomegalovirus, a serine protease. Figure 
1.15c shows the superimposition of five active-site-bound inhibitors of rennin, an aspartic 
protease, each in an extended β-strand conformation. 
 
 
          (a)                                                       (b) 
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                                                                                (c)  
 
Figure 1.15. Superimposition of (a) cysteine protease-inhibitor structure, (b) serine 
protease inhibitor structure, (c) aspartic protease-inhibitor structure.47  
 
1.4.1: The β-Strand conformation  
 
A β-strand is a linear or saw-toothed arrangement of amino acids in which the amide 
bonds are almost coplanar and the side chains alternate above and below the plane of the 
peptide backbone. A β-strand conformation for a peptide backbone can be defined by the 
Φ and Ψ torsion angles where -160° < Φ < -100° and 90° < Ψ < 160° (Figure 1.16). 52 
 
  
 
Figure 1.16. Definition of β-strand conformation of peptides.53 
 
The positions of the amino acid side chains within an extended β-strand conformation are 
separated by a maximum distance with the i and i+4 residues which are normally 14.5 Å 
apart (Figure 1.17).54 This large separation minimizes the intramolecular and steric 
interactions of side chains and exposes amide hydrogen-bonding atoms thereby 
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promoting the intermolecular interactions with the enzyme. A β-strand peptide in solution 
exhibits the JNHCαH coupling constants in the range 9-10 Hz in proton NMR. 
 
 
 
 
Figure 1.17. A β-strand composed of Ala residues. 
 
Based on the observations that proteases bind their substrates and inhibitors in an 
extended β-strand backbone we and others have reported cyclic protease inhibitors that 
mimic this geometry.43,55  Structures of this type are conformationally pre-organized into 
a shape that is recognized by an active site, which can increase affinity towards the 
enzyme by reducing the entropic penalty of inhibitor-enzyme binding.  
 
1.4.2: β-Strand macrocyclic protease inhibitors  
 
Macrocycle 1.8 has been reported as a potent aspartic protease BACE inhibitor (IC50 = 
156 nM) by linking the P1 and P3 residues in acyclic BACE inhibitor 2.56 The X-ray 
crystal structure (Figure 1.18) shows the macrocyclic inhibitor 1.8 in dark green 
overlapping with linear peptide 1.9 (orange) in an extended β-strand conformation in the 
active site of the aspartic protease BACE. The crucial hydrogen-bonding interactions 
observed in the complex of the acyclic inhibitor 1.9 with active site of aspartic protease 
BACE (including interactions with Gly34, Pro70, Thr72, Gln73, Gly230, and Thr232) are 
also observed with macrocycle 1.8. The introduction of the intramolecular ring enhanced 
 24          Chapter 1: Introduction 
the propensity of a bioactive β-strand conformation, known to favour active-site binding 
and thereby accounting for improved affinity for the enzyme.  
 
 
 
 
 
Figure 1.18. X-ray structure of macrocycle 1.8 (dark green)-BACE complex (top) and 
overlay of the X-ray structures of BACE complexes with macrocycle 1.8 (dark green) 
and acyclic 1.9 (orange) (bottom).  
 
The linear compound 1.10 has been shown by NMR and molecular modelling to bind 
with HCV NS3 serine protease in an extend β-strand conformation (IC50 = 400 nM). 
Modification of 1.10 by ring closure between the of P1 and P3 side chains to a 15-
membered macrocycle 1.11 with a trans P2 amide bond and Z double bond results in a 
potent HCV NS3 serine protease inhibitor (IC50 value of 24 nM).57  
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The cyclic linkage of 1.12 improves the poor isoform selectivity displayed by the linear 
tripeptide analogue inhibitor 1.13 against matrix metalloproteinase (MMP)-8.58 The X-
ray crystal structure of inhibitor-bound MMP shows that 1.13 adopts the expected 
extended β-strand conformation, with the P1 and P2’ side chains directed away from the 
active site and situated in close to each other. The X-ray crystal structure of 1.12, a 14-
membered macrocycle with linking of the P1 and P2’ side chains, in a complex with 
MMPs shows overlap with the acyclic peptide inhibitor 1.13 in that crystal structure. The 
macrocycle allows the same hydrogen-bonding interactions as found for the acyclic 
inhibitor.  
 
 
 
The 14-membered macrocycle 1.12 is more active to MMP-8 (17 nM) than the open-
chain analogue 1.13 (293 nM) and both are selective to MMP8 over other MMP enzymes 
(Table 1.5).58  
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Table 1.5. Macrocycle 1.12 have a more potency and selectivity to MMP-8 than acyclic 
1.13. 
Ki  (nM) 14-m macrocycle 1.12 Linear peptide 1.13 
MMP-1 2500 2860 
MMP-2 8100 1533 
MMP-3 13500 14088 
MMP-8 17 293 
MMP-9 6600 404 
 
The 17-membered macrocycle 1.14 has been reported to mimic an extended β-strand 
conformation adopted by compound 1.15 bound to HIV-1 protease. This structure has 
improved potency and proteolytic stability.59 Compound 1.15, a tetra peptide inhibitor, is 
a poor drug candidate because it readily undergoes hydrolysis. Macrocycle 1.14 links the 
P1 and P3 side chains. The X-ray crystallographic structure of 1.14 in a complex with 
HIV protease shows that it forms a β-strand conformation similar to that observed for the 
acyclic peptide 1.15. Macrocycle 1.14 is stable to proteases found in plasma or in a cell, 
where linear peptides are completely hydrolysed under these conditions. The amide 
bonds in the macrocycles are therefore in general less susceptible to cleavage than in the 
acyclic analogues and thus the macrocycle 1.14 exhibits favourable stability as a drug. 
 
 
 
Macrocyclization also impacts on membrane permeability and cellular activity. For 
example, the 18-membered macrocycle 1.16, an analogue of the acyclic inhibitor 1.17, 
has improved cell permeability and inhibitory activity of cellular enzymes.60 Compound 
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1.17, adopts a  β-strand geometry. It exhibits sub-nanomolar inhibitory activity and is a 
potent antiviral compound but poor cell penetration makes this compound unsuitable as a 
drug.  
 
 
 
The effect of a macrocycle structure on cell permeability is apparent in a comparison of 
the EC50/IC50 ratio for macrocycle 1.16 with the acyclic analogue 1.17. This ratio for 1.16 
is ca 30-fold higher than that for 1.17 showing that macrocycle 1.16 has improved 
cellular permeability relative to the acyclic analogue.  
 
Macrocyclic analogues of the lead calpain inhibitor SJA-6017, where the core is 
constrained as a β-strand, also offer potential to reduce the entropic penalty of inhibitor-
enzyme binding and to improve pharmacokinetic properties such as target affinity, 
membrane permeability, enzyme selectivity, stability to proteolysis. In particular, the 16-
19 membered macrocycles 1.18-1.23 have been reported by our research group to be 
constrained with a β-strand core.43 Compounds 1.18 and 1.19 incorporate the Val-Leu 
dipeptide backbone of SJA-6017 but in a macrocycle by linking the P1 leucine and P3 
tyrosine side chains. Compounds 1.20-1.23, which have the 4-fluorobenzyl sulphonamide 
of 1.18 and 1.19 replaced with a Cbz group and the P2 valine of SJA-6017 replaced by 
Leucine, have been reported. These compounds have been studied because it was thought 
the macrocyclic structure may increase potency and bioavailability. Alcohols 1.20b-
1.23b are precursors to aldehydes 1.20a-1.23a. 
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The assay results of 1.18-1.23 with ovine calpain 2 shows that the 17-membered 
macrocyclic aldehyde 1.21a (CAT811) is most potent against o-calpain 2, with an IC50 of 
30 nM.43 This compound significantly retards calcium-induced opacification in an in 
vitro ovine lens culture assay and shows promise in slowing the progression of cortical 
cataract in animal trials with a hereditary ovine cataract model. 61 Aldehydes 1.19 (280 
nM) and 1.22a (180 nM) also proved to be potent with nanomolar inhibitory activity. 
Interestingly the 17-membered alcohol 1.21b, a precursor to 1.21a, shows potency with 
the IC50 value of ca. 700 nM.43  
 
1.5: Metathesis and its use in the synthesis of macrocyclic protease inhibitors 
 
The macrocycles of the protease inhibitors 1.18-1.23 above were introduced by ring 
closing metathesis of a suitable diene precursor, a sequence discussed in detail in this 
thesis. Such alkene metathesis62 was discovered in mid-1950 by researchers studying 
Ziegler polymerization.63 Its subsequent wide applicability to organic synthesis has 
resulted from the discovery by Schrock64 and Grubbs65 of well defined and function-
group-tolerant metathesis catalysts. 
 
Alkene metathesis can be classified into four categories: cross metathesis (CM), ring 
closing metathesis (RCM), ring opening metathesis (ROM) and ring opening metathesis 
polymerization (ROMP) (Figure 1.19). CM forms an acyclic carbon-carbon bond with an 
intermolecular mutual exchange of carbene fragments between the two alkenes. RCM 
involves intramolecular reaction of two alkenes with catalyst to generate medium-to-large 
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ring architecture. Ring opening metathesis is a process through which a cyclic alkene 
reacts with an acyclic alkene to give a new acyclic diene. The driving force for ring 
opening metathesis is the release of ring strain. Finally, ROMP also requires a 
constrained cyclic structure and ring open to give a diene with terminal double bonds 
complexed with a metal, the metal-carbon carbene reacts with the double bond on the 
next monomer, thus propagating the reaction to produce linear polymers.  
 
 
 
Figure 1.19. Main types of alkene metathesis: CM, RCM, ROM and ROMP. 
 
As a carbon-carbon double bond forming reaction alkene metathesis has distinct 
advantages:  
         (i) The alkene substrates can often be easily prepared; 
         (ii) The reaction conditions tolerate a wide range of functional groups; 
         (iii) Alkene products allow for further functionalisation; 
         (iv) Alkene metathesis often provide product in high yield; 
         (v) Ethylene is often a byproduct of metathesis and is easily removed. 
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1.5.1: Development of alkene metathesis catalyst  
 
Advances in the synthesis of transition metal complexes led to the synthesis of a 
numerous metal organic carbene complexes. Selected complexes of titanium, tungsten, 
molybdenum and ruthenium have been shown to effect metathesis reactions of alkenes. 
The metal-carbon double bond of the complex, often referred to as a carbene complex, 
e.g. Mo=C, Ru=C, reacts with alkenes as shown in Scheme 1.1. 
 
 
 
Scheme 1.1. Mechanism of ruthenium-catalyzed alkene metathesis. 
 
In catalytic alkene metathesis, the presence of functional groups (such as oxygen, 
heteroatoms) or solvents (including oxygen and water) can interfere with catalytic 
activity by binding to the active metal center or reacting directly with the metal center. 
Therefore the development of metathesis catalysts required use of a metal that can react 
preferably with alkene and tolerate other reactive functional groups. A selection of 
metathesis catalysts is shown in Figure 1.20 along with their tolerance of functionality in 
the reacting systems and a comparison of their reactivity.  
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Figure 1.20. Metal center functional groups.66 
 
Although titanium and tungsten based carbene catalysts promote alkene metathesis, their 
use has been limited because of their low stability and reactivity. Molybdenum-based 
carbene complexes are more reactive towards alkenes but also react with aldehydes and 
polar or protic groups. Ruthenium is the metal of choice because ruthenium-based 
carbene complexes react preferably with alkenes over other functional group and tolerate 
many functional groups including carboxylic acids, alcohols and aldehydes and ketones, 
but are rendered inactive in the presence of amides. Ruthenium catalysts with the general 
formula (PR3)2(X)2Ru=CHR1 are commonly used because of their air stability and ease of 
handling.  
 
A mechanism of ruthenium-catalyzed alkene metathesis (Scheme 1.1) requires phosphine 
(PR3) dissociation to form active 14-electron species B. which can either reform A with a 
rate constant k-1 or react with alkene with a rate constant k2 to give complex C and 
metallacyclobutane E. The geometry of intermediate C and E can be cis or trans.  
 
The effect of ligand L, substituents X, R and R1 on the activity of ruthenium-based 
catalysts 1.24 has been investigated (Figure 1.21).67 The air stable complex 1.25 has been 
found to be an effective catalyst for polymerization of norbornenes in protic media. 
Although 1.25 is not particularly active, its well-defined structure provides a scaffold by 
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which to make structural changes for catalyst optimization. The activity of the catalyst 
1.25 was shown to be increased by replacing PPh3 with PCy3 (1.26).  
 
 
 
Figure 1.21. Ruthenium-based alkene metathesis catalysts. 
 
The ligand R1 also influences the phosphine dissociation rate k1. For example, changing 
the carbene ligand from CHCHC(Ph)2 in 1.27 to CHPh in 1.28 results in an increase in k1 
and this can be rationalized on the basis of the steric and electronic nature of the R1 
substitute. The CHPh group is sterically bulky and less electron withdrawing than 
CHCHC(Ph)2 thereby promoting phosphine dissociation and leading to a high 
dissociation rate.  
 
The rate of metathesis increases on changing the ligand L from a phosphine ligand in 
1.28 to N-heterocyclic carbene (NHC) in 1.29. This increase is attributed to electron 
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donating ability and the steric bulk of the NHC ligand. Similarly IMesH2 catalyst 1.29 is 
more active than IMes complex 1.30 because the IMesH2 ligand is a better electron donor 
than IMes. 
 
Phosphine ligands also affect catalyst activity. For example, replacing the PCy3 of 
catalyst 1.29 with PPh3 results in a more active catalyst 1.31 and this is considered to be 
related with the lower basicity of the PPh3 ligand relative to PCy3. The less electron 
donating phosphine ligand is expected to be more liable, facilitating the equilibrium to 
the active 14 electron form of the catalyst.  
 
1.5.2: Ring closing metathesis  
 
A general mechanism for ring closing metathesis (RCM) is shown in Figure 1.22. 
Reaction between an active carbene [M]=CH2 and one of the two alkenes of i results in a 
metallacyclobutane ii, which can give a metal-carbene intermediate iii. Addition of the 
carbene to the other alkene gives a metallacyclobutane iv and subsequent fragemenataion 
gives v and regenerates catalyst [M]=CH2 which can propagate additional reaction cycles.  
 
 
 
Figure 1.22. Mechanism of RCM. 
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1.6: Overview of the work reported in this thesis 
 
The yield of RCM used to prepare the macrocyclic compounds 1.18-1.23 is generally at 
best, moderate.43 In chapter 2, the factors that influence the efficiency of such RCM 
reactions are investigated including the metathesis catalyst, solvent, reaction temperature, 
and the addition of Lewis acids. A series of diene precursors to 1.20-1.22, has been 
synthesized and RCM under various conditions investigated. The results of this study 
have recently been published.68 The best reaction conditions developed were then used to 
synthesize a most potent calpain inhibitor 1.21a (CAT811).  
 
An efficient large scale synthesis of macrocyclic aldehyde CAT811 that does not involve 
RCM was also investigated (see Chapter 3). 69  This synthetic route employs an 
intramolecular nucleophilic substitution for ring closure which is particularly suited to a 
multi-gram synthesis. This intramolecular nucleophilic substitution methodology was 
also used in an attempted synthesis of a 19-membered macrocycle 3.21. 
 
In Chapter 4, the synthesis, biological assay and molecular modelling of imidazole-
containing macrocycles 4.1-4.3 are discussed. The 15- and 16-membered macrocycles 4.1 
and 4.2, with a histidine at P3, have been shown to adopt β-strand conformation when 
docked with our modeling methodology. Another 15-membered macrocycle 4.3, with 
histidine in the P1 position, was also prepared in an attempt to develop some structure-
activity relationships and to investigate the validity of the modelling.  
 
 
Several intramolecular macrocyclisation strategies were investigated for the synthesis of 
the histidine containing macrocycles 4.1-4.3, with intramolecular lactamization proving 
to be the most efficient (see Chapter 4).  
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RCM is generally carried out in organic solvents. In chapter 5 we report RCM reactions 
of a ruthenium catalyst containing a polyethylene glycol ligand in aqueous media (see 
Chapter 5).  
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Chapter 2: The synthesis of macrocyclic β-strand templates by 
ring closing metathesis 
 
2.1: Introduction 
 
Ring closing metathesis (RCM) has been widely used in the field of peptide synthesis and 
peptidomimetics to produce macrocyclic molecules. The incorporation of a macrocyclic 
ring in an acyclic peptide analogue can lead to desirable conformational and 
pharmacological properties as discussed in the previous chapter. 1  For example, 
macrocyclization using RCM has been used as a strategy to produce mimics of protein 
structures including an extended β-strand, a conformation universally adopted by 
substrates or inhibitors for binding to proteases (see Chapter 1).2   
 
The resulting macrocyclic peptides (Figure 2.1) are characterized by a number of 
parameters including: 
(i) the number (m) of atoms in the macrocycles; 
(ii) the presence or absence of carbon carbon double bonds; 
(iii) the configuration of the double bond in the bridge; 
(iv) the position and nature of constituent heteroatoms, multiple bonds, stereogenic 
centers and side chains within and on the bridge; 
(v) the sequence of amino acids in the parent peptide chain; 
(vi) the atoms e.g. Cα, Cβ, N or carbonyl carbon of the parent peptide backbone at 
which the alkene functionality was introduced.  
(vii) the positions of Cα, Cβ, N or carbonyl carbon in the peptide backbone (e.g. i 
and i+k).  
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Figure 2.1. Classification of macrocyclic peptides 
 
This chapter reports the synthesis of the macrocyclic β-strand templates 2.1-2.4 using 
RCM of dienes 2.5-2.8 respectively (Scheme 2.1).  
 
The vinyl and allyl groups of the key dienes 2.5, 2.6 and 2.7 can be introduced using 
commercially available (S)-vinyl-Gly-OMe and (S)-allyl-Gly-OMe. The allyl substituted 
tyrosine derivatives of 2.5, 2.6, and 2.8 were introduced using commercially available N-
Boc-Tyr(O-allyl)-OMe. The O-homoallyl N-Boc-tyrosine used in the preparation of 2.7 
was prepared by reaction of tyrosine with 4-bromobut-1-ene (see Scheme 2.4). The 
homoallyl-substituted glycine required for the preparation of 2.8 was prepared by the 
method of Fairlie3 (see Scheme 2.5). Incorporation of these resulting building blocks into 
the peptide backbone gave the acyclic RCM precursors 2.5-2.8. 
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Scheme 2.1. RCM of dienes 2.5-2.8.  
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These dienes were subjected to RCM using Grubbs 2nd generation catalyst to give the 
desired alkene macrocycles 2.1-2.4 as E/Z isomeric mixtures as determined by 1H NMR 
spectroscopy. RCM is known to be influenced by solvent, temperature and by the 
presence of Lewis acid and as such various reaction conditions were investigated in an 
attempt to improve yields.  
 
 
 
2.2: Synthesis of 17-membered macrocycle 2.2  
 
2.2.1: Preparation of diene 2.6  
 
The detailed synthesis of 17-membered macrocycle 2.2 is shown in Scheme 2.2. EDCI 
(1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide hydrochloride) catalysed coupling of 
the commercially available allylic ether 2.9 with Leu-OMe 2.10, in the presence of 1-
hydroxy-7-aza-benzotriazole (HOAt) as a peptide coupling reagent, gave dipeptide 2.11 
(79%). The molecular formula of 2.11 was confirmed by mass spectrometry with a parent 
ion at m/z 449.2655 and by 1H NMR spectroscopy with two resonances at 4.54 and 4.30 
ppm corresponding to α-protons of leucine and tyrosine, respectively. Hydrolysis of the 
methyl ester of 2.11, under basic conditions, gave carboxylic acid 2.12 in almost 
quantitative yield. A EDCI mediated coupling of 2.12 with commercially available (S)-
allyl-Gly-OMe 2.13 gave 2.6 in 77% yield, with its structure confirmed by the presence 
of three α-proton resonances for the leucine, allylglycine and tyrosine residues centered at 
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4.53, 4.43 and 4.33 ppm, respectively. RCM of diene 2.6 was then carried out and factors 
that influence the efficiency of the reaction investigated.  
 
 
 
Scheme 2.2. Synthesis of 17-membered macrocycle 2.2 by RCM. 
 
2.2.2: Investigation of conditions for RCM of diene 2.6 to macrocycle 2.2  
 
The most commonly used solvents in Ru-catalyzed RCM include dichloromethane, 
toluene, benzene, and 1,1,2-tichloroethane (TCE). TCE was selected as the solvent of 
choice for all the RCM reactions described herein because of its frequent use in 
metathesis reactions in combination with Ru catalyst including reactions under 
microwave conditions 4  
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It is generally acknowledged that heating is required to initiate the dissociation of the 
catalyst to generate the reactive metal carbene. For a ruthenium based catalyst, 
decomposition is generally observed at temperature above 50 oC within a few hours.5 
RCM of diene 2.6 was first carried out in TCE (bp 60.3 oC) with three successive 
additions of 10 mol % Grubbs 2nd generation catalyst under reflux conditions (A, in Table 
2.1).  
 
Table 2.1. RCM of diene 2.6 under varying conditions. 
Diene  Condition a Product  Ratiob Yield c 
A 10(E):1(Z) 22% 
B 9(E):1(Z) 37% 
Cd 
Ce 
9(E):1(Z) 
9(E):1(Z) 
34% 
82% 
2.6 
D 
2.2 
2.2 
2.2 
2.2 
2.2 9(E):1(Z) 90% 
a All reactions were performed in TCE with 3 separate additions of 10 mol % Grubbs 2nd generation 
catalyst. Condition A: Thermal reflux 18 h. Condition B: Microwave reflux 1 h. Condition C: Thermal 
reflux with Lewis acid 18 h. Conditions D: Microwave reflux with Lewis acid 1 h. b RCM metathesis result 
in mixtures of geometric isomers as confirmed by 1H NMR spectroscopy. c Isolated yields following 
column chromatography. d Titanium-based Lewis acid. e chlorodicyclohexylborane 
 
Under these conditions, the product 2.2 was isolated in 22% yield as a mixture of E and Z 
alkenes (10:1 by 1H NMR) after chromatography on silica gel. The molecular formula 
was confirmed by the parent ion in the mass spectrum at m/z 518.2769. The configuration 
of major product alkene in the mixture was established by 1H NMR analysis. This isomer 
exhibited a coupling constant of J = 15.5 Hz for the Ha and Hb protons, which is 
consistent with an (E) configuration6 (Figure 2.2). 
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Figure 2.2. Coupling constants (Hz) of the alkenic protons in macrocycle 2.2  
 
The 1H NMR spectra of 2.2 (Figure 2.3) shows the alkene proton Ha centered at δ 5.54 
ppm as an app dt (J = 15.5, 3.8, 3.8 Hz) and Hb centered at δ 5.44 ppm as ddd (J = 15.5, 
6.5, 1.5 Hz). The two methyl ester resonances were centered at 3.757 and 3.779 ppm in a 
ratio of 10:1.  The major isomer is the E alkene, and the minor isomer is considered to be 
the Z isomer but it was not possible to identify the alkene protons in the NMR spectrum. 
 
 
Figure 2.3. 1H NMR spectrum of alkene macrocycle 2.2. 
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Microwave irradiation has been reported to increase the yield in RCM reactions and to 
reduce reaction times.7 Thus RCM of 2.6 was carried out with the same catalyst loading 
as before (3 x 10 mol %) but under microwave conditions (condition B, Table 2.1). This 
resulted in an improved yield of 2.2 (37%) with an E/Z alkene isomer mixture of 9:1. 
Thus both thermal reflux and microwave-assisted conditions gave macrocycle 2.2 in 
moderate yields, 22% and 37% respectively. Attempts were made to improve the yield. It 
has been reported that the presence of polar functional groups (e.g. ester, ketone, ether, 
urethane) within dienes can be detrimental to RCM due to associated coordination of the 
ruthenium carbene.8 This led us to propose that ruthenium carbene in diene 2.6 might 
coordinate with carbonyl oxygen to form a stable 6-membered chelate structure (Figure 
2.4), thus sequestering the catalyst in an unproductive complex. 
 
 
 
Figure 2.4. Structure of a six-membered chelate.  
 
Fürstner has reported9 that the addition of the Lewis acid Ti(OiPr)4 can increase the yield 
of alkene metathesis in the cases where the dienes carry an ester functionality. The Lewis 
acid presumably functions by suppressing the formation of an unproductive chelate. 
Alkoxides of Ti4+ species can undergo kinetically labile coordination with an ester 
moiety, and the introduction of the Lewis acid Ti(OiPr)4 to the reaction system may 
prevent coordination of carbonyl oxygen with ruthenium carbene intermediate and 
thereby suppress the formation of such a carbene chelate. RCM of diene 2.6, in the 
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present of 10 mol% of Ti(OiPr)4 under reflux (conditions Cd, Table 2.1), resulted in a 
slight increase in the yield of 2.2 to 34%.  
 
Vedrenne10 has studied the effect of a number of Lewis acids on olefin metathesis. This 
study found that while titanium Lewis acid was unsatisfactory, the addition of 
chlorodicyclohexylborane (a boron-based Lewis acid) significantly improved the yield of 
a metathesis reaction. RCM of 2.6 was therefore performed in the presence of a borane-
based Lewis acid (under thermal reflux) with three sequential additions of Grubbs 2nd 
generation catalyst (conditions Ce, Table 2.1). The addition of chlorodicyclohexylborane 
resulted in a significant increase in yield of 2.2 (82%), with the similar E/Z alkene isomer 
ratio of 9:1. The use of the borane-based Lewis acid under microwave-assisted conditions 
(see conditions D) gave further improvement in yield (90%). 
 
2.3: Synthesis of 16-membered macrocycle 2.1 via RCM under conditions A-D  
 
The synthesis of the alkene macrocycle 2.1 was attempted by RCM of diene 2.5 under 
conditions A, B, C and D. The diene 2.5 was prepared from commercially available N-
Boc-Tyr-OMe 2.9 as shown in Scheme 2.3. Reaction with Leu-OMe 2.10 in the presence 
of EDCI and HOAt gave the dipeptide 2.11. The methyl ester was then hydrolysed under  
basic conditions to give the acid 2.12. This was coupled with commercially available (S)-
vinyl-Gly-OMe 2.14, in the presence of EDCI and HOAt, to give 2.5 (76%). The 
molecular formula of 2.5 was confirmed by a parent ion in the mass spectrum at m/z 
532.3027 and its structure confirmed by 1H NMR spectroscopy.  
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Scheme 2.3. Synthesis of 16-membered alkene macrocycle 2.1 by RCM. 
 
RCM of 2.5 under conditions A (Table 2.2) gave the macrocycle 2.1 as an E/Z mixture in 
moderate yield of 49% after purification by column chromatography. A mass spectrum of 
the product confirmed the expected molecular formula with a parent ion at m/z 504.2727. 
The configuration of the major alkene isomer was established by the 1H NMR 
spectroscopy. This revealed a vinylic coupling constant of J = 15.5 Hz, which is again 
consistent with the (E) configuration (Figure 2.5).  
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Table 2.2. RCM of diene 2.5 under different conditions 
Diene  Condition a Product  Ratiob Yield c 
A 19(E):1(Z) 49% 
B 
C 
20(E):1(Z) 
19(E):1(Z) 
58% 
50% 
2.5 
D 
2.1 
2.1 
2.1 
2.1 20(E):1(Z) 47% 
a All reactions performed in 1,1,2 TCE with 3 separate additions of 10 mol % Grubbs 2nd generation 
catalyst. Condition A: Thermal reflux 18 h. Condition B: Microwave reflux 1 h. Condition C: Thermal 
reflux with borane-based Lewis acid 18 h. Conditions D: Microwave reflux with Lewis acid 1 h. b RCM 
results in mixtures of geometric isomers. c Isolated yields following column chromatography. 
 
 
 
Figure 2.5. Coupling constants (Hz) of alkenic protons in macrocycle E-2.1  
 
The mixture revealed two methyl ester resonances in a ratio of 19:1. These are centered at 
3.786 ppm and 3.747 ppm and correspond to the major and minor alkene, respectively. 
The Ha proton on the double bond centered at 5.72 ppm appears to be a ddd (J = 15.5, 4.0, 
8.0 Hz) and the alkene Hb centered at 5.42 ppm was shown as dd (J = 15.5, 8.6 Hz). The 
coupling constants observed for alkenic protons Ha and Hb (J = 15.5 Hz) reveal the 
major isomer of 2.1 is the (E) isomer. The corresponding signals for the minor isomer 
were not resolved.  
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Figure 2.6. 1H NMR spectrum of macrocycle 2.1. 
 
The microwave assisted RCM of 2.5 (condition B, Table 2.2) resulted in an improved 
yield of macrocycle 2.1 (58%) after purification by chromatography. The addition of 
chlorodicyclohexylborane to the reaction mixture of 2.5, in this case, gave no significant 
improvement in yield (see conditions C in Table 2.2). We suggest that the carbene 
intermediate could form a particularly stable five membered ring chelate in this case (see 
Figure 2.7). The addition of chlorodicyclohexylborane might not disrupt. 
 
 
Figure 2.7. Structure of a five-membered chelate. 
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The addition of chlorodicyclohexylborane under microwave irradiation (condition D in 
Table 2.2) similarly did not improve the yield.  
 
2.4: Synthesis of 18-membered macrocycle 2.3 via RCM under conditions A-D 
 
The macrocycle 2.3 was prepared as shown in Scheme 2.4. Compound 2.19 was provided 
by Dr Steve Aitkin. 2.19 had been made from the commercially available N-Boc-Tyr-
OMe 2.15, via reaction with 4-bromobut-1-ene to give the homoallylic ether 2.16 in 30% 
yield. Hydrolysis of the methyl ester, under basic conditions, gave the carboxylic acid 
2.17, which was coupled with Leu-OMe 2.10 in the presence of EDCI/HOAt to give the 
dipeptide 2.18. Hydrolysis of the ester then gave 2.19 in almost a quantitative yield.  
 
Diene 2.7 was prepared by me by coupling of 2.19 with (S)-allyl-Gly-OMe 2.13. 
Subsequent RCM was examined under varying conditions as shown in Table 2.3.  
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Scheme 2.4. Synthesis of 18-membered alkene macrocycle 2.3 by RCM. 
 
RCM of 2.7 under the thermal conditions (condition A) gave macrocycle 2.3 in 51% (see 
Table 2.3). The molecular formula was confirmed by a parent ion in the mass spectra at 
m/z 532.3034. The 1H NMR spectrum revealed two methyl ester peaks centered at 3.733 
and 3.745 ppm in a ratio of 1.3:1. These were assigned to the E and Z isomers 
respectively (Figure 2.8). Two multiplets centered at 5.47 and 4.93 were also observed in 
a ratio of ca. 1:1.3 and assigned as alkene Ha of the Z (dd, J = 10.6, 8.0 Hz) and E 
isomers (ddd, J = 15.0, 7.0, 5.3 Hz) respectively. The major compound was again 
assigned as the E isomer based on the large coupling constant (15 Hz).  
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Figure 2.8. 1H NMR spectrum of alkene macrocycle 2.3. 
 
RCM of 2.7 under microwave irradiation (condition B in Table 2.3) resulted in an 
improved yield of 2.3 (58%), with an E/Z isomers ratio of 1.7:1. A strikingly improved 
yield (74%) was observed under thermal reflux RCM conditions with the inclusion of a 
10 mol% of chlorodicyclohexylborane (condition C, Table 2.3). The addition of 
chlorodicyclohexylborane and microwave irradiation (condition D) resulted in further 
improvement and a near quantitative yield of 2.3 (96%). The inclusion of 
chlorodicyclohexylborane, under both thermal and microwave conditions, increased the 
yield of macrocyclisation such that these conditions are considered best for a scaled up 
synthesis of 2.3. 
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Table 2.3. RCM of diene 2.7 under different conditions 
Diene  Condition a Product  Ratiob Yield c 
A 1.3(E):1(Z) 51% 
B 
C 
1.7(E):1(Z) 
1.9(E):1(Z) 
58% 
74% 
2.7 
D 
2.3 
2.3 
2.3 
2.3 1.8(E):1(Z) 96% 
a All reactions performed in 1,1,2 TCE with 3 separate additions of 10 mol % Grubbs 2nd generation 
catalyst. Condition A: Thermal reflux 18 h. Condition B: Microwave reflux 1 h. Condition C: Thermal 
reflux with borane-based Lewis acid 18 h. Conditions D: Microwave reflux with Lewis acid 1 h. b RCM 
metathesis result in mixtures of geometric isomers. c Isolated yields following column chromatography. 
 
2.5: Synthesis of 18-membered macrocycle 2.4 via RCM under conditions A-D 
 
The required diene 2.8 was prepared as shown in Scheme 2.5. Coupling of commercially 
available N-Boc-Tyr (O-allyl) 2.9 with Leu-OMe 2.10, in the presence of EDCI and 
HOAt, gave dipeptide 2.11 in 79% yield. Hydrolysis of the constituent methyl ester, 
under basic conditions, gave the carboxylic acid 2.12 in almost a quantitative yield.  
 
The other key starting material 2.22 was prepared from N-Boc-Lys-OH 2.20. 
Diazotization of 2.20 with sodium nitroprusside, under basic aqueous conditions (pH 9), 
gave homoallyl substituted glycine derivative 2.21 in 30% yield.11 The amino acid 
derivative 2.21 was then treated with thionyl chloride in methanol to give 2.22 as the 
hydrochloride salt in nearly quantitative yield. 
 
Coupling of 2.12 with the homoallyllic hydrochloride salt glycine 2.22, in the presence of 
EDCI/HOAt, gave diene 2.8 in 77% yield. A mass spectrum confirmed the expected 
molecular formula with a parent ion at m/z 504.2727. The 1H NMR spectrum showed 
three resonances at 4.52 ppm, 4.50 ppm and 4.38 ppm corresponding to α-protons of 
leucine, homoallylglycine and tyrosine, respectively.  
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Scheme 2.5. Synthesis of 18-membered alkene macrocycle 2.4 by RCM. 
 
RCM of diene 2.8 (500 mg) using Grubbs 2nd generation catalyst under thermal 
conditions (A), resulted in some ring contraction to give a mixture of 18- and 17-
membered macrocycles 2.4 and 2.2  (102 mg) as demonstrated by the presence of two 
parent ions in the mass spectrum: 532.28 and 518.27 m/z respectively (see Tables 2.4). 
The product mixture could not be separated by column chromatography. The 1H NMR 
spectrum of the mixture showed the presence of three methyl ester signals centered at 
3.732 ppm, 3.747 ppm and 3.756 ppm in the ratio of 2.7:1:1(see Tables 2.5). 
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Table 2.4. RCM of diene 2.8 under different conditions 
Diene 2.8 Condition a Productb Amount c 
A 102 mg 
B 
C 
169 mg 
240 mg 
500mg 
500mg 
500mg 
500mg D 
18- and 17- membered 
18-, 17- and 16- membered 
18- and 17- membered 
18-, 17- and 16- membered 191 mg 
a All reactions performed in 1,1,2 TCE with 3 separate additions of 10 mol % Grubbs 2nd generation 
catalyst. Condition A: Thermal reflux 18 h. Condition B: Microwave reflux 1 h. Condition C: Thermal 
reflux with chlorodicyclohexylborane 18 h. Conditions D: Microwave reflux with Lewis acid 1 h. b 
Multiple macrocyclic products were formed. c Amount following column chromatography.  
 
The formation of the 17-membered ring compound 2.2 was consistent with a methyl ester 
resonance at 3.756 ppm which was identical to an authentic sample as prepared in 
Scheme 2.2. The resonances centered at 3.732 ppm and 3.747 ppm were observed in ratio 
of 2.7:1 by 1H NMR and were assigned to the E/Z isomers of the 18-membered 
macrocycle 2.4.  
 
This ring contracted product 2.2 likely results from double bond migration of the 
homoallyl substituent of diene 2.8 (Scheme 2.6). A ruthenium hydride species formed by 
degradation of Grubbs catalyst has been previously reported to give rise to migration of a 
terminal double bond.12 The 17-membered macrocycle 2.2 forms by RCM of diene where 
the double bond migrated on the homoallyl substituent (2.23).  
 
The alkene mixtures formed were then subjected to hydrogenation in the presence of 
palladium on carbon to give a mixture of saturated macrocycles 2.28 and 2.29 as 
confirmed by the molecular ions in mass spectrum at m/z 534.30 and 520.30, respectively 
(see Scheme 2.6).  
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Scheme 2.6. Proposed migration of double bonds in RCM, resulting in reduced ring size 
macrocycles 
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Microwave assisted RCM of 2.8 (condition B in Table 2.5) gave a mixture of 18-, 17- 
and 16-membered alkene macrocycles 2.4, 2.2, 2.26, 2.27, as confirmed by the 
appropriate molecular ions in the mass spectrum, 532.28, 518.27 and 504.28 m/z (Figure 
2.9).   
 
 
Figure 2.9. Mass spectrometry of alkene macrocycles resulting from double bond 
migration in the RCM of 2.8.  
 
The localized higher temperature associated with the microwave conditions results in 
greater double bond migration with a corresponding increase in 17- and 16-membered 
ring macrocycles. It has been reported that the extent of migration of a double bond 
depends on the metathesis conditions, particularly the reaction temperature.13 The 1H 
NMR of the mixture showed the presence of six methyl ester resonances centered at 
3.779, 3.757, 3.745, 3.740, 3.732, 3.724 ppm in the ratio of 1.3: 12.1: 1.6: 1: 5.2: 7.3. 
Two signals centered at 3.732 and 3.745 ppm, in the ratio of 3.4:1, correspond to two of 
532.28 
518.27 
504.28 
519.29 
520.31 
533.31 
16m alkene macrocycle 
17m alkene macrocycle 
18m alkene macrocycle 
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the methyl ester signals formed under conditions A and correspond to the E/Z isomers of 
18-membered macrocycle 2.4. The signals at 3.757 and 3.779 ppm, observed in a ratio of 
9:1, correspond to two methyl esters of the 17-membered ring macrocycle 2.2 as 
confirmed by comparison with the samples as prepared asScheme 2.2. A molecular ion at 
504.28 m/z (see Figure 2.9) suggests the formation of a 16-membered ring compound 
2.27 and therefore at least one of the remaining two methyl ester signals at 3.703 and 
3.723 ppm are considered to be from the E or Z isomers of a 16-membered ring 2.27. 
 
Table 2.5. RCM of diene 2.8 under different conditions 
diene conditionsa  productsb Ring size OCH3 (ppm) isomer ratioc 
A 2.4 
2.2 
18 
17 
3.732, 3.747 
3.756 
(E/Z) 2.7:1  
E 
B 2.4 
2.2 
2.27 
18 
17 
16 
3.732, 3.745 
3.757, 3.779 
3.724 /3.740  
(E/Z) 3.4:1 
9:1 
E/Z 
C 2.4 
2.2 
18 
17 
3.732, 3.747 
3.757 
3.5:1 
E 
2.8 
D 2.4 
2.2 
2.27 
18 
17 
16 
3.732, 3.744 
3.756, 3.778 
3.724/3.739 
3.4:1 
9:1 
E/Z 
a All reactions performed in 1,1,2 TCE with 3 separate additions of 10 mol % Grubbs 2nd generation 
catalyst. Condition A: Thermal reflux 18 h. Condition B: Microwave reflux 1 h. Condition C: Thermal 
reflux with borane-based Lewis acid 18 h. Conditions D: Microwave reflux with Lewis acid 1 h. b Multiple 
macrocyclic products were formed. c RCM result in mixtures of geometric isomers.  
 
RCM with the addition of chlorodicyclohexylborane to the reaction mixture of 2.8 under 
both thermal reflux (condition C) and microwave condition (D) did not significantly 
improve the yield of macrocyclization (Table 2.4). The reaction of homoallyl group in 2.8 
with ruthenium catalyst could result in a seven-membered chelate (see Figure 2.10) but 
the decreased stability of this chelate compared with the 6-membered chelate (Figure 2.4) 
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suggests that this chelate would unlikely interfere with cyclization. Thus these reactions 
were not affected by the addition of a Lewis acid.  
 
 
 
Figure 2.10. Structure of a seven-membered chelate.  
 
In all cases, the alkene mixtures formed under each of the four conditions (A-D, Table 
2.5) were separately subjected to hydrogenation to give saturated compounds as shown in 
Scheme 2.6. The alkene macrocycles prepared under conditions A and C gave a mixture 
of two compounds, as shown by the molecular ions in the mass spectrum at 534.30 and 
520.30 m/z consistent with the formation of 2.28 and 2.29 (see Scheme 2.6). 
Hydrogenation of alkenes formed under condition B and D gave mixtures of three 
compounds exhibiting parent ions at 534.30, 520.30 and 506.28 m/z in the mass spectrum 
considered be from the 18, 17, 16-membered macrocycles 2.28, 2.29 and 2.30 (see Figure 
2.11).  
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Figure 2.11. Mass spectroscopy of saturated macrocycles resulting from double bond 
migration in RCM of 2.8 under conditions B and D. 
 
2.6: Synthesis of CAT811 via RCM under an optimum condition  
 
The published synthetic route to CAT811 employed RCM under thermal reflux 
conditions as a key step. This reaction provided a modest yield of the product (22%). As 
discussed above (see section 2.2 and Table 2.1), the best RCM conditions developed in 
the current study involved the use of chlorodicyclohexylborane and microwave 
irradiation. A synthesis of CAT811 was therefore carried out under these conditions 
(Scheme 2.7).  
 
m/z 496  498  500  502  504  506  508  510  512  514  516  518  520  522  524  526  528  530  532  534  536  538  
1: TOF MS ES+  
1.26e3 534.30 
520.30 
506.28 
521.31 
522.27 
535.28 
536.33 
18m saturated macrocycle 
17m saturated macrocycle 
16m saturated macrocycle 
 
 
63 Chapter 2: The synthesis of macrocyclic β-strand templates by RCM 
 
 
EDCI catalysed coupling of commercially available 2.9 with 2.10 in the presence of 
HOAt gave 2.11 in 79% yield. Hydrolysis of ester 2.11, under basic conditions, gave 
carboxylic acid 2.12 in nearly quantitative yield. An EDCI mediated coupling of 2.12 
with 2.13 gave 2.6 in 77%. RCM of 2.6 was carried out, under the “best” conditions, to 
give the desired alkene macrocycle 2.2 in 91% yield, a 4-fold increase compared to the 
published thermal conditions (22%, see Table 2.1, condition D). 
 
Reaction of 2.2 in a hydrogen atmosphere in the presence of palladium on carbon then 
gave the saturated macrocycle 2.29 in almost quantitative yield (95%). The Boc 
protecting group of compound 2.29 was removed by treatment of hydrochloride acid in 
dioxane (4 M) and the resulting hydrochloride salt 2.31 reacted with benzyl 
chloroformate to give Cbz-protected ester 2.32 in 42% yield. Reduction of 2.32 with 
lithium aluminium hydride in THF gave alcohol 2.33 (82%) which was oxidized with 
SO3/Pyr and DMSO to give the aldehyde CAT811 in 75% yield.  
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Scheme 2.7. Synthesis of CAT811 by using the best RCM conditions. 
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2.7: X-ray analysis of 2.2 showing the (E)-configuration and β-strand 
conformation 
 
A sample of an E/Z mixture of macrocycle 2.2 was recrystallised from methanol to give 
fine-plate like needles that had a 1H NMR spectrum previously assigned to the E-isomer. 
Single crystal X-ray analysis of this material confirmed the (E)-isomer (Figure 2.12).14 
This is consistent with the coupling constant observed for the alkenic protons (J = 15.5 
Hz) in the major alkene of the mixture.6 The crystal structure also revealed that 
macrocycle 2.2 adopts a β-strand geometry for the peptide backbone as defined by P2 
(Leu) Φ [C(4)-C(3)-N(2)-C(2)] and Ψ [N(2)-C(3)-C(4)-N(4)] torsion angles being within 
the ranges -160° < Φ < -100° and 90° < Ψ < 160° (see also Appendix C).  
 
 
 
Figure 2.12. ORTEP diagram of the X-ray crystal structure of (E)-2.2 showing a β-strand 
peptide backbone with Φ = -147.3° and Ψ = 119.7° with respect to the P2 (Leu) Φ and Ψ 
angles.   
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2.8: Conclusion  
 
Factors that influence of efficiency of RCM of dienes 2.5-2.7 have been investigated. The 
addition of chlorodicyclohexylborane to the reaction mixture for the RCM of 2.6 and 2.7 
results in an improved yield of the respective macrocyclic products 2.2 and 2.3. This may 
be attributed to chlorodicyclohexylborane interfering with the formation of a 6-membered 
ring intramolecular ruthenium carbene chelate. However, the addition of 
chlorodicyclohexylborane did not improve the yield of RCM of diene 2.5. In this case, 
the more stable 5-membered ruthenium carbene chelate is presumed not to be disrupted 
by the addition of Lewis acid. The addition of titanium (IV) isoproxide as an Lewis acid 
to RCM of 2.6 results in a lower yield of 2.2 compared to the use of 
chlorodicyclohexylborane. 
 
Ring contraction was observed in the RCM reaction of diene 2.8 under reflux conditions 
to give the 17-membered ring macrocycle 2.2 in addition to the expected 18-membered 
macrocycle 2.4. Reaction under microwave irradiation conditions gave mixtures of the 
16-, 17- and 18-membered macrocycles. The ring contracted macrocycles are considered 
to result from double bond migration on either or both of homoallyl and allyl substituents 
of diene 2.8.  
 
The configuration of alkene in the macrocycles 2.1, 2.2 and 2.3 was determined by 1H 
NMR analysis. The alkene coupling constants for 2.1, 2.2 and 2.3 (J = 15.5, 15.5 and 
15.0 Hz, respectively) are consistent with the (E) configuration for the major isomer in 
each case. The configuration of the major alkene product (2.4) could not assigned as ring 
contraction gives a mixture of macrocycles.   
 
A detailed X-ray crystallographic structural investigation was undertaken for macrocycle 
2.2 revealing the (E) configuration and a β-strand conformation.  
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The best RCM reaction conditions we developed involved the use of 
chlorodicyclohexylborane and microwave irridiation. These conditions were used in a 
synthesis of our most potent calpain inhibitor CAT811 and resulted in a 4-fold increase 
in yield.  
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14 The structures were solved by standard methods, and the atomic coordinates have been 
deposited with the Cambridge Structural Database. 
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Chapter 3: A new approach to the synthesis of CAT811 and 
analogue 3.21 
 
3.1: Introduction 
 
As discussed in Chapters 1 and 2 the 17-membered macrocyclic aldehyde CAT811 is a 
potent inhibitor of calpain 2 (30 nM), and to a lesser extent calpain 1 (270 nM),1 and it 
shows significant promise in the treatment of cataract. A large scale synthesis of CAT811 
was required to obtain material for in vitro or in vivo testing.2 
 
The original synthesis of CAT811 is based on a ring closing of diene 2.6 to give the 
alkene macrocycle 2.2, which was converted by standard chemical methods into CAT811 
(see Scheme 2.7, Chapter 2). This synthetic route involves nine steps and occurs in an 
overall yield of 12% using the optimized conditions developed in Chapter 2. Several 
problems were expected on applying this strategy to a large scale synthesis. Ring closing 
metathesis is expensive as it requires the expensive and patented Grubbs second 
generation catalyst. The benzylation (step 7, Scheme 2.7) involves the use of 
benzylchloroformate which can result in environmental and safety problems. Moreover 
hydrogenation of 2.2 to 2.29 (step 5, Scheme 2.7) is normally conducted under 20 
atmosphere pressure, which is not desirable for a larger scale laboratory synthesis. The 
hydrogenation apparatus available to us only achieves pressure to 500KP (ca 5 At). 
Finally, the original synthesis uses a flammable reducing agent LiAlH4 for the reduction 
of the ester of 2.32 to the alcohol 2.33 (step 8). An alternative strategy was therefore 
required for a multi-gram synthesis of CAT811.  
 
3.2: Application of an intramolecular nucleophilic substitution strategy for 
macrocyclisation 
 
Farlie3 has reported the preparation of 17-membered macrocyclic β-strand compounds 
3.1a-c (shown in Scheme 3.2) as templates for the development of HIV-1 protease 
inhibitors, using an intramolecular nucleophilic substitution strategy for ring closure.  In 
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his method the primary amine in 3.28a-c at P1 is converted into an iodide, as in 3.29a-c 
(step 1) by diazotization of Boc-Lys with sodium nitroprusside under basic aqueous 
conditions to give the primary alcohol. This alcohol was converted to a bromide by 
treatment with triphenylphosphine (PPh3) and tetrabromomethane (CBr4) and the 
bromide converted to the iodide by refluxing with sodium iodide in acetone. The 
resulting tripeptide precursor 3.29a-c undergoes intramolecular cyclisation (step 2) with 
the halide in P3 being displaced by the phenol nucleophile in P1 to give the macrocycles 
templates 3.1a-c. 
 
 
 
Scheme 3.2. Synthesis of macrocycles 3.1a-c by intramolecular nucleophilic substitution.  
 
An advantage of this intramolecular nucleophilic substitution strategy, over the ring 
closing metathesis route, is that it avoids the use of the expensive Grubbs reagent. 
Clemene Buisan, a French summer undergraduate student in our group at UC 
investigated a small scale synthesis of CAT811 as shown in Scheme 3.3 using this 
methodology. This chapter describes the optimisation of this preliminary synthesis on a 
larger scale and the completion of the last step which was not undertaken. 4 We prepared 
1.5 grams of CAT811 by this route.  
 
A retrosynthetic analysis of CAT811 is shown in Figure 3.1 where cyclisation occurs by 
a reaction in which halide in P1 is displaced by the hydroxyl of the tyrosine residue in 
P3.5 The corresponding full synthetic route is shown in Scheme 3.3.  
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Figure 3.1. Retrosynthetic analysis of CAT811  
 
 
 
Scheme 3.3. Synthesis of CAT811 via intramolecular nucleophilic substitution  
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An EDCI6 mediated coupling of N-Cbz-Tyr-OH 3.2 with Leu-OMe 3.3, in the presence 
of HOAt and DIPEA, gave dipeptide 3.4 in 87%. The formation of 3.4 was confirmed by 
1H NMR analysis as shown in Figure 3.2, which revealed key resonances at 4.51 and 4.42 
ppm corresponding to α-protons of tyrosine and leucine respectively. 
 
 
 
Figure 3.2. 1H NMR spectrum of dipeptide 3.4 showing two α-protons. 
 
Hydrolysis of the methyl ester of dipeptide 3.4 was carried out in aqueous sodium 
hydroxide solution to give 3.5. The key compound 3.8 was prepared from commercially 
available Boc-Lys-OH 3.6 as shown in Scheme 3.3. In particular, diazotization of 3.6 
with sodium nitroprusside, under a basic aqueous conditions (pH 9), gave 3.7 in 33% 
yield.7 Simultaneous deprotection of N-Boc group and esterification of the carboxyl acid 
of 3.7, by reaction with thionyl chloride in the presence of methanol, gave the 
hydrochoride salt 3.8. Methanol reacts with thionyl chloride to give methoxy-sulfonyl 
chloride and releases hydrochloride acid. The acid sensitive tert-butoxycarbonyl group 
(Boc) of 3.7 is removed by acidolysis to give an ammonium salt, while the carboxyl 
group of 3.7 reacts with methyoxy sulfonyl chloride to form a carboxylic acid-sulfinic 
acid anhydride which facilitates nucleophilic substitution by methanol to give the desired 
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methyl ester. The resulting salt 3.8 was coupled with 3.5, in the presence of EDCI and 
HOAt, to give the tripeptide 3.9 in 87% yield, the structure of which was confirmed by 
the presence of three α-protons centred at 4.41, 4.38 and 4.32 ppm in the 1H NMR 
spectrum (Figure 3.3).  
 
 
Figure 3.3. 1H NMR spectrum of tripeptide Cbz-Tyr-Leu-Gly-OMe 3.4.  
 
The iodination of primary alcohol in 3.9 was next investigated. Iranpoor8 has reported the 
use of triphenylphosphine (PPh3), 2, 3-dichloro-5, 6-dicyano-1,4-benzoquinone (DDQ) 
and tetrabutyl ammonium halides for the conversion of alcohols, thiols and selenols into 
alkyl halides. The main advantage of this method is that it can be applied to the 
preparation of an alkyl halide from alcohols that contain other reactive functional groups, 
including carbon-carbon double bonds, carbonyl, amino, ethereal bonds. The use of a 
halide as a quaternary ammonium salt is safer and more convenient on a large scale 
synthesis relative to the use of molecular halogen.9 Moreover this method shows high 
selectivity for conversion of a primary alcohol into the corresponding alkyl iodide. For 
example, the conversion of phenol to the corresponding halide is as expected not 
observed under these conditions. This method allows for the conversion of the primary 
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alcohol in 3.9 into the corresponding iodide (3.10) in the presence of phenol group of 
tyrosine.  
 
 
 
Scheme 3.4. Iodination of 3.9 to 3.10 via Iranpoor’s method. 
 
It proved more efficient to iodinate alcohol 3.9 directly using tetrabutylammonium iodide 
(TBAI), DDQ, and PPh3. The mechanism proposed for the formation of 3.10 is shown in 
Scheme 3.5. The triphenylphosphine oxide by-product is separated from the iodide by 
recrystallisation from ethyl acetate and pentane.  
 
 
 
Scheme 3.5. Proposed mechanism of iodination of primary alcohol 3.9 to give alkyl 
iodide 3.10. 
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Macrocyclisation of 3.10 was investigated by nucleophilic displacement of the iodide by 
the hydroxyl of the phenol group of the tyrosine. Macrocyclisation was first attempted on 
a small scale (100 mg) by treatment of 3.10 with the amine base DIPEA in DCM (Table 
3.1). However, only starting material was isolated after 16 h. The use of K2CO3 in 
toluene proved effective and gave macrocyclic product in 64% yield after 
chromatography. The use of K2CO3 in DMF or acetonitrile gave the somewhat improved 
yield of 67% and 68%, respectively. The best yield obtained was for reaction using 
K2CO3 in the presence of a catalytic quantity of Cs2CO3 (Table 3.1). A large scale 
reaction (> 5 g) under these conditions gave the desired macrocycle 3.11 in 70% yield 
after purification by recrystallisation from ethyl acetate and pentane.  
 
Table 3.1. Conditions for the macrocyclization of 3.10 
Base Solvent Temperature/Time Yield  
DIPEA DCM Reflux/16 h 0% 
K2CO3 Toluene Reflux/16 h 64% 
K2CO3 DMF Reflux/16 h 67% 
K2CO3 MeCN Reflux/16 h 68% 
K2CO3/Cs2CO3 MeCN Reflux/16 h 70% 
 
The final steps in the synthesis of CAT811 (Scheme 3.3) involve the reduction of the C-
terminal methyl ester of 3.11 to the alcohol 3.12, followed by oxidation to give the 
desired aldehyde 3.1. LiAlH4 was used for this on a small scale, see Scheme 2.7.10 
However, LiAlH4 reacts violently with water and the solvent can readily catch fire in the 
presence of moisture thereby limiting its use in large scale synthesis. NaBH4 is easy to 
handle and its reducing power towards esters can be enhanced with the addition of metal 
salts, for example AlCl3, ZnCl2 and LiCl.11 
 
Reduction of ester 3.11 was therefore carried out using NaBH4 in the presence of various 
salts including AlCl3, ZnCl2 and LiCl to give the desired alcohol 3.12 in isolated yields of 
9%, 36% and 90%, respectively. NaBH4 reacts with LiCl to give LiBH4 which allows for 
the reduction of ester. The reaction conditions were further optimised by directly using 
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LiBH4 in THF and this gave an improvement in the yield after recrystallisation from ethyl 
acetate of 3.12 (97%, see entry 4 in Table 3.2). 
 
It has also been reported12 that the Lewis acid B(OMe)3 can catalyse the reduction of an 
ester by LiBH4. The borane-based Lewis acid B(OMe)3 is thought to function by 
coordination with the carbonyl oxygen to increase the electron deficiency of the carbonyl 
carbon thereby facilitating attack by borohydride. The use of LiBH4 with B(OMe)3 gave a 
somewhat improved yield of 12 (98%, see entry 5 in Table 3.2).  
 
Table 3.2. Varying conditions for the reduction of 3.11 
Entry  Reducing agent Solvent Additive  Yield  
1 NaBH4 THF AlCl3 9% 
2 NaBH4 THF ZnCl2 36% 
3 NaBH4 THF LiCl 90% 
4 LiBH4 THF - 97% 
5 LiBH4 THF (MeO)3B 98% 
 
The alcohol 3.16 was then oxidized to CAT811 (75%) using dimethyl sulfoxide (DMSO) 
in the presence of SO3·pyridine complex.13 DMSO is first activated by the electrophlic 
SO3.Pyr to form a sulfonium species and the activated DMSO functions as an oxidizing 
reagent for oxidation of a primary alcohol to an aldehyde (Scheme 3.6). The sulfonium 
species contains a good leaving group linked to the electrophilic sulfur atom. The leaving 
group is displaced by alcohol to give an alkoxydimethylsulfonium salt which is followed 
by deprotonation by DIPEA to form the sulfur ylide. Intramolecular elimination leads to 
the formation of aldehyde and dimethyl sulfide. 
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Scheme 3.6. DMSO oxidation with sulphur trioxide pyridine as an activating reagent. 
 
 
3.3: Attempted synthesis of the related 19-membered Tyr-Leu-Ser based 
macrocycle 3.21  
 
Oxygen and sulfur are isosteric having identical outer shells of electrons resulting in 
some chemical and physical similarity.14 Isosteres are commonly used in drug design to 
vary the characteristics of molecules including size, polarity, electronic distribution and 
H-bonding characteristics. For example, Davies15 reported that the sulfur and oxygen 
isosteres can affect the binding affinity and biological activity of melatonin 3.22 and N-
acetyl 5-ethoxytryptamine 3.23 against human and amphibian melatonin receptors. The 
replacement of the oxygen atoms in 3.22 and 3.23 with sulfur gives analogues 3.24-3.27 
which show decreased binding affinity and reduced potential on biological assay. For 
example, introducing sulfur in place of the amide oxygen (compound 3.24) and methoxy 
oxygen (compound 3.25) results in ca 2.5-fold and 35-fold reduction in bonding affinity 
to human melatonin receptors, respectively. 
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A preparation of 19-membered macrocycle 3.21 was attempted using an analogous 
procedure to that discussed in the previous section for the preparation of CAT811. This 
derivative is an analogue of the known macrocycle 1.23a1, with the sulfur replaced by 
oxygen at the P1 position. The 19-membered macrocycle 1.23a is reported to have 
modest activity against both calpain 1 (IC50 = 3.15 µM) and calpain 2 (IC50 = 1.01 µM) 
(see 1.4.2, Chapter 1).  
 
 
 
The intramolecular nucleophilic substitution methodology developed for the synthesis of 
the 17-membered macrocycle CAT811, was therefore investigated in our attempted 
synthesis of the 19-membered macrocycle 3.21. A retrosynthetic analysis of 3.21 
(Scheme 3.7) suggests that macrocyclisation would be achieved by sequentially 
nucleophilic substitutions of 1,4-dibromobutane 3.17 by the phenol of tyrosine and the 
serine hydroxyl group of 3.18. The phenol is more acidic and hence alkylation of the 
phenol of tyrosine with the appropriate alkyl halide would be expected to occur in the 
presence of K2CO3 and Cs2CO3 (see Table 3.1). A stronger base would be required to 
deprotonate the serine hydroxyl before reaction with dibromobutane 3.17. The attempted 
synthesis of 3.21 was shown in Scheme 3.8.  
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Scheme 3.7. Retrosynthetic analysis of macrocycle 3.21.  
 
A synthetic route to macrocycle 3.21 based on an intramolecular nucleophilic substitution 
reaction is shown as Scheme 3.8. The route commenced with the coupling of N-Cbz-Tyr-
OH 3.2 and Leu-OMe 3.3 in the presence of EDCI/HOAt to give the dipeptide 3.4 in 
85% yield. Hydrolysis of the methyl ester of 3.4, under basic conditions, followed by 
coupling with Ser-OtBu 3.14 in the presence of EDCI and HOAt, gave the tripeptide 3.16 
in 78% yield.  
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Scheme 3.8. Attempted synthesis of 19-membered serine based macrocycle 3.21. 
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The formation of 3.16 was confirmed by a parent ion in a mass spectrum at 572.23 m/z 
and three α-protons at 4.45, 4.55 and 4.58 ppm in the 1H NMR spectrum (see Figure 3.4). 
The intermediate 3.14 was prepared by hydrogenation of commercially available N-Cbz-
Ser-OtBu 3.13 under a hydrogen atmosphere in the presence of palladium on carbon.  
 
 
 
Figure 3.4. 1H NMR spectrum of tripeptide 3.16 showing three α-protons.  
 
Selective alkylation of the phenol of 3.16 was attempted by reaction with 1,4-
dibromobutane 3.17 in the presence of K2CO3 and Cs2CO3. Alkylation gave the desired 
product 3.18 in 53% yield after purification by chromatography on silica. The molecular 
formula of 3.18 was confirmed by a parent ion in a mass spectrum at 728.2 m/z (MNa+). 
The formation of 3.18 was confirmed by a Heteronuclear Multiple Bond Correlation 
(HMBC) experiments. As shown in Figure 3.5, H1 with a resonance at 3.90 ppm is 
coupled with C2 (two bond distant) and C3 (three bond distant) and in particular with one 
aromatic C-H carbon namely C5 (159.2 ppm) which is three bond distant. It is the 
coupling with C5 that defines that alkylation has occurred at phenol.  
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Figure 3.5. HMBC spectrum of compound 3.18. Selected proton resonances H1 and H4 
are labelled at the side of the spectrum and selected carbon resonances are labelled beside 
the coupled peak.  
 
H4 at δ 3.45 ppm is only coupled with C2 and C3 confirming that substitution only 
occurred at the phenol (compound 3.18). H4 would also have been coupled with the 
serine CH2 group (namely C6) if alkylation had occurred on both the phenol and serine 
hydroxyl in forming the macrocycle 3.19. 
 
          
 
An intramolecular alkylation of serine hydroxyl of 3.18 was first attempted in the 
presence of NaH in anhydrous DMF. However, only starting material was isolated under 
these conditions as evidenced by the NMR spectrum of the crude reaction mixture. 
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Further attempts to prepare 3.19 involved conversion of alkyl bromide 3.18 to the alkyl 
iodide 3.20 as the iodide would be a better leaving group. The formation of 3.20 was 
confirmed by the 1H NMR, which revealed a shift in the chemical shift of H4 protons 
from δ 3.42 ppm in bromide 3.18 to δ 3.28 ppm in iodide 3.20 (Figure 3.6). Base induced 
cyclisation of 3.20, however, again only gave starting material.  
 
 
 
 
 
Figure 3.6. Conversion of bromide 3.18 into iodide 3.20.  
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3.4: Conclusion 
 
A new route to CAT811 is reported in this chapter involving an intramolecular 
nucleophilic substitution reaction as a key step.  The overall sequence required seven 
steps compared to nine steps in the original route involving ring closing metathesis, see 
Chapter 2. The RCM-based route to CAT811 gives an overall yield of 12% which was 
increased to 21% using the intramolecular nucleophilic substitution sequence. In addition, 
this new route is economically viable as it avoids the use of Grubbs catalyst. The reaction 
conditions, particularly for iodination, macrocyclisation, and reduction steps, were 
examined and optimized to give high yields. The reaction intermediates generated were 
either used without purification, or were readily purified by recrystallisation to negate the 
need for chromatography. The new route also avoids reactions that require the use of 
potentially hazard and toxic reagents.  
 
An intramolecular nucleophilic substitution methodology developed for the efficient 
synthesis of CAT811, was also applied in an attempted synthesis of 19-membered 
macrocycle 3.21. This involved reaction of 1,4-dibromobutane with the phenol of 
tyrosine at P3 and hydroxyl group of a serine at P1 in tripeptide 3.16. Alkylation of the 
phenol group, under the conditions developed for the synthesis of CAT811 proceeded 
well in the presence of K2CO3 and Cs2CO3 to give alkyl bromide 3.18 in 67% yield. 
Alkylation of serine hydroxyl group with alkyl bromide was first attempted in the 
presence of NaH in acetonitrile; however reaction gave only starting material. Alkyl 
bromide 3.18 was then converted into alkyl iodide 3.20 with a better leaving group in 
attempt to facilitate the subsequent intramolecular cylisation, but again there was no 
evidence of the desired macrocycle by NMR studies of the crude reaction material.   
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Chapter 4: Synthesis of histidine containing macrocyclic 
calpain inhibitors 
 
4.1: Introduction  
 
Molecular modelling studies on the 16-19 membered macrocycles 1.20-1.23 showed that 
they are constrained into a β-strand geometry, a conformation universally adopted by 
inhibitors of proteases as discussed in Chapter 1.1 These aldehydes, 1.20a-1.23a, and the 
corresponding alcohols, 1.20b-1.23b, were prepared by previous members of the research 
group and assayed against ovine calpain 1 and 2, with the results reported in Chapter 1. 
These studies showed the 17-membered aldehyde 1.21a (CAT811) to be particularly 
potent against o-calpain 2 with an IC50 value of 30nM and a seven-fold selectivity for o-
calpain 2 over o-calpain 1 (220 nM). The synthetic precursor to CAT811, namely alcohol 
1.21b, displayed nanomolar inhibitory activity against o-calpain 2 (700 nM) with less 
potency for o-calpain 1 (1750 nM). As discussed earlier, CAT811 shows promise in the 
treatment of cortical cataract in lambs, with a genetic predisposition to cataract 
development.2  
 
 
In this chapter we report a study on imidazole analogues of CAT811, which contain an 
imidazole in place of the benzene ring, in an attempt to expand the available macrocyclic 
protease inhibitors and to better understand the structural features that lead to potent 
inhibition. The imidazole ring within histidine derivatives has aromatic characteristics 
and an ability to be a hydrogen bond donor and acceptor. 3 Thus the incorporation of an 
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imidazole ring in the macrocycles 4.1-4.3 may influence binding interactions within the 
binding site of calpain as discussed below. 
 
 
4.2: Molecular modelling of 4.1–4.3 
 
A conformational search on the target macrocycles 4.1a-c, 4.2a-c, and 4.3a-c was carried 
out at Canterbury by Wanting Jiao in order to assess their ability to adopt a β-strand (see 
Table 4.2). We were interested in using conformational analysis to determine if the 
position of the imidazole in the macrocycle influences the propensity of the macrocycle 
to adopt the critical β-strand geometry required for protease binding. Docking studies 
were also carried out using the established calpain 1 construct model developed by Dr 
Blair Stuart. 
 
Table 4.2. Molecular modelling results for histidine-based macrocycles 4.1a-c, 4.2a-c 
and 4.3a-c studies carried out with Wanting Jiao 
Compounds % β-strand Essential H 
bondsa 
Glide Score Emodel Score WHD 
Å 
4.1a 96.10 A,C +2 -6.05 -65.5 3.51 
4.1b 73.06 A,B,C +1 -7.48 -58.5 3.69 
4.1c 74.57 A,B,C +1 -6.05 -64.1 3.33 
4.2a 81.76 A,B +1 -4.38 -61.2 4.35 
4.2b 99.11 A,B,C +3 -6.24 -60.8 3.41 
4.2c 46.80 A,B,C +1 -5.72 -59.0 3.51 
4.3a 12.07 A,B +1 -5.42 -60.2 5.51 
4.3b 41.58 A +1 -6.17 -56.0 3.79 
4.3c 4.24 NONE +3 -5.93 -50.8 10.7 
a Hydrogen bonds from the carbonyl group of Gly208, the NH group of Gly208, and the carbonyl group of 
Gly271 of the o-CAPN1 homology model are labeled A, B and C respectively. b War head distance (WHD) 
is the distance between the warhead carbon and the active site cysteine sulfur in Å. 
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These computational studies revealed the following key points: 
 
i. Macrocyclic alcohols 4.1b and 4.2b and aldehydes 4.1c and 4.2c exhibit three 
essential hydrogen bonds (denoted as A, B and C) with Gly271 and Gly208 of the 
active site of calpain 1 that stabilize a β-strand conformation of the peptide chain 
(Figure 4.1).  
 
               
 
Figure 4.1. Representative bonding mode of 15-membered macrocyclic aldehyde 
4.1c with a histidine at P3. 
 
These three hydrogen bonds are also observed in X-ray crystal structures of leupeptin 
in a complex with the calpain 1 construct (1TL9), SNJ-1715 complexed with calpain 
1 construct (2G8E), E-64 conplexed with calpain 1 construct (1TL0) and AK-295-D2 
complexed with calpain 1 construct (2R9C) supporting the importance of these 
hydrogen bonds (see Figure 1.14, Chapter 1).  
 
ii. The warhead distance (WHD) for aldehydes 4.1c and 4.2c, as defined by the distance 
between the warhead carbonyl carbon and the active cysteine sulfur in Å, is less than 
4.5 Å. A distance of less than 4.5 Å is required for nucleophilic attack by the sulfur of 
cysteine for a reversible covalent inhibitor (Table 4.2).4  
 
iii. All nine compounds 4.1a-c, 4.2a-c and 4.3a-c have low energy Glide scores and 
Emodel Scores5,6 suggesting tight binding for the protein–ligand complex (Table 4.2).  
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iv. The macrocycles 4.1a-c and 4.2a,b have a high percentage of β-strand conformers 
(>70%) while the macrocycles 4.2c and 4.3b exhibit reduced 47% and 41% β-strand 
conformers, respectively. Macrocycles 4.3a,c did not adopt a β-strand conformation. 
The Boltzmann weighted percentage of β-strand for each macrocycle was based on 
the ψ (Psi) and φ (Phi) angles of the P2 leucine amino acid. Ramachandran plots of ψ, 
φ angles for β-strand or β-sheet regions of protein X-ray crystal structures show that 
typical ψ angles to be between 90º and 160º and that of φ angles to be between -90º 
and -160º (see Figure 1.16, Chapter 1).7 
 
v. Compounds 4.3a-c did not exhibit three essential hydrogen bonds with residues 
Gly271 and Gly208 of the active site binding pocket of µ-calpain. They do not appear 
to adopt a β-strand conformation. 
 
The macrocycles 4.1a-c, 4.2a-c and 4.3a-c were prepared and assayed against calpains as 
described in following sections in attempt to develop some structure-activity relationships 
and to investigate the validity of the modeling results. 
 
4.3: Synthesis of macrocycles 4.1-4.3  
 
A number of routes were considered for the preparation of the macrocycles. The first 
involved intramolecular nucleophilic substitution as was developed for the synthesis of 
CAT811, see Chapter 3. The key macrocyclic precursor 4.4 to the 15-membered 
macrocycles 4.1a-c required a histidine at P3 and a terminal alkyl iodide at P1. 
Macrocyclisation would then be achieved by intramolecular nucleophilic displacement of 
alkyl iodide with N-1 of the imidazole (Scheme 4.1). The corresponding full synthesis is 
shown in Scheme 4.3, however this methodology was not successful. 
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Scheme 4.1. Retrosynthesis of macrocycle 4.1a-c by intramolecular nucleophilic 
substitution. 
 
Two alternative routes to compounds 4.1a-c were also investigated involving an 
intramolecular lactamization of either 4.15 or 4.16, as shown in Scheme 4.2. The route 
(blue) involving 4.15 was investigated first and this proved successful. On this basis the 
alternative route involving 4.16 was not investigated.  
 
 
 
Scheme 4.2. Retrosynthesis of macrocycles 4.1a-c by intramolecular lactamization. 
 
 
 91 Chapter 4: Synthesis of histidine containing macrocyclic calpain inhibitors 
It was envisioned that the key precursor 4.15 (Scheme 4.2) would be prepared by 
alkylation at N-1 of the imidazole ring of Cbz-histidine 4.7 with alkyl halide 4.17 
followed by coupling with leucine derivative 4.20. Alternatively it could be prepared by 
coupling Cbz-histidine 4.7 with leucine 4.20 to give a dipeptide that would be alkylated 
on the imidazole with alkyl halide 4.17. The intramolecular lactamization methodology 
developed for the synthesis of 4.1a-c was then used to prepare 4.2a,b and 4.3a-c. This 
will be discussed in Sections 4.3.2 and 4.3.3. 
 
All the proposed syntheses of N-1 substituted histidine containing macrocycles 4.1, 4.2 
and 4.3 required specific alkylation at the N-1 of an imidazole of histidine derivatives as 
shown in Figure 4.2. However, imidazoles exist as a tautomeric mixture and as such 
alkylation can occur at either N-1 or N-3. The difficulty in separating such a mixture 
renders this route unattractive.  
 
 
 
Figure 4.2. N(1)-alkyl-histidine containing macrocycles 4.1, 4.2 and 4.3. 
 
However, it has been reported that alkylation of the imidazole of N-Boc-His with alkyl 
halide (RX) occurs specifically at N-1 using the base sodium hydride at -15oC in DMF.8 
This suggests that it should be possible to prepare our target macrocycles under similar 
conditions. 
 
 
 
 92 Chapter 4: Synthesis of histidine containing macrocyclic calpain inhibitors 
4.3.1: Synthesis of 15-membered macrocycles 4.1a-c  
 
The synthesis of the 15-membered macrocycles 4.1a-c by intramolecular nucleophilic 
substitution was first attempted as shown in Scheme 4.3. The sequence began as follows. 
EDCI-mediated coupling of commercially available Cbz-histidine 4.7 with Leu-OMe 4.8 
gave dipeptidyl ester 4.9 in 88% yield. The methyl ester of 4.9 was hydrolysed under 
basic conditions, however the resulting carboxylic acid 4.10 proved to be highly water 
soluble and we were thus unable to extract it from the crude reaction mixture. The crude 
reaction product, after evaporation of the water, was therefore used in subsequent 
coupling with 4.13 in an attempt to prepare the less polar tripeptide ester 4.14. The 
required alcohol 4.13 was prepared by the reaction of N-Boc-Lys-OH 4.11 with sodium 
nitroprusside to give 4.12 in 33% yield. This was followed by removal of NBoc group 
and esterification by treatment with thionyl chloride, in the presence of methanol, to give 
the hydrochloride salt 4.13.  
 
Coupling of the crude sample of dipeptide 4.10 with the hydrochloride salt 4.13, in the 
presence of EDCI/HOAt, proved to be unsuccessful with only starting material being 
isolated. This route was not explored further because of the high aqueous solubility of 
4.10 and the associated problems.  
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Scheme 4.3. Attempted synthesis of 15-membered histidine containing macrocycles 
4.1a-c by intramolecular nucleophilic substitution.  
 
The next method investigated involved the intramolecular lactamization shown in 
Scheme 4.4. The route began with treatment of Boc-lysine 4.11 with sodium 
nitroprusside. Esterification of the resulting amino acid derivative 4.12, under basic 
conditions, gave (S)-2-tert-butoxycarbonylamino-6-hydroxy-hexanoic acid methyl ester 
4.18 in 65% yield. Iodination of 4.18 was then attempted by reaction with PPh3, DDQ, 
and TBAI, not shown in the Scheme. Purification of the resulting reaction mixture by 
column chromatography gave only a trace amount of product 4.17 based on an NMR 
 94 Chapter 4: Synthesis of histidine containing macrocyclic calpain inhibitors 
analysis. The presence of 4.17 was confirmed by the signal in mass spectrum at 387.2365 
m/z. 
 
 
 
Scheme 4.4. Intramolecular lactamization for the synthesis of 15-membered macrocycles 
4.1a-c. 
 
By contrast, iodination of 4.18 with PPh3 (1.5 equiv), I2 (1.5 equiv) and imidazole (1.6 
equiv) gave a 66% yield of 4.17 after purification by chromatography on silica gel, see 
Scheme 4.4.  
 95 Chapter 4: Synthesis of histidine containing macrocyclic calpain inhibitors 
Alkylation of Cbz protected histidine 4.7 with alkyl halide 4.17 was then carried out in 
the expectation that it would occur at N-1. However, a mixture of mono- and di- 
alkylation was observed as revealed by mass spectrometry, see Figure 4.3. This mixture 
proved challenging to separate because of the high polarity of 4.19a and 4.19b 
(C38H58N5O12+ (M+.-I-) 776.4094 m/z; calculated 776.4076 m/z) and as such this route 
was abandoned. 
  
 
Figure 4.3. Mass spectrum of a mixture of mono and di alkylation. 
 
A second lactamization-based route to the 15-membered macrocycles 4.1a-c as shown in 
Scheme 4.5 proved to be more successful. This involved coupling of Cbz-histidine 4.7 
with leucine tert-butyl ester 4.20 to give the dipeptide 4.22 in 89% yield. The imidazole 
ring of 4.22 was then deprotonated with NaH at a low temperature in DMF and the 
resulting anion alkylated with previously prepared alkyl halide 4.17 to give 4.21 in 50% 
yield after purification by chromatography on silica gel.  
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Scheme 4.5. Synthesis of 15-membered macrocycles 4.1a-c via intramolecular 
lactamization.  
 
Selective alkylation of 4.22 at N-1 to give 4.21 was confirmed using a Heteronuclear 
Multiple Bond Correlation (HMBC) experiment, which correlates 1H and 13C resonances 
for atoms separated by 2-3 bonds with suppression of 1-bond correlations. The HMBC 
spectrum of 4.21 (Figure 4.4) shows that H6 at 3.90 ppm is coupled with C7 (a 2-bond 
coupling), and with C8 and two imadazole carbons namely C2 (137.1 ppm) and C5 
(117.8 ppm) (all involve three bond coupling). Correlation from H6 to imidazole carbon 
C4 is not apparent, which is a four bond coupling. These observations are consistent with 
the structure of compound 4.21 that is the result of specific alkylation on N-1 position of 
4.22.   
 97 Chapter 4: Synthesis of histidine containing macrocyclic calpain inhibitors 
 
 
Figure 4.4. HMBC spectrum of compound 4.21. Selected proton resonances H6 are 
labeled at the side of the spectrum and selected carbon resonances are labeled beside the 
coupled peak. 
 
If substitution had occurred on N3 to give the alternative isomer 4.23 with its structure 
shown below, coupling would not be observed between H6 and the C5 of the imidazole 
as this represents a 4 bond distance. However, one would expect to observe coupling with 
C4, C2, C7 and C8. However such correlations were not observed in the HMBC 
spectrum (see Figure 4.4) which demonstrates that alkylation has occurred at (N-1) 
position of imidazole ring. 
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The tert-butyl and N-Boc protecting groups of 4.21 were removed by acidolysis with 
trifluoroacetic acid to give 4.15 in almost quantitative yield. Intramolecular lactamization 
of compound 4.15 was then carried out by treatment with HATU to give macrocycle 4.1a 
in 52% yield after purification by chromatography. The molecular formula of tripeptide 
4.1a was confirmed by a parent ion in the mass spectrum at 528.2830 m/z. The 1H NMR 
spectrum (Figure 4.5) shows key resonances centered at δ 4.64, 4.54, and 4.35 ppm, 
corresponding to the three α-protons of leucine, tyrosine and glycine derivatives in 4.1a, 
respectively. Two multiplets centered at 4.23 and 4.12 ppm correspond to the H4 
methylene.  
 
 
Figure 4.5. 1H NMR spectrum of 15-membered macrocyclic ester 4.1a. 
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The final steps in synthesis of 4.1c involved reduction of the ester 4.1a to the alcohol 
4.1b, and oxidation to aldehyde (see Scheme 4.5). The best established conditions 
developed for the reduction of 3.11 (see Table 3.2, Chapter 3) were used here. Thus 
reduction of methyl ester of 4.1a, in the presence of LiBH4 (2 equiv) in THF, gave 4.1b 
in 98% yield after recrystallisation from ethyl acetate. The structure of the alcohol 4.1b 
was confirmed by 1H NMR spectroscopy, with the absence of a resonance for a methyl 
ester (as in 4.1a) and the appearance of resonances centered at 3.16 and 3.23 ppm 
corresponding to two protons adjacent to the hydroxyl group.  
 
Oxidation of primary alcohol 4.1b was first attempted using DMSO and sulphur trioxide-
pyridine complex as the oxidant. However, this gave only starting material. DMSO-based 
oxidation on a small scale has been reported9 using a sacrificial amount of iso-propyl 
alcohol to allow larger quantities of reagent to be used. However, attempted oxidation 
under these conditions gave only returned starting material.  
 
Dess-Martin periodinane 4.26 has been reported10 for the oxidation of primary and 
secondary alcohols to the corresponding aldehyde or ketone. The preparation of this 
reagent is shown in Scheme 4.6. 2-Iodobenzoic acid 4.24 was treated with potassium 
bromate in sulphuric acid to give the cyclic tautomer of 2-iodobenzoic acid 4.25 (93%). 
Treatment of the intermediate 4.25 with acetic anhydride and acetic acid gave the desired 
Dess-Martin periodinane 4.26 in 72%. 
 
 
 
Scheme 4.6. Synthesis of Dess-Martin periodinane 4.26. 
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Dess-Martin oxidation of 4.1b, in the presence of 4.26 (2 equiv) in dichloromethane, was 
successful and gave the desired aldehyde 4.1c however in a low yield (< 10%) using 
Dess-Martin periodinane that I have prepared. A sample was send to Ashok Pehere in 
Adelaide who used a commercially available Dess-Martin periodinane 4.26 and obtained 
a improved yield (67%). . 
 
4.3.2: Synthesis of 16-membered macrocycles 4.2a,b 
 
The methodology developed to prepare the 15-membered macrocycles 4.1a-c was then 
applied to synthesis of 16-membered macrocycles 4.2a-c as shown in Scheme 4.7.  The 
key acyclic precursor 4.5 was prepared by alkylation of Cbz-His-Leu-OtBu 4.22 with 
alkyl halide 4.27.  
 
 
 
Scheme 4.7. Retrosynthesis of 16-membered histidine containing macrocycles 4.2a-c. 
 
The iodo compound 4.27 was prepared from Boc-lysine 4.11 as shown in Scheme 4.8. 
Treatment of 4.11 with sodium nitroprusside, followed by methylation with methyl 
iodide gave (S)-2-tert-butoxycarbonylamino-hex-5-enoic acid methyl ester 4.29 in 68% 
yield. Cross metathesis of 4.29 with allyl alcohol in presence of the second generation 
Grubbs catalyst gave a poor yield (< 10%) of (S)-2-tert-butoxycarbonylamino-7-hydroxy-
hept-5-enoic acid methyl ester 4.32. The proposed route to 4.27 involving cross 
metathesis of 4.29 with allyl alcohol was abandoned because of this low yield.  
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Scheme 4.8. Synthesis of alkyl iodide 4.27. 
 
However, an alternative route to 4.27, involving cross metathesis of 4.29 with an excess 
allyl chloride and 10 mol% Grubbs catalyst as a key step, proved to be successful (see 
Scheme 4.8). This gave (S)-2-tert-butoxycarbonylamino-7-chloro-hept-5-enoic acid 
methyl ester 4.30 in 60% yield. The chloride 4.30 was converted to alcohol 4.32 in two 
steps according to the Eustache’s method. 11. Hydrogenation of the allylic alcohol 4.32, 
over platinum oxide in a hydrogen atmosphere, gave the saturated alcohol 4.33 in 92% 
yield.12 Iodination of the primary alcohol of 4.33 in presence of iodine, PPh3 and 
imidazole gave 4.27 in 61%. 
 
The imidazole N-1 of dipeptide 4.22 was deprotonated with sodium hydride at -15oC in 
DMF and the resulting anion alkylated with alkyl halide 4.27 (2 equiv) to give 4.35 in 
56% yield (see Scheme 4.9). The molecular formula of this was confirmed by a parent 
ion in a mass spectrum at 716.4 m/z. 
 102 Chapter 4: Synthesis of histidine containing macrocyclic calpain inhibitors 
 
 
Scheme 4.9. Synthesis of 16-membered macrocycles 4.2a and 4.2b with intramolecular 
lactamization.  
 
Monoalkylation occurred at N-1 of 4.22 to give 4.35 as confirmed by a HMBC 
experiment. The HMBC spectrum of 4.35 (Figure 4.6) reveals correlations from H6 (3.98 
ppm) to C7 (30.3 ppm) (2-bond coupling), and also to C8 (25.7 ppm) C2 (136.1 ppm) and 
C5 (118.1 ppm) which are three bond coupling. H6 is not coupled with the quaternary 
center C4 (137.0 ppm) which is four bonds removed.  
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Figure 4.6. HMBC spectrum of compound 4.35. Selected proton resonances H6 are 
labelled at the side of the spectrum and selected carbon resonances are labelled beside the 
coupled peak. 
 
If alkylation had occurred on N-3 of 4.22 to form the isomer 4.37. H6 would also have 
been coupled with imidazole carbon C4 (3-bond coupling) but not with C5, a 4-bond 
coupling. However these correlations were not observed in the HMBC spectrum (Figure 
4.6) that demonstrates the alkylation did not occur on N-3. 
 
 
 
 
 104 Chapter 4: Synthesis of histidine containing macrocyclic calpain inhibitors 
The tert-butyl and Boc protecting groups of 4.35 were removed by acidolysis, in the 
presence of trifluoroacetic acid, to give 4.36 in nearly quantitative yield. Intramolecular 
lactamization of 4.36, in the presence of HATU, then gave the macrocycle 4.2a in 50% 
after purification by chromatography. The formation of 4.2 was confirmed by the 
presence of a signal in its mass spectrum at 542.2979 m/z. The 1H NMR spectrum 
(Figure 4.7) shows the presence of three key overlapping α-protons at δ 4.42-4.52 ppm.  
 
 
 
Figure 4.7. 1H NMR of 16-membered macrocycle 4.2a. 
 
Reduction of the methyl ester of 4.2a with LiBH4 (2 equiv) in THF resulted in a 62% 
conversion to the alcohol 4.2b as determined by 1H NMR analysis of the crude product. 
However purification by column chromatography and recrystallisation failed to give the 
pure compound. Oxidation of crude alcohol 4.2b to 4.2c was therefore not attempted.  
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4.3.3: Synthesis of 15-membered macrocycles 4.3a-c 
 
The intramolecular lactamization was applied to the synthesis of macrocycle 4.3a-c. A 
retrosynthetic analysis of 4.3a-c (Scheme 4.10) suggests the pseudotripeptide 4.39 as a 
key intermediate, with the amine and carboxyl groups protected by N-Boc and t-butyl 
group, respectively. Both protecting groups are acid sensitive and can thus be 
simultaneously removed on treatment with trifluoroacetic acid to give 4.38. 
Intramolecular lactamization would then give the macrocycles 4.3a-c. The intermediate 
4.39 would be prepared by alkylation of the imidazole N-1 of 4.40 with alkyl iodide 4.41. 
 
 
 
Scheme 4.10. Retrosynthetic analysis of macrocycles 4.3a-c with histidine at P1. 
 
Such a protection methodology was also used in the synthesis of macrocycles 4.1a-c and 
4.2a,b (Scheme 4.11) as previously discussed in sections 4.3.1 and 4.3.2.  
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Scheme 4.11. Retrosynthesis of macrocycles 4.1a-c and 4.2a-c with histidine at P3.  
 
The alkyl iodide 4.41 was prepared from the commercially available N-Cbz-Lys-OH 4.42 
as shown in Scheme 4.12. The synthetic route required esterification of carboxylic acid of 
4.42 with t-butyl alcohol to give 4.45, the primary amine of which was converted to 
iodide 4.41. 
 
 
Scheme 4.12. Synthesis of alkyl iodide 4.41. 
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However esterification of 4.42 to 4.45, in the presence of EDCI or DCC, may lead to an 
intramolecular lactamization to give a seven-membered byproduct 4.47, see Scheme 4.13. 
Therefore the free amine of 4.42 was first protected with a 9-fluorenylmethyloxycarbonyl 
(FMOC) protecting group that is stable towards acid and catalytic hydrogenation, but 
readily removed under mildly basic conditions.13 Reaction of the primary amine of 4.42 
with 9-fluorenylmethyl chloroformate (Fmoc-Cl) gave 4.43 in 92% yield (Scheme 4.12).  
 
 
 
Scheme 4.13. A side reaction derived from the EDCI-mediated esterification of 4.42. 
 
Esterification of 4.43 with t-butyl alcohol was investigated using three coupling reagents 
as shown in Table 4.3.  
 
Table 4.3. Conditions for tert-butyl esterification of carboxylic acid 4.43. 
Coupling reagents  Solvents  Yields  
2,4,6-trichlorobenzoyl chloride, TEA, DMAP THF 0% 
DCC, DMAP DCM 45% 
EDCI, DMAP DCM 65% 
 
Yamaguchi esterification14 was attempted first. Here the carboxylic acid is reacted with 
2,4,6-trichlorobenzoyl chloride in the presence of triethylamine and the resulting 
anhydride reacted with t-butyl alcohol, in the present of DMAP, to give the t-butyl ester. 
However treatment of 4.43 under these conditions (Scheme 4.14) gave starting material 
as the only isolatable material. 
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Scheme 4.14. Yamaguchi esterification. 
 
A second method involving reaction of 4.43 with DCC/DMAP and tert-butanol gave the 
desired product 4.44 in 45% yield (see Scheme 4.15). The formation of 4.44 was 
confirmed by the presence of a singlet at δ 1.46 ppm in its 1H NMR spectrum 
corresponding to the tert-butyl ester group. A third method, involving esterification of 
4.43 with tert-butanol and EDCI and DMAP, proved to be the best coupling conditions  
and gave 4.44 in a 65% yield.15  
 
 
 
Scheme 4.15. DCC mediated tert-butyl esterification. 
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The Fmoc protecting group of 4.44 was removed on treatment with excess diethylamine 
in acetonitrile to give 4.45 in 90% yield, see Scheme 4.12. Diazotization of 4.45 gave 
hydroxy amino acid 4.46 (42%).16 Iodination of primary alcohol of 4.46 in the presence 
of iodine, PPh3 and imidazole gave alkyl iodide 4.41 in 62% yield. This route to 4.41 
(Scheme 4.12) required 6 steps and resulted in an overall yield of 14%. 
 
A more efficient preparation of 4.41 was effected by diazotization of primary amine 4.42 
to form the corresponding alcohol 4.48 in 45% yield, see Scheme 4.16. Esterification of 
4.48 with tert-butyl bromide, in dimethylacetamide (DMAC) in the presence of 
benzyltriethylammonium chloride (BTEAC) and potassium carbonate, gave 4.46 in 
89%.17 Iodination of 4.46, in the presence of PPh3, imidazole and iodine, gave the desired 
alkyl iodide 4.41 in 62%.  
 
This sequence to 4.41 (Scheme 4.16) involves three steps and proceeds in an improved 
overall yield of 25%. 
 
 
 
Scheme 4.16. A more efficient route to the synthesis of alkyl iodide 4.41. 
 
Coupling of commercially available His-OMe 4.49 with Boc-Leu-OH 4.50, in presence 
of EDCI/HOAt, gave dipeptide 4.40 in 85% yield (Scheme 4.17). The alkylation of the 
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imidazole ring of 4.40 with alkyl halide 4.17 was carried out in the presence of NaH in 
DMF to give the pseduotripeptide 4.39 in 41% yield. The molecular formula of 4.39 was 
confirmed by a parent ion at m/z 702.4044 in the mass spectrum. 
 
 
 
Scheme 4.17. Synthesis of 15-membered histidine containing macrocycles 4.3a-c 
 
The specificity of the alkylation at N-1 of dipeptide 4.40 was determined using 
established methodology discussed in Sections 4.3.1 and 4.3.2. An HMBC spectrum 
(Figure 4.8) shows that H6, at δ 3.94 ppm, is coupled with C7 (29.8 ppm) and C8 (22.6 
ppm) and with the imidazole carbon C5 (117.2 ppm) and C2 (136.7 ppm). However H6 is 
not coupled with C4 (137.0 ppm) which is four bonds removed. These observations are 
 111 Chapter 4: Synthesis of histidine containing macrocyclic calpain inhibitors 
consistent with the structure of compound 4.39 that is the result of specific alkylation on 
N-1 position of 4.40. 
 
 
 
Figure 4.8. HMBC spectrum of compound 4.39. Selected proton resonance H6 is 
labelled at the side of the spectrum and selected carbon resonances are labelled beside the 
coupled peak. 
 
If alkylation had occurred on the N-3 position to form an alternative isomer 4.51 as 
shown below, H6 would be coupled with C4 of the imidazole ring which is a 3-bond 
coupling, but not with C5 (a 4-bond coupling). However such correlations conflict with 
the assigned HMBC spectrum, see Figure 4.8.  
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Cyclisation of 4.39 was achieved by first the removal of its Boc and t-butyl groups 
followed by HATU mediated lactamization to give the macrocyclic methyl ester 4.3a in 
an overall yield of 51% (Figure 4.9). Reduction of the ester of 4.3a, with LiBH4 in THF, 
gave alcohol 4.3b in 72% yield. Dess-Martin oxidation of 4.3b was carried out by Ashok 
Pehere to give aldehyde 4.3c in 50% yield.  
 
 
 
Figure 4.9. 1H NMR spectrum of macrocycle 4.3a. 
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4.4: Biological assay of macrocycles 4.1a-c, 4.2a,b and 4.3a-c  
 
The Christchurch earthquake has resulted in delays in obtaining the assay results. This 
data has come to hand as I print the thesis. Macrocycles 4.1-4.3 were assayed against 
ovine calpain 2 by Dr Ondrej Zvarec. Esters 4.1a-4.3a show no activities (IC50  > 50 µM). 
 
Aldehyde 4.3c has a moderate inhibitory activity with an IC50 of 1 µM and the 
corresponding alcohol 4.3b shows no activity, consistent with the modelling reported 
above which indicated that these two compounds did not adopt a β-strand conformation 
in the docking studies.   
 
Aldehyde 4.1c, on the other hand, shows significant inhibitory activity with an IC50 of 
238 nM but as expected the corresponding alcohol 4.1b shows little activity (IC50 = 29 
µM). Modelling studies showed that both the aldehyde 4.1c and the alcohol 4.1b on 
docking can form a β-strand with appropriate H-bonding interactions. The aldehyde is 
more active than the alcohol due to the reactivity of the aldehyde warhead allowing for 
the reversible formation of a hemiacetal. A similar difference in reactivity is observed for 
CAT811 (30nM) and its alcohol analogue (700nM). 
 
4.5: Conclusion 
 
Molecular modelling with the calpain 1 construct model show that macrocyclic alcohols 
4.1b and 4.2b and aldehydes 4.1c and 4.2c bind in the active site in a β-strand 
conformation and with appropriate warhead distance and low negative Glide scores and 
Emodel scores. On the basis of these results, macrocycles 4.1a-c and 4.2a-c were chosen 
for synthesis and biological evaluation. To develop structure-activity relationships and to 
investigate the validity of the modelling, macrocycles 4.3a-c (where modelling suggested 
they could not bind in a β-strand conformation) were also prepared. 
 
We have investigated strategies for the synthesis of macrocycles 4.1-4.3. An 
intramolecular nucleophilic substitution methodology, developed for an efficient large 
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scale synthesis of CAT811, was unsuccessful for the preparation of 4.1 as a key 
intermediate 4.10 could not be isolated and purified. An alternative synthetic route to 4.1 
was investigated involving intramolecular lactamization. This methodology proved to be 
successful for the synthesis of 4.1, 4.2 and 4.3. The macrocycles 4.1-4.3 required 
alkylation on N-1 of the imidazole ring of the histidine derivatives 4.22 and 4.40. The 
selective alkylation was confirmed from 1H NMR analysis including Heteronuclear 
Multiple Bond Correlation (HMBC), HSQC, COSY, etc.  
 
The assay results above demonstrate the value of molecular modelling as a screening 
mechanism before unproductive synthetic work is considered. 
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Chapter 5: A study on a water soluble polyethylene glycol 
immobilized ruthenium catalyst 
 
5.1: Introduction 
 
Ruthenium-based catalysts 1.28 and 1.29 are widely used in a range of organic solvent-
based olefin metathesis reactions because of their high functional group tolerance and 
ease of handling (e.g. see section 1.5.1 in Chapter 1). Catalyst 1.29 shows increased 
stability and activity when compared to 1.28, which has been attributed to electron 
donating ability and the steric bulk of the NHC ligand.1 Hoveyda and co-workers 
reported a further advancement in catalyst design with the complex 5.1, where a 
remaining phosphine ligand is replaced by a chelating ether, further decreasing the air 
sensitivity of the catalyst and improving catalyst stability.2 
 
 
 
We considered that alkene metathesis in aqueous media3,4 would be useful for the 
preparation of water soluble examples of the macrocyclic-based calpain inhibitors 
discussed in the previous chapters of this thesis. However, the low water solubility of 
existing catalysts limits their use under these aqueous conditions. A number of water-
soluble catalysts have been reported5 and these have been used for alkene metathesis in 
aqueous solution. Catalysts 5.2 and 5.3 were developed by substituting a hydrophobic 
phosphine in 1.28 with electron-rich, cationic phosphine.6 These catalysts are completely 
soluble in water and methanol mixtures and they have been shown to catalyze the ROMP 
of compounds 5.4 and 5.6 in water, methanol and aqueous emulsions (Scheme 5.1). The 
catalyst 5.3 is more active for RCM in water and methanol compared to 5.2.  
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Scheme 5.1: ROMP of compounds 5.4 and 5.6 in water, methanol and aqueous 
emulsions in the presence of catalyst 5.2 and 5.3. 
 
Grubbs and coworkers7 have reported the aqueous soluble polymer-supported catalyst 5.8 
which has a polyethyleneglycol (PEG) attached to the N-benzyl NHC of catalyst 1.29 
rendering it soluble in water and some organic solvents such as dichloromethane and 
toluene, but insoluble in diethyl ether. Catalyst 5.8 can therefore be recovered and reused 
from alkene metathesis product by simple extraction from diethyl ether thereby being 
economically attractive. 8  The ROMP of 5.9 with catalyst 5.8 gave 5.10 in 73% 
conversion after 24 h. Further conversion was not observed after additional 12 h, 
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however, reaction in the presence of 1 equiv of HCl gave an improved conversion (95%) 
after 12 h.  
 
 
 
Scheme 5.2: ROMP of 5.9 with catalyst 5.8.7 
 
Hong and Grubbs9 reported 5.11 formed by linking the PEG to the NHC backbone of a 
Hoveyda-Grubbs type catalyst. This catalyst shows significant activity in catalyzing the 
RCM in aqueous media. Jordon and Grubbs10 have also reported small-molecule water-
soluble catalysts 5.22 and 5.23 by attaching quaternary ammonium salts to the 
benzylidene, and NHC ligands respectively. Both catalysts are efficient for RCM, ROMP, 
and CM in water.  
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Grubbs10 has reported RCM of dienes (as shown in Table 5.1) with catalysts 5.11, 5.22 
and 5.23 in water. RCM of dienes 5.12 and 5.14 (Table 5.1) gave 5- and 6-membered 
ring compounds 5.13 and 5.15 in good yields. Cyclisation of diene 5.16 to 5.17 gave a 
satisfactory conversion with catalyst 5.22, but low conversions using 5.11 and 5.23. RCM 
of 5.18 with catalysts 5.11, 5.22 and 5.23 gave modest yields of the cyclic product, and 
RCM of 5.20 with 5.11, 5.22 and 5.23 give poor yields 
 
Table 5.1. RCM reactions in water. 
Catalysts Substrate Product Time (h) Conversion (%) 
 
5.11 
5.22 
5.23 
  
 
 
12 
24 
0.5 
 
>95% 
>95% 
>95% 
5.11 
5.22 
5.23 
  
 
24 
24 
4 
 
>95% 
>95% 
84% 
 
5.11 
5.22 
5.23 
  
36 
24 
6 
 
67% 
>95% 
36% 
5.11 
5.22 
5.23 
  
24 
24 
4 
42% 
70% 
26% 
 
5.11 
5.22 
5.23 
  
 
 
24 
24 
24 
 
<5% 
<5% 
<5% 
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Grela and Connon 11, 12 also reported the diethylmethylammonium-substituted catalyst 
5.24 which shows moderate solubility in water, with similar activity to 5.22 and 5.23 for 
RCM and CM. Catalyst 5.24 also mediates RCM of dienes in homogeneous water/alcohol 
mixtures to give macrocycles in good and excellent yields. The high activity of catalyst 
5.24 is ascribed to the electron-withdrawing ammonium group that enhances the catalyst 
initiation rates.  
 
 
5.2: Studies on a new water soluble metathesis catalyst  
 
Work in the Abell group by Dr Shazia Zaman recently lead to development of the 
complex 5.25, which constitutes immobilization of Hoveyda-Grubbs catalyst 5.1 on a 
water soluble polyethylene glycol (PEG).5 This catalyst has been shown to have activity 
in RCM of various dienes in dichloromethane in air and an ability to be recycled. 13 For 
example, RCM of diene 5.26 under reflux in the presence of 10% catalyst 5.25 gave 
olefin5.27 in near quantitative conversion after 1 h. The addition of diethyl ether to the 
final reaction mixture precipitates the catalyst which can be filtrated and reused in the 
subsequent RCM. This sequence was repeated a further three times without significant 
loss in catalytic activity (see Table 5.2). 
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Table 5.2. Recyclability studies of catalyst 5.25 in RCM of diene 5.26. 
 
 
 
Cycle Conversion (%) 
1 >98 
2 95 
3 95 
4 90 
5 89 
 
We recently reported the results of using this catalyst 5.25 to promote RCM reactions of a 
range of dienes in water-organic solvent media.14 First, organic solvents were screened as 
co-solvent for RCM using catalyst 5.25 in aqueous media. RCM of the dienes 5.28 and 
5.30 were investigated using 5.25 in methanol/water, ethanol/water and acetone/water, in 
order to establish catalyst efficiency and to develop optimum conditions (Table 5.3). The 
dienes 5.28 and 5.30 were chosen as model compounds as they have been used in related 
studies.15 These dienes were then treated with 5 mol% of catalyst 5.25 at rt in the 
specified solvent system as shown in Table 5.3. Conversion to 5.29 and 5.31 was 
monitored after both 1 h and 16 h by 1H NMR analysis of the crude reaction.  
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Table 5.3. Studies of catalyst 5.25 in different aqueous systems in the RCM of diene 5.28 
(entry 1-3) and 5.30 (entry 4-6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a Determined by analysis of the crude 1H NMR spectrum. 
 
The results in Table 5.3 show acetone/water (2:1, v/v) is a good solvent system. Reaction 
of 5.28, in solvents acetone/water, methanol/water, ethanol/water, gave 73%, 42% and 
57% conversions to 5.29 respectively after 1 h which increased to 95%, 50% and 72% 
after 16 h (entry 1-3, Table 5.3).  
 
The conversion percentages were established by 1H NMR analysis of resonances in both 
diene 5.28 and cyclic alkene5.29 (Figure 5.1). For example, the 1H NMR spectrum for 
Entry Solvent (2/1) Time (h) Conversion (%)a 
1 Acetone/H2O 1 73% 
  16 95% 
2 1 42% 
 
MeOH/H2O 
 16 50% 
3 1 57% 
 
EtOH/H2O 
 16 72% 
4 Acetone/H2O 1 98% 
  16 98% 
5 1 88% 
 
MeOH/H2O 
 16 91% 
6 1 93% 
 
EtOH/H2O 
 16 94% 
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the reaction mixture in acetone/water after 1 h (Figure 5.1a) showed the presence of two 
resonances centered at 2.62 and 3.01 ppm, in the ratio of 1:2.7, corresponding to 
methylene protons H4 and H1 in diene 5.28 and cyclic alkene 5.29 respectively. The ratio 
of 1:2.7 represents the molar ratio of 5.28 to 5.29 in the crude and the reaction therefore 
gave an approximately 73% conversion. 
 
 
(a) 
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(b) 
 
 
(c) 
 
Figure 5.1. Investigation of the solvent systems for RCM of 5.28 by 1NMR analysis.  
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RCM of diene 5.30 was also investigated in solvents acetone/water, methanol/water, and 
ethanol/water, respectively. Similarly acetone/water solution also gave the best 
conversion of diene 5.30 to 5.31 (98%) which compares to methanol/water and 
ethanol/water systems with 91% and 94% conversion respectively (see entry 4-6, Table 
5.3). 
 
The efficiency of catalyst 5.25 for RCM reactions with a range of alkenes in 
acetone/water solution was then investigated. The substrates were prepared by Dr Shazia 
Zaman for the study of RCM reactions (Table 5.4). The N-tosyl based-dienes 5.32, 5.34, 
5.36, 5.38, β-amino acid derived dienes (5.40 and 5.42) and the water-soluble ammonium 
chloride based diene 5.44 were synthesized by Dr Zaman according to literature 
procedures.16,17  
 
The 1H NMR spectra of the RCM products 5.33, 5.35, 5.37, 5.39, 5.41, 5.43 and 5.45 
were compared with previously reported16,17,18,19 structures. The conversion to RCM 
products was evaluated by 1H NMR spectroscopy after both 1 h and 16 h reaction times 
(Table 5.4). All the reactions were carried out with 0.2 M of dienes in acetone and water 
solvent system (2:1) in the presence of 5 mol% of catalyst 5.25. The reaction mixture was 
stirred at rt without the exclusion of air.  
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Table 5.4. Ring closing metathesis of substituted olefins in acetone and water. 
Entry Substrates Product Time (h) Conversion (%)a 
 
1 
 
   
 
1 
16 
 
98% 
98% 
 
2 
  
 
 
1 
16 
 
 
95% 
98% 
 
3 
  
 
1 
16 
 
 
72% 
83% 
 
 
4 
 
 
 
 
 
1 
16 
 
 
52% 
71% 
 
 
 
5 
 
 
 
 
1 
16 
 
90% 
98% 
 
6 
  
 
1 
16 
 
67% 
72% 
 
 
7 
  
 
1 
16 
 
<5% 
35% 
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The catalyst shows significant efficiency in the ring-closing metathesis reaction to form 
both 5- and 6-membered N-containing heterocycles. For example, RCM of N-tosyldiallyl 
dienes 5.32 and 5.34 with catalyst 5.25 gave the 5- and 6-membered heterocycles 5.33 
and 5.35 in almost quantitative conversion after 1 h (Table 5.4, entries 1-2). Reaction of 
gem-disubstituted alkene 5.36 results in conversion to 5.37 in 72% after 1 h and 83% 
after 16 h (Table 5.4, entry 3). 
 
Catalyst 5.25 proved less efficient at forming a 7-membered heterocycle compared with 
5- and 6-membered rings. RCM of 5.38, under the above conditions, resulted in only 52% 
conversion to the 7-membered heterocycle 5.39 after 1 h. The conversion was increased 
to 71% after an extended 16h reaction.  
 
It appears that introducing a methyl ester substitution (not on the alkene) to the acyclic 
precursor diene, as in 5.40 (Figure 5.2), significantly enhances conversion to the 
heterocycle, with 90% conversion to 5.41 after only 1 h reaction. This observation is 
consistent with the well-known Thorpe Ingold effect20 which states that substitutions on 
acyclic precursors compress the internal angle (θ) of carbons in the open-chain structure, 
leading to the two reactive terminal groups closer to each other, thereby facilitating ring 
closure. The ester substitution on diene 5.40 (see Figure 5.2) results in a reduced internal 
angle (θ) of carbons in acyclic structure. This brings two terminal alkenes closer together 
and facilitates RCM of 5.40 to 5.41.  
 
 
Figure 5.2. Thorpe Ingold effect on diene 5.40. 
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The diene 5.42, which lacks an amine, underwent cyclisation less efficiently to give the 
5-memberred compound 5.43 in only 67% yield after 1 h (see entry 6, Table 2). Finally, 
RCM of the water soluble-diene substrate 5.44 in the presence of catalyst 5.25 resulted in 
a 35% conversion to the 5-membered heterocycle 5.45 after an extended 16 h reaction 
time (entry 7, Table 5.4).  
 
5.3: Conclusion  
 
In summary, catalyst 5.25 with a water soluble polyethylene glycol chain (PEG) 
positioned in Hoveyda-Grubbs catalyst 5.1 shows, like the Grubbs compound, RCM 
activity in aqueous solvent mixtures (acetone/water, ethanol/water, methanol/water: 2:1, 
v/v) with acetone/water being best. This catalyst 5.25 and solvent system, namely 
acetone/water, could be explored for the preparation of water soluble versions of the 
macrocyclic protease inhibitors discussed in this thesis and this work is currently 
underway in Adelaide. 
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H-bond for SJA-6017 and its alcohol precursor in the S3 
pocket of cysteine proteases  
 
6.1: Introduction 
 
SJA-6017 has been reported by Senju Pharmaceuticals Ltd1 to be a potent calpain 1 
inhibitor and is effective in preventing calcium-induced cortical cataract in rats (see 
Chapter 1). The inhibitory activity of SJA-6017 on two other cysteine proteases namely 
papain and cathepsin B shows that SJA-6017 is more potent toward cathepsin B (22 nM) 
than to calpain 1 (130 nM) and papain (23 nM) (Personal communication from Dr Jim 
Morton at the University of Lincoln). 
 
 
 
This difference of inhibitory activity of SJA-6017 was consistent with the computer 
docking studies by Wanting Jiao which showed compound SJA-6017 in the active sites 
of cathepsin B, calpain 1 and papain exhibited three hydrogen bonds between the peptide 
backbone and the enzyme active site residues, namely Gly66/Gly74/Gly208 and 
Asp158/Gly198/Gly271 respectively (Figure 6.1). These three hydrogen bonds are 
crucial for stabilisation of an inhibitor into a β-strand, a conformation that is generally 
recognised by active sites of proteases (see section 1.4, introduction).9 However, there 
was an additional H-bond formed between the fluorine of fluorobenzyl ring of SJA-6017 
and the NH group of Asp69 in the S3 pocket of cathepsin B (Figure 6.1a). This F-H bond 
was not observed for SJA-6017 when docked with papain and calpain 1. The extra H-
bond formed between SJA-6017 and cathepsin B would be expected to further stabilise 
the β-strand conformation of this compound in the active site resulting in a higher 
potency towards cathepsin B than to calpain and papain. 
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                   (a)                                                (b)                                           (c) 
 
Figure 6.1: Modelling results for Compounds SJA-6017 in active sites of (a) cathepsin (b) 
papain and (c) calpain 1. All structures are displayed in element colour scheme, where 
oxygen is in red, nitrogen in blue, sulphur in yellow, hydrogen in white, fluorine in green, 
and carbon in grey. H-bonding interactions are shown by yellow dashed lines. 
 
The F-hydrogen bond was not observed in modelling results for SJA-6017 in papain 
because the large tyrosine side chain 61 at the active site of papain is located at the same 
position as the hydrogen bonding Asp69 in cathepsin B (Figure 6.1b). The tyrosine side 
chain block with the fluorobenzyl ring of SJA-6017 such that the F atom is 4.268Å from 
the NH group of Tyr61, a distance too great for the formation a F-H bond.  
 
For calpain 1, the loop of cathepsin B that contains the H-bonding Asp69 residue to the 
fluorine atom is not present (Figure 6.1c) and therefore formation of the F-hydrogen bond 
at this position is not observed thereby accounting for the selectivity of SJA-6017 
towards cathepsin B as observed in the assay results. 
 
The assay results of the fluorobenzylsulfonyl alcohol 6.1, the synthetic precursor of SJA-
6017, was also selective for cathepsin B (9.2 µM) over calpain 1 (50 µM) and papain (> 
50 µM). These assay results are consistent with the molecular modelling studies which 
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show that an extra F-hydrogen bond was observed in the active site of cathepsin but not 
in papain and calpain 1. 
 
 
The alcohol 6.1 proved to be relatively more selective for cathepsin B than its 
corresponding aldehyde SJA-6017 (Table 6.1). For an inhibitor with a reactive warhead 
such as an aldehyde, the effect of the extra F-H interaction at the P3 position of the 
inhibitor will not be as important as for the alcohol inhibitors where bonding to the 
warhead is weaker and interaction relies on non-covalent interactions. Therefore, an extra 
F-hydrogen bond has a greater impact on the relative activity of the alcohols compared to 
the aldehydes.  
 
Table 6.1 
IC50 (µM) Compound 
papain cathepsin B calpain 1 
SJA-6017 0.023 0.022 0.13 
6.1 >50 9.2 50 
 
The results above led us to propose that the fluoro group of 6.1 and SJA-6017 may be 
important in forming a H-bond with the S3 pocket of the active site of cathepsin B. As 
such, removal of the fluoro group of SJA-6017 will be expected to result in a compound 
(6.9) that is less selective than SJA-6017 to cathepsin B. To investigate the validity of the 
modelling and develop a structure-activity relationship we prepared 6.8 and 6.9 as des-
fluoro analogues of 6.1 and SJA-6017, respectively. 
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6.2: Synthesis of alcohol 6.8 and aldehyde 6.9  
 
The synthetic route to dipeptide alcohol 6.8 and aldehyde 6.9 is shown in Scheme 6.1. 
Commercially available Val-OMe 6.2 was reacted with benzene sulfonyl chloride 6.3 to 
give 6.4 in an 82% yield. Hydrolysis of the ester 6.4 under basic conditions gave 
carboxylic acid 6.5 (95%). Coupling of 6.5 with the commercially available Leu-OMe 6.6 
in the present of EDCI and HOAt gave the dipeptide 6.7 (87%). The molecular formula 
of 6.7 was confirmed by a parent ion at m/z in mass spectrum and 1H NMR spectrum of 
this compound shows two resonances at 3.62 ppm and 4.32 ppm corresponding to α-
protons of valine and leucine. The ester group of 6.7 was reduced with LiBH4 to give 
alcohol 6.8 in 79%. Freshly prepared Dess-Martin periodinane2 was reacted with 6.8 to 
give aldehyde 6.9 (72%).  
 
 
 
Scheme 6.1. Synthesis of alcohol 6.8 and aldehyde 6.9. 
 
Samples of these two compounds have been submitted to Dr Jim Morton at Lincoln 
University for biological assay but the earthquake has delayed this work. 
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7.1: General Experimental Methods 
 
1H NMR spectra were recorded on an Inova 500 spectrometer operating at 500 MHz 
unless otherwise stated. Carbon NMR spectra were obtained on a Varian Unity XL 300 
MHz Fourier Transform spectrometer operating at 75 MHz. Chemical shifts are reported 
in parts per million (ppm, δ) referenced relative to the residual solvent peak; coupling 
constants are reported in Hz. Electrospray ionization (ESI) mass spectra were determined 
on a micromass liquid chromatography time of flight mass spectrometer, with a probe 
voltage of 3200 V, temperature of 150 oC and a source temperature of 80 oC. Direct 
ionization used 10 µL of a 10 µgmL−1 solution, using a carrier solvent of 50% 
acetonitrile/water at a flow rate of 20µL min−1. Ionization was assisted by the addition of 
0.5% formic acid. Melting points were obtained on an electrothermal melting point 
apparatus and are uncalibrated. TLC was performed on aluminium-backed Merck 
Kieselgel KG60F254 silica plates. Amino acid starting materials were purchased from 
GL Biochem (Shanghai) Limited. Reagents and other chemicals were purchased from 
Aldrich Chemicals. 
 
General procedure A1: 1-[3-(Dimethylamino)propyl]-3-ethylcarbodiimide hydro 
chloride (EDCI) mediated peptide coupling reaction. 
To a stirred solution of the N-protected amino acid derivative (1.0 equiv) in dry DMF 
(0.1-0.5 M) was added amine (1.1 equiv), DIPEA (2.4 equiv), EDCI (1.2 equiv) and 
HOAt (1.2 equiv). The solution was stirred at rt overnight, diluted with ethyl acetate and 
the organic layer washed twice with aqueous HCl (1 M), saturated aqueous NaHCO3 and 
brine. The organic layer was dried over MgSO4 and the solvent removed in vacuo. 
 
General Procedure A2: O-(7-azabenzotriazole-1-yl)-N,N,N’,N’-tetramethyluronium 
hexa fluorophosphate (HATU) mediated peptide coupling reaction.  
To a stirred solution of the N-protected amino acid derivative (1.0 equiv) in dry DMF 
(0.1-0.5 M) was added amine (1.1 equiv), DIPEA (2.4 equiv) and HATU (1.2 equiv). The 
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solution was stirred at rt overnight, diluted with ethyl acetate and the organic layer 
washed twice with aqueous HCl (1M), saturated aqueous NaHCO3 and brine. The organic 
layer was dried over MgSO4 and the solvent removed in vacuo. 
 
General procedure B: Ester hydrolysis with base. 
To a solution of the ester in methanol was added NaOH (4 equiv) pre-dissolved in water. 
The solution was heated to 65oC with stirring overnight. The aqueous layer was acidified 
to pH 2 with 1M HCl and the product extracted twice with ethyl acetate. The combined 
organic layers were washed with water, brine, and dried over MgSO4 and the solvent was 
removed in vacuo.  
 
General procedure C1: Ring closing metathesis under thermal reflux.  
To a solution of diene in anhydrous 1,1,2-trichloroethane (0.01 M) under an inert 
atmosphere was added Grubb’s second generation catalyst (10 mol %) and the mixture 
heated under reflux. After 1 h a second portion of catalyst (10 mol %) was added, and the 
mixture was heated for 1 h before the final portion (10 mol %) was added. The reaction 
mixture was heated under reflux for a further 16 h, cooled, stirred overnight with 
activated charcoal, filtered, and the solvent was removed in vacuo. 
 
General procedure C2: Ring closing metathesis under microwave reflux. 
To a solution of diene in anhydrous 1,1,2-trichloroethane (0.01 M) under an inert 
atmosphere was added Grubb’s second generation catalyst (10 mol %), and the reaction 
mixture was heated for 20 min in a microwave (1200 W, 110-115 °C). Two further 
portions of catalyst (2 × 10 mol %) were added with 20 min heating between each 
addition. The reaction mixture was cooled, stirred overnight with activated charcoal, 
filtered, and the solvent removed in vacuo. 
 
General procedure C3: Ring closing metathesis under thermal condition with 
chlorodicyclohexylborane.  
To a solution of diene in anhydrous 1,1,2-trichloroethane (0.01 M) under an inert 
atmosphere was added Grubb’s second generation catalyst (10 mol %) and chlorodicyclo- 
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hexylborane (1 M solution in hexane, 10 mol %). After 1 h a second portion of catalyst 
(10 mol %) was added, and the mixture was heated for 1 h before the final portion (10 
mol %) was added. The reaction mixture was heated under reflux for a further 16 h, 
cooled, stirred overnight with activated charcoal, filtered, and the solvent was removed in 
vacuo. 
 
General procedure C4: Ring closing metathesis under microwave reflux with 
chlorodicyclohexylborane. 
To a solution of diene in anhydrous 1,1,2-trichloroethane (0.01 M) under an inert 
atmosphere was added Grubb’s second generation catalyst (10 mol %) and 
chlorodicyclohexyl borane (1 M solution in hexane, 10 mol %). The reaction mixture was 
then heated for 20 min in a microwave (1200 W, 110-115oC). Two further portions of 
catalyst (2 × 10 mol %) were added with 20 min heating between each addition. The 
reaction mixture was cooled, stirred overnight with activated charcoal, filtered, and the 
solvent removed in vacuo. 
 
General procedure C5: Ring closing metathesis under thermal condition with 
titanium-based Lewis acid.  
To a solution of diene in anhydrous 1,1,2-trichloroethane (0.01 M) under an inert 
atmosphere was added Grubb’s second generation catalyst (10 mol%) and Ti(OiPr)4 (0.1 
equiv). After 1 h a second portion of catalyst (10 mol %) was added, and the mixture was 
heated for 1 h before the final portion (10 mol %) was added. The reaction mixture was 
heated under reflux for a further 16 h, cooled, stirred overnight with activated charcoal, 
filtered, and the solvent was removed in vacuo. 
 
General procedure C6: Ring closing metathesis in aqueous media. 
A soluble polyethylene glycol immobilized ruthenium catalyst (0.05 equiv) was added to 
a 1 ml vial, equipped with a magnetic stirring-bar and sealed with a septa-cap. The vial 
was then charged with a 0.2 M solution of diene in aqueous media (2:1, v/v). The 
reaction was stirred at rt without exclusion of air. The progress of the reaction was 
analyzed by 1H NMR after 1 h and 16 h for all the reactions studied. 
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General procedure D: Hydrogenation of a carbon-carbon double bond. 
The alkene was dissolved in a 1:1 mixture of methanol and ethyl acetate and 20% (w/w) 
of 10% palladium on carbon catalyst was added. The mixture was stirred vigorously in an 
atmosphere of hydrogen at rt for 18 h. The mixture was filtered through celite and 
concentrated in-vacuo.  
 
General procedure E1: N-Boc deprotection. 
Acetyl chloride was added dropwise to an ice-cooled solution of dry methanol and stirred 
for 20 minutes before adding the N-Boc protected compound. The reaction solution was 
stirred overnight and concentrated in vacuo.  
 
General procedure E2: N-Boc deprotection. 
To a solution of N-Boc protected amino acid derivative in methanol (0.01 M) cooled in 
ice bath, thionyl chloride (1.2 equiv) was added drop wise. The solution was stirred on an 
ice bath for 1 h and allowed to warm to rt and stirred for 18 h. The solvent was removed 
in vacuo. 
 
General procedure E3: N-Boc deprotection. 
N-Boc protected amino acid derivative was dissolved in dichloromethane (0.05 M) and 
trifluoroacetic acid (30 ml) was added drop wise. The solution was stirred under the 
nitrogen atmosphere at rt for 3 hours. The solvent was removed in vacuo and residue was 
dissolved in toluene, and the solution re-evaporated to give the product without 
purification.  
 
General Procedure F: Cbz N-terminal protection.  
To amine dissolved in anhydrous DMF was added benzyl chloroformate (1.5 equiv) and 
DIPEA (4.0 equiv) and the mixture stirred at rt for 18 h. The reaction mixture was 
partitioned between ethyl acetate and aqueous HCl (1 M). The aqueous phase was 
extracted twice with ethyl acetate and the combined organic extracts were washed with 
brine, dried over MgSO4 and the solvent was removed in vacuo. 
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General Procedure G1: Lithium aluminium hydride reduction of methyl ester.  
A solution of the methyl ester in anhydrous THF (0.1 M) under a nitrogen atmosphere 
was cooled on an ice bath. LiAlH4 (1.1 equiv) in THF (1 M) was added and the mixture 
stirred in ice for 1 h and allowed to warm to rt and stirred for a further 16 h. Methanol 
was added drop wise with stirring. The solvent was removed in vacuo and the residue 
partitioned between ethyl acetate and aqueous KHSO4 (1 M). The aqueous phase was 
extracted twice with chloroform and the combined organic phase was washed with brine, 
dried over MgSO4 and the solvent removed in vacuo. 
 
General Procedure G2: Lithium borohydride reduction of methyl ester.  
To a suspension of macrocyclic methyl ester (1 equiv) in dry THF were added methanol 
(2 equiv) and solution of LiBH4 (2 equiv) in THF (2.0 M). The resulting mixture was 
stirred overnight at rt and then THF evaporated in vacuo washed with aq. HCl (1 M) and 
ethanol. The organic phase was separated, further washed with water, dried over MgSO4, 
and the solvent removed in vacuo. 
 
General Procedure H1: SO3.pyridine oxidation.  
The macrocyclic alcohol (1 equiv) was dissolved in a mixture of dichloromethane and 
DMSO (2:1 v/v) and the solution cooled in an ice-bath. DIPEA (4 equiv) was added and 
the solution was stirred for 5 min before the addition of a warmed solution (approx 40 oC) 
of SO3.pyridine complex (4 equiv) in DMSO. The reaction mixture was stirred for 3 h, 
allowed to warm to rt, and then it was diluted with ethyl acetate. The organic phase was 
separated and then washed successively with aq. HCl (1 M), sat. aq. NaHCO3, and brine, 
dried over MgSO4 and the solvent was removed in vacuo. 
 
General Procedure H2: Oxidation of an alcohol using SO3.Py complex with a 
sacrificial isopropyl alcohol. 
Under nitrogen, the alcohol (x equiv, where x < 373 µmol) and isopropyl alcohol (373-x 
equiv, so total of moles alcohol and isopropyl alcohol is 373 µmol) were dissolved in 
DMSO (4 ml). To this dichloromethane (2 ml) was added and the solution cooled on an 
ice bath. While stirring under nitrogen, DIPEA (4 equiv., 1.49 mmol, 260 µL) was added. 
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To this a solution of SO3.Py complex (4 equiv, 1.49 mmol) dissolved in DMSO (1.5 ml) 
was added drop wise over 5 minutes. The reaction mixture was left stirring for 3 hours 
while allowing to warm to rt. The reaction mixture was then diluted with ethyl acetate (40 
ml), washed with HCl (1M, 2 x 30 ml), sat. NaHCO3 (2 x 30 ml) and brine (2 x 30 ml). 
The organic layer was dried over MgSO4 and the solvent was removed in vacuo. 
 
General Procedure H3: Dess-Martin oxidation.   
Alcohol (1.0 equiv) was suspended in anhydrous dichloromethane (0.1 M) under a 
nitrogen atmosphere. Dess-Martin reagent (3.0 equiv) was added to the solution with 
vigorous stirring under a nitrogen atmosphere.  The reaction mixture was stirred for 1 h at 
rt and was then quenched by adding saturated sodium bicarbonate solution containing 10 
% of Na2S2O5. The aqueous layer was extracted with dichloromethane and the combined 
organic phase was washed with water and dried with brine and sodium sulphate and 
solvent evaporated in vacuo. 
 
General Procedure I1: Diazotization. 
To a suspension of N-Boc-Lys-OH (1 equiv) in water (0.2 M) at 60 °C was added 4M 
NaOH (2 equiv). Sodium nitroprusside (1.5 equiv) was added in portions over 1 h, while 
maintaining the pH at 9.5 by the addition of 4 M NaOH as required. After the 
nitroprusside was completely added, the resulting red suspension was stirred for a further 
6 h at 60 °C. The resulting suspension was cooled to 10 °C, and 1 M HCl added until a 
pH of 1 was achieved. The resulting solution was extracted with ethyl acetate, the 
combined organic fractions were dried over MgSO4, and solvent removed in vacuo.  
 
General Procedure I2: Diazotization 
A solution of N-Cbz-Lys-OtBu (1 equiv) in aqueous AcOH (50% v/v) was treated with 
NaNO2 (11 equiv) and the resulting mixture was stirred at rt for 4 h. The mixture was 
then made basic by the addition of aqueous NaOH (40%) and extracted with diethyl ether. 
The organic layer was treated with a methanolic solution of KOH (0.1 M) for 2 h in order 
to complete hydrolysis of the formed acetyl derivate of the alcohol. The reaction mixture 
was then concentrated under reduced pressure, diluted with water and extracted twice 
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with ethyl acetate. The combined organic fractions were dried over MgSO4, and solvent 
was removed in vacuo.  
 
General Procedure J1: Methylation of carboxylic acid.  
Potassium carbonate (1.2 equiv) was dissolved in anhydrous DMF. To this solution was 
added carboxylic acid (1 equiv) followed by dropwise addition of methyl iodide (1.2 
equiv). The reaction mixture was stirred at rt overnight. The mixture was diluted by ethyl 
acetate, washed by brine and the organic layer concentrated in vacuo.  
 
General Procedure J2: Methylation of carboxylic acid.  
The carboxylic acid (1 equiv) was suspended in methanol (1 M) and cooled on an ice 
bath. Thionyl chloride (1.2 equiv) was added dropwise and the solution was stirred on ice 
bath for 1 hour and at rt overnight. The reaction solution was concentrated in vacuo to 
give crude product.  
 
General Procedure K1: N,N'-Dicyclohexylcarbodiimide (DCC) mediated t-butyl 
esterification of carboxylic acid.  
A solution of the N-protected amino acid (1 equiv), 4-(dimethylamino)pyridine (DMAP)  
(0.1 equiv), and the t-butyl alcohol (5 equiv) in dichloromethane (0.2 M) was cooled with 
stirring in an ice bath. DCC (1.1 equiv) was added, and the reaction mixture was stirred 
in ice for 2 h and at rt overnight. The solvent was removed in vacuo, and the residue was 
taken up in ethyl acetate and water. The organic layer was separated, washed twice with 
saturated NaHCO3 and water, and dried over MgSO4 and the solvent removed in vacuo. 
 
General Procedure K2: l-Ethyl-3-[3-(dimethylamino)propyl]carbodiimide hydro 
chloride (EDCI) mediated t-butylation of carboxylic acid.  
A solution of the N-protected amino acid (1 equiv), 4-(dimethylamino)pyridine (DMAP)  
(0.5 equiv), and t-butyl alcohol (1.1 equiv) in dichloromethane (0.2 M) was cooled with 
stirring in an ice bath. EDCI (1.2 equiv) was added, and the reaction mixture was stirred 
in ice for 2 h and at rt overnight. The solution was concentrated to dryness in vacuo, and 
the residue was taken up in ethyl acetate and water. The organic layer was separated, 
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washed twice with saturated NaHCO3 and water, and dried over MgSO4. The solvent was 
removed in vacuo. 
 
General Procedure K3: t-Butylation of carboxylic acid  
An N-protected amino acid derivative (1 equiv) was dissolved in dimethylacetamide (0.1 
M) in the presence of benzyltriethylammonium chloride (BTEAC) (1 equiv). Dried 
potassium carbonate (26 equiv) was then added, followed by t-butyl bromide (48 equiv) 
and the mixture was stirred at 55oC for 24 hours. After cooling, cold water was added to 
the reaction mixture, and the resulting solid precipitate was filtered and washed several 
times with water. The organic layer was separated, washed with water, dried over sodium 
sulfate and concentrated in vacuo.  
 
General Procedure L1: Iodination of primary alcohol. 
Triphenylphosine (1.5 equiv), imidazole (1.6 equiv) and iodine (1.5 equiv) were added 
sequentially to a solution of alcohol dissolved in THF (0.5 M) at rt under nitrogen 
atmosphere. The reaction mixture was stirred overnight and concentrated in vacuo.  
 
General Procedure L2: Iodination of primary alcohol. 
To a solution of triphenylphosphine (1.5 equiv) in dry dichloromethane under a nitrogen 
atmosphere was added recrystallised DDQ (1.5 equiv). The resulting red solution was 
treated with TBAI (1.5 equiv). After stirring for 5 mins, alcohol (1 equiv) was added and 
reaction was stirred overnight under an inert atmosphere. The solution was diluted with 
ethyl acetate, washed with saturated NaHCO3 until the aqueous layer was no longer 
yellow, washed with distilled water, dried over MgSO4 and filtered, and the solvent 
removed in vacuo. 
 
General Procedure M1: Alkylation of tyrosine hydroxyl with dibromobutane. 
Alcohol (1 equiv), K2CO3 (1.5 equiv) and Cs2CO3 (0.1 equiv) were dissolved in 
acetonitrite. To 1,4-Dibromobutane (10 equiv) was added and the solution heated at 
reflux overnight. The solution was concentrated in vacuo and residue was partitionated 
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between ethyl acetate and 1M aq.HCl. The organic layer was washed successively with 
1M HCl, brine, dried over MgSO4 and concentrated in vacuo.  
 
General Procedure M2: Specific alkylation at the N-1 position of imidazole.  
Sodium hydride (60% suspension, 3 equiv) was washed with dry hexanes three times and 
dried under vacuum. N-protected histidine derivative (1 equiv) in DMF was added under 
a nitrogen atmosphere at -15oC. The reaction mixture was stirred for 30 min at -15oC, and 
alkyl halide (2 equiv) added. The temperature of the reaction was raised to -5oC and the 
reaction mixture stirred for 4 h under a nitrogen atmosphere. The reaction was quenched 
by the addition of methanol and the solvent removed under reduced pressure. The residue 
was extracted with chloroform and dried over MgSO4 and the solvent was removed in 
vacuo.  
 
General Procedure N: Boc and tert-butyl deprotection. 
A pseudo-tripeptide (0.2 mmol) was dissolved in dichloromethane (5 ml) under a 
nitrogen atmosphere. Trifluoroacetic acid (2 ml) was added and the solution was stirred at 
rt for 3 h. The solvent was removed in vacuo and the residue dissolved in toluene, and the 
solution re-evaporated to give the crude.  
 
General Procedure O1: Intramolecular lactamization.  
A macrocyclic precursor was dissolved in DMF. EDCI (1.2 equiv), HOAt (1.2 equiv) and 
DIPEA (2.4 equiv) were added and reaction solution stirred at rt overnight. The product 
was extracted with ethyl acetate, washed with distilled water, and dried with brine and 
MgSO4 and the solvent was removed in vacuo.  
 
General Procedure O2: Intramolecular lactamization  
To a macrocyclic precursor dissolved in DMF (0.1 M), was added HATU (1.2 equiv) and 
DIPEA (2.4 equiv) and the reaction mixture was stirred at rt overnight. The solution was 
diluted by ethyl acetate, washed by distilled water, dried with brine and MgSO4 and 
solvent was removed in vacuo.  
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General Procedure P: Intramolecular nucleophilic substitution.  
The iodide (0.01 mol), K2CO3 (1.5 equiv) and Cs2CO3 (0.1 equiv) were dissolved in dry 
acetonitrile (0.3 M) under a nitrogen atmosphere and reacted under reflux conditions 
overnight. The reaction mixture was cooled to rt and the solvent removed in vacuo to 
give a yellow residue. This residue was partitioned between ethyl acetate and aq. HCl 
(1M).  The organic phase was separated and washed with aq. HCl (1M) and brine, dried 
over MgSO4 and the solvent was removed in vacuo to give the crude product. To solid 
was dissolved in ethyl acetate and activated charcoal added and the mixture stirred 
overnight at rt. The charcoal was filtrated and the solvent was removed in vacuo.  
 
General Procedure Q: N-Fmoc protection 
To a solution of an amino acid derivative (1 equiv) dissolved in 10% NaCO3 (5 equiv) on 
an ice bath was added a solution of Fmoc-C1 (1 equiv) in ether. The mixture was stirred 
at rt for 2 h, diluted with distilled water, and extracted twice with ether to remove small 
amounts of 9-fluorenylmethanol and the high-melting polymer, dibenzofulvene. The 
aqueous layer was cooled in an ice bath and acidified with concentrated HCl to pH 2. The 
white precipitate was extracted with ethyl acetate and the organic layer was washed with 
water, dried over MgSO4 and concentrated in vacuo. 
 
General Procedure R: Fmoc deprotection 
To a solution of N-Fmoc protected amino acid in acetonitrile (0.1 M) was added 
diethylamine (20 equiv). The reaction mixture was stirred overnight at rt and the solvent 
was removed in vacuo. 
 
7.2: Experimental work described in chapter 2  
 
(E)-(6S,9S,12S)-12-tert-Butoxycarbonylamino-9-isobutyl-8,11-dioxo-2-oxa-7,10-
diazabicyclo[12.2.2]octadeca-1(17),4,14(18),15-tetraene-6-carboxylic acid methyl 
ester (2.1). 
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RCM under thermal reflux: Diene 2.5 (100 mg, 0.18 mmol) was subjected to RCM 
(General procedure C1) and the crude product was purified by flash chromatography on 
silica gel and elution with ethyl acetate/petroleum ether (3:2) to give 2.1, a white solid 
(44 mg, 49%) as a mixture of as a 19(E):1(Z) mixture of isomers. 
 
RCM under microwave irradiation: Diene 2.5 (100 mg, 0.18 mmol) was subjected to 
RCM (General procedure C2) and the crude product was purified by flash 
chromatography on silica gel and elution with ethyl acetate/petroleum ether (3:2) to give 
2.1, a white solid (52 mg, 58%) as a mixture of as a 20(E):1(Z) mixture of isomers. 
 
RCM under thermal reflux with chlorodicyclohexylborane: Diene 2.5 (100 mg, 0.18 
mmol) was subjected to RCM (General procedure C3) and the crude product was purified 
by flash chromatography on silica gel and elution with ethyl acetate/petroleum ether (3:2) 
to give 2.1, a white solid (45 mg, 50%) as a mixture of as a 19(E):1(Z) mixture of isomers. 
 
RCM under microwave  irradiation with chlorodicyclohexylborane: Diene 2.5 (100 mg, 
0.18 mmol) was subjected to RCM (General procedure C4) and the crude product was 
purified by flash chromatography on silica using a gradient of ethyl acetate and 
petroleum ether to give 2.1, a white solid (43 mg, 47%) as a mixture of as a 20(E):1(Z) 
mixture of isomers. Mp 241-243 °C; 1H NMR for major isomer from mixture (500 MHz, 
CDCl3): δ 7.15-7.17 (1H, m, HArO), 6.87 (2H, m, HArO), 6.59-6.61(1H, m, HArO), 6.31 
(1H, d, J = 7.3 Hz, NH), 5.88 (1H, d, J = 8.5 Hz, NH), 5.72 (1H, ddd, J = 15.5, 8.0 and 
4.0 Hz, OCH2CHCH), 5.42 (1H, dd, J = 15.5 and 8.5 Hz, OCH2CHCH), 5.35 (1H, d, J = 
8.5 Hz, NH), 4.89 (1H, app t, J = 8.0 and 8.0 Hz, CHCO2CH3), 4.67 (2H, m, 
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OCH2CHCH), 4.26-4.31 (1H, dd, J = 15.0, 8.0 Hz, CHCH2CH(CH3)2), 4.15 (1H, m, 
CHCH2ArO), 3.78 (3H, s, OCH3), 3.03 (1H, dd, J = 12.5 and 4.5 Hz, CHCHHArO), 2.69 
(1H, app t, J = 12.5 and 12.5 Hz, CHCHHArO), 1.39-1.57 (12H, m, CHCH2CH(CH3)2, 
CHCH2CH(CH3)2 and (CH3)3), 0.87 (6H, m, 2 x CH3). 13C NMR (75 MHz, CDCl3): δ 
170.7, 170.1, 155.3, 155.1, 130.8, 130.0, 129.5, 129.4, 128.8, 119.4, 115.9, 79.6, 67.0, 
57.3, 53.9, 52.8, 50.9, 42.8, 38.7, 28.3, 24.6, 22.7, 22.6. HRMS (ES) 504.2727 (MH+); 
C26H38N3O7 requires 504.2710. 
 
(E)/(Z)-(7S,10S,13S)-13-tert-Butoxycarbonylamino-10-isobutyl-9,12-dioxo-2-oxa-
8,11-diaza-bicyclo[13.2.2]nonadeca-1(18),4,15(19),16-tetraene-7-carboxylic acid 
methyl ester (2.2). 
 
 
RCM under thermal reflux: Diene 2.6 (100 mg, 0.18 mmol) was subjected to RCM 
(General procedure C1) and the crude product was purified by flash chromatography on 
silica gel and elution with ethyl acetate/petroleum ether (1:1) to give 2.2, a white solid 
(21.8 mg, 22%) as a mixture of as a 10(E):1(Z) mixture of isomers. 
 
RCM under microwave irradiation: Diene 2.6 (100 mg, 0.18 mmol) was subjected to 
RCM (General procedure C2) and the crude product was purified by flash 
chromatography on silica gel and elution with ethyl acetate/petroleum ether (1:1) to give 
2.2, a white solid (35 mg, 37%) as a mixture of as a 9(E):1(Z) mixture of isomers. 
 
RCM under thermal reflux with chlorodicyclohexylborane: Diene 2.6 (100 mg, 0.18 
mmol) was subjected to RCM (General procedure C3) and the crude product was purified 
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by flash chromatography on silica gel and elution with ethyl acetate/petroleum ether (1:1) 
to give 2.2, a white solid (77 mg, 82%) as a mixture of as a 9(E):1(Z) mixture of isomers. 
 
RCM under microwave irradiation with chlorodicyclohexylborane: Diene 2.6 (100 mg, 
0.18 mmol) was subjected to RCM (General procedure C4) and the crude product was 
purified by flash chromatography on silica gel and elution with ethyl acetate/petroleum 
ether (1:1) to give 2.2, a white solid (85 mg, 90%) as a mixture of as a 9(E):1(Z) mixture 
of isomers.  
 
RCM under thermal reflux with titanium(IV) isopropoxide: Diene 2.6 (50 mg, 0.09 mmol) 
was subjected to RCM (General procedure C5) and the crude product was purified by 
flash chromatography on silica gel and elution with ethyl acetate/petroleum ether (1:1) to 
give 2.2, a white solid (16 mg, 34%) as a mixture of as a 9(E):1(Z) mixture of isomers.1H 
NMR for major isomer from mixture (500 MHz in CDCl3): δ 7.01 (2H, m, HArO), 6.78 
(2H, m, HArO), 5.87 (1H, d, J = 8.5 Hz, NH), 5.78 (1H, d, J = 7.0 Hz, NH), 5.54 (1H, 
app dt, J = 15.5, 3.8 and 3.8 Hz, OCH2CHCHCH2), 5.44 (1H, ddd, J = 15.5, 6.5 and 1.5 
Hz, OCH2CHCHCH2), 5.34 (1H, d, J = 8.5 Hz, NH), 4.73 (1H, ddd, J = 9.0, 8.5 and 3.0 
Hz, CHCO2CH3), 4.55-4.68 (2H, m, OCH2CHCHCH2), 4.09-4.20 (2H, m, CHCH2ArO 
and CHCH2CH(CH3)2), 3.74 (3H, s, OCH3), 3.08 (1H, dd, J = 12.5 and 5.0 Hz, 
CHCHHPh), 2.65-2.74 (1H, m, CHCHHPh), 2.26-2.34 (2H, m, CH2CHCO2CH3), 1.82-
1.90 (1H, m, CHCH2CH(CH3)2), 1.52-1.58 (2H, m, CHCH2CH(CH3)2), 1.44 (9H, s, 
(CH3)3), 0.84-0.88 (6H, m, CHCH2CH(CH3)2). 13C NMR for major isomer from mixture 
(75 MHz, CDCl3): δ 171.9, 171.0, 170.7, 156.1, 155.0, 129.7, 128.4, 128.1, 127.5, 115.8, 
79.8, 66.4, 57.0, 52.5, 51.8, 51.6, 42.8, 38.8, 34.7, 28.3, 24.5, 24.3, 22.7, 22.5. HRMS 
(ES) 518.2869 (MH+). C27H40N3O7 requires 518.2866. 
 
(E)/(Z)-(8S,11S,14S)-14-tert-Butoxycarbonylamino-11-isobutyl-10,13-dioxo-2-oxa-
9,12-diazabicyclo[14.2.2]icosa-1(19),5,16(20),17-tetraene-8-carboxylic acid methyl 
ester (2.3).  
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RCM under thermal reflux: Diene 2.7 (100 mg, 0.17 mmol) was subjected to RCM 
(General procedure C1) and the crude product was purified by flash chromatography on 
silica gel and elution with ethyl acetate/petroleum ether (1:1) to give 2.3, a white solid 
(46 mg, 51%) as a mixture of as a 1.3(E):1(Z) mixture of isomers. 
 
RCM under microwave irradiation: Diene 2.7 (100 mg, 0.17 mmol) was subjected to 
RCM (General procedure C2) and the crude product was purified by flash 
chromatography on silica gel and elution with ethyl acetate/petroleum ether (1:1) to give 
2.3, a white solid (52 mg, 58%) as a mixture of as a 1.7(E):1(Z) mixture of isomers. 
 
RCM under thermal reflux with chlorodicyclohexylborane: Diene 2.7 (100 mg, 0.17 
mmol) was subjected to RCM (General procedure C3) and the crude product was purified 
by flash chromatography on silica gel and elution with ethyl acetate/petroleum ether (1:1) 
to give 2.3, a white solid (66 mg, 74%) as a mixture of as a 1.9(E):1(Z) mixture of 
isomers. 
 
RCM under microwave irridation with chlorodicyclohexylborane: Diene 2.7 (100 mg, 
0.17 mmol) was subjected to RCM (General procedure C4) and the crude product was 
purified by flash chromatography on silica gel and elution with ethyl acetate/petroleum 
ether (1:1) to give 2.3, a white solid (85 mg, 96%) as a mixture of as a 1.8(E):1(Z) 
mixture of isomers. 1H NMR of the major isomer from the mixture (500 MHz in CDCl3): 
δ 7.09 (2H, app d, J = 8.0 Hz, HArO), 6.75 (2H, d, J = 8.0 Hz, HArO), 6.17 (1H, d, J = 
7.5 Hz, NH), 6.12 (1H, d, J = 8.0 Hz, NH), 5.57 (1H, m,OCH2CH2CHCHCH2), 5.24 (1H, 
d, J = 8.5 Hz, NH), 4.93 (1H, ddd, J = 15.0, 7.0, 5.3 Hz, OCHHCH2CHCHCH2), 4.45 
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(1H, ddd, J = 8.8, 8.6, 3.4 Hz, CHCO2CH3), 4.10-4.32 (4H, m, CHCH2ArO, 
CHCH2CH(CH3)2 and CH2OAr), 3.74 (3H, s, OCH3), 3.01 (1H, dd  J = 12.0, 4.7 Hz, 
CHCHHAr), 2.82-2.84 (1H, m, CHCHHAr), 2.57 (1H, m, CHCHCHHCHCO2Me), 2.37-
2.48 (2H, m, OCH2CH2CH), 2.27 (1H, m, CHCHCHHCHCO2Me), 1.47-1.60 (3H, m, 
CHCH2CH(CH3)2 and CHCH2CH(CH3)2), 1.45 (9H, s, C(CH3)3), 0.84-0.90 (6H, m, J = 
5.8 Hz, CHCH2CH(CH3)2). 13C NMR for major isomer from the mixture (75 MHz, 
CDCl3): δ 171.9, 171.0, 170.9, 170.4, 156.6, 155.1, 130.7, 130.0, 128.9, 126.1, 115.8, 
79.9, 65.5, 56.8, 52.5, 52.4, 51.6, 42.1, 38.0, 35.4, 30.6, 28.3, 24.3, 22.7, 22.4. Selected 
1H NMR signals for minor isomer from the mixture (500 MHz in CDCl3): δ 7.12 (2H, d, 
J = 8.5 Hz, HArO), 6.79 (2H, d, J = 8.5 Hz, HArO), 6.37 (1H, d, J=7.5 Hz, NH), 6.28 
(1H, d, J = 8.5 Hz, NH), 5.56 (1H, m,  OCH2CH2CHCHCH2), 5.47 (1H, dd,  J = 10.6, 
8.0 Hz, OCHHCH2CHCHCH2), 4.09-4.33 (5H, m, CHCH2ArO, CHCH2CH(CH3)2, 
CH2OAr and CHCO2CH3, 3.71 (3H, s, OCH3), 2.99 (1H, m, CHCHHAr), 2.86 (1H, m, 
CHCHHPh), 2.49 (1H, m, C=CHCHHCHCO2Me), 2.32 (1H, m, C=CHCHHCHCO2Me), 
1.90-2.05 (2H, m, OCH2CH2CH), 1.47-1.60 (3H, m, CHCH2CH(CH3)2 and 
CHCH2CH(CH3)2), 1.45 (9H, s, C(CH3)3), 0.84-0.90 (6H, m, CHCH2CH(CH3)2). 
Selected 13C NMR signals for minor isomer from the mixture (75 MHz, CDCl3): δ 172.1, 
171.0, 170.4, 170.3, 155.9, 155.3, 128.7, 128.4, 128.2, 126.6, 115.7, 80.1, 65.8, 55.9, 52.6, 
52.3, 50.8, 40.8, 37.5, 31.2, 28.3, 25.8, 22.9, 22.0. HRMS (ES) 532.3034 (MH+) 
C28H42N3O7; requires 532.3023. 
 
(Z)-(8S,11S,14S)-14-tert-Butoxycarbonylamino-11-isobutyl-10,13-dioxo-2-oxa-9,12-
diaza-bicyclo[14.2.2]icosa-1(19),4,16(20),17-tetraene-8-carboxylic acid methyl ester 
(2.4). 
 
 
 150 Chapter 7: Experimental 
RCM under thermal reflux: Diene 2.8 (500 mg, 0.89 mmol) was subjected to RCM 
(General procedure C1) and the crude product was purified by flash chromatography on 
silica gel and elution with ethyl acetate/petroleum ether (3:2) to give a white solid (102 
mg) as a mixture of 17- and 18-membered macrocyclic products. 
 
RCM under microwave irradiation: Diene 2.8 (500 mg, 0.89 mmol) was subjected to 
RCM (General procedure C2) and the crude product was purified by flash 
chromatography on silica gel and elution with ethyl acetate/petroleum ether (3:2) to give 
a white solid (169 mg) as a mixture of 16-, 17- and 18-membered macrocyclic products. 
 
RCM under thermal reflux with chlorodicyclohexylborane: Diene 2.7 (500 mg, 0.89 
mmol) was subjected to RCM (General procedure C3) and the crude product was purified 
by flash chromatography on silica gel and elution with ethyl acetate/petroleum ether (3:2) 
to give a white solid (240mg) as a mixture of 17- and 18-membered macrocyclic products. 
 
RCM under microwave irradiation with chlorodicyclohexylborane: Diene 2.7 (500 mg, 
0.89 mmol) was subjected to RCM (General procedure C4) and the crude product was 
purified by flash chromatography on silica gel and elution with ethyl acetate/petroleum 
ether (3:2) to give a white solid (191 mg) as a mixture of 16-, 17- and 18-membered 
macrocyclic products. 1H NMR for major 18-membered macrocycle 2.4 from the mixture 
(500 MHz in CDCl3): δ 7.07 (2H, app d, J = 8.0 Hz, HArO), 7.00 (2H, app d, J = 8.0 Hz, 
HArO), 6.80 (2H, app d, J = 8.5 Hz, HArO), 6.75 (1H, app d, J = 8.5 Hz, HArO), 6.21 
(1H, d, J = 7.5 Hz, NH), 6.15 (1H, d, J = 8.0 Hz, NH), 6.06-6.10 (1H, m, NH), 5.84 (1H, 
d, J = 8.5 Hz, NH), 5.77 (1H, d, J = 7.5 Hz, NH), 5.46-5.70 (2H, m, OCH2CHCH and 
OCH2CHCH), 5.32-5.35 (1H, d, m, NH), 5.26-5.28 (1H, m, NH), 4.60-4.62 (2H, m, 
OCH2CHCH), 4.49-56 (1H, m, CHCO2CH3), 4.34-4.44 (1H, m, CHCH2ArO), 4.15-4.30 
(1H, m, CHCH2CH(CH3)2), 3.75 (3H, s, OCH3), 3.74 (3H, s, OCH3), 3.73 (3H, s, OCH3), 
2.85-3.05 (2H, m, CHCH2ArO), 2.64-2.74 (2H, m, CH2CH2CHCO2CH3), 2.05-2.15 (2H, 
m, CH2CHCO2CH3), 1.89-1.96 (1H, m, CHCH2CH(CH3)2), 1.53-1.63 (2H, m, 
CHCH2CH(CH3)2), 1.41-1.52 (9H, m, (CH3)3), 0.86-0.89 (6H, m, 2 x CH3).  MS (ES) 
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532.35 (18-membered macrocycle [M+H]+, 40%); 518.35 (17-membered macrocycle 
[M+H]+, 30%); 504.35 (16-membered macrocycle [M+H]+, 10%). 
 
(S)-2-{(S)-2-[(S)-3-(4-Allyloxy-phenyl)-2-tert-butoxycarbonylamino-propionyl 
amino]-4-methyl-pentanoylamino}-but-3-enoic acid methyl ester (2.5).1 
 
 
Carboxylic acid 2.12 (1.5 g, 3.45 mmol) was coupled with vinyl-Gly-OMe 2.14 (General 
Procedure A1). The crude product was purified by flash chromatography on silica and 
elution with ethyl acetate/ petroleum ether (1:5) to give 2.5 as a glassy white solid (1.39 g, 
76 %). 1H NMR (500 MHz, CDCl3): δ 7.10 (2H, d, J = 8.3 Hz, HArO), 6.95 (1H, d, J = 
6.3 Hz, NH), 6.80 (2H, d, J = 8.5 Hz, HArO), 6.31 (1H, d, J = 6.5 Hz, NH), 6.02-6.10 
(1H, m, OCH2CHCH2), 5.85-5.95 (1H, m, CHCHCH2), 5.25-5.40 (4H, m, OCH2CHCH2 
and CHCHCH2), 5.05 (1H, m, CHCO2CH3), 4.92 (1H, br s, NH), 4.42-4.51 (3H, m, 
CHCH2CH(CH3)2 and OCH2CHCH2), 4.29 (1H, m, CHCH2ArO), 3.75 (3H, s, OCH3), 
3.01 (2H, m, CHCH2ArO), 1.61-1.72 (2H, m, CHCHHCH(CH3)2 and CHCH2CH(CH3)2), 
1.38 (9H, s, (CH3)3), 0.85-0.91 (6H, m, CHCH2CH(CH3)2).  
Lit cit: 1Abell, A. D.; Jones, M. A.; Coxon, J. M.; Morton, J. D.; Aitken, S. G.; McNabb, 
S. B.; Lee, H. Y. Y.; Mehrtens, J. M.; Alexander, N. A.; Stuart, B. G.; Neffe, A. T.; 
Bickerstaffe, R. Molecular Angew. Chem. Int. Ed., 2009, 48, 1455 –1458.  
mp 102-104 ºC; 1H NMR (500 MHz, CDCl3): 7.08 (2H, app d, J = 8.5 Hz, HArO), 6.96 (1H, 
d, J = 6.5 Hz, NH), 6.81 (2H, app d, J = 8.5 Hz, HArO), 6.49 (2H, d, J = 7.0 Hz, NH), 6.03 
(1H, m, OCH2CHCH2), 5.88 (1H, m, CHCHCH2), 5.42-5.22 (4H, m, OCH2CHCH2 and 
CHCHCH2), 5.11-5.02 (2H, m, CHCO2CH3 and NH), 4.61-4.40 (3H, m, CHCH2CH(CH3)2 
and OCH2CHCH2), 4.32 (1H, m, CHCH2ArO), 3.76 (3H, s, OCH3), 2.97 (2H, m, 
CHCH2ArO), 1.66 (1H, m, CHCHHCH(CH3)2), 1.57 (1H, m, CHCH2CH(CH3)2), 1.48 (1H, 
m, CHCHHCH(CH3)2), 1.39 (9H, s C(CH3)3), 0.90 (6H, m, 2 x CH3); 13C NMR (75 MHz, 
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CDCl3): 171.7, 171.4, 170.5, 157.5, 155.7, 133.2, 131.6, 130.3, 130.2, 128.6, 117.9, 117.5, 
114.7, 80.0, 68.8, 55.7, 55.6, 54.4, 52.6, 51.6, 40.9, 37.1, 28.2, 24.5, 22.7, 22.1; HRMS (ES) 
532.3027 (MH+); C28H42N3O7 requires 532.3023. 
 
(S)-2-{(S)-2-[(S)-3-(4-Allyloxyphenyl)-2-tert-butoxycarbonylaminopropionylamino]-
4-methylpentanoylam-ino}-pent-4-enoic acid methyl ester (2.6).1  
 
 
 
Carboxylic acid 2.12 (4.35 g, 10 mmol) was coupled with allyl-Gly-OMe 2.13 (General 
Procedure A1) and the crude material was purified by flash chromatography on silica gel 
and elution with ethyl acetate/petroleum ether (2:3) to give.2.6 as a white solid (4.17 g, 
77%). 1H NMR (500 MHz in CDCl3) δ 7.09 (2H, m, HArO), 6.87 (1H, d, J = 7.7 Hz, 
NH), 6.82 (2H, d, J = 8.5 Hz, HArO), 6.67 (1H, d, J = 7.6Hz, NH), 6.04-6.06 (1H, tdd, J 
= 17.0, 10.5, 5.2 and 5.2 Hz, OCH2CHCH2), 5.74-5.79 (1H, m, CHCH2CHCH2), 5.38 
(1H, dd, J = 17.5 and 1.5 Hz, OCH2CHCHtransH), 5.27 (1H, dd, J = 10.5 and 1.5 Hz, 
OCH2CHCHHcis), 5.05-5.09  (2H, m, OCH2CHCH2), 4.99 (1H, d, J = 7.5Hz, NH), 4.52-
4.54 (1H, m, CHCH2CH(CH3)2), 4.49 (2H, m, OCH2CHCH2), 4.43-4.48 (1H, m, 
CHCH2CHCH2), 4.33 (1H, m, CHCH2Ph), 3.73 (3H, s, CO2CH3), 2.94-3.05 (2H, m, 
CHCH2Ph), 2.04-2.09 (2H, m, CHCH2CHCH2), 1.91-1.94 (1H, m, CHCHHCH(CH3)2), 
1.74-1.78 (1H, m, CHCHHCH(CH3)2), 1.43-1.50 (1H, m, CHCH2CH(CH3)2) 1.39 (9H, s, 
C(CH3)3), 0.91 (6H, m, CHCH2CH(CH3)2). 13C NMR (75 MHz in CDCl3). δ 172.7, 171.8, 
171.3, 157.8, 155.4, 137.0, 133.5, 132.0, 130.5, 130.1, 128.8, 119.2, 119.0, 117.9, 115.1, 
80.6, 69.0, 56.0, 52.5, 52.0, 41.1, 40.7, 37.2, 36.2, 28.2, 24.4, 22.8, 22.2. MS (ES) 546.31 
(MH+) C29H43N3O7 requires 546.31.  
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Lit cit: 1Abell, A. D.; Jones, M. A.; Coxon, J. M.; Morton, J. D.; Aitken, S. G.; McNabb, 
S. B.; Lee, H. Y. Y.; Mehrtens, J. M.; Alexander, N. A.; Stuart, B. G.; Neffe, A. T.; 
Bickerstaffe, R. Molecular Angew. Chem. Int. Ed., 2009, 48, 1455 –1458.  
mp 105-110 ºC; 1H-NMR (500 MHz, CDCl3): 7.09 (2H, app d, J = 8.5 Hz, HArO), 6.82 (2H, 
app d, J = 8.5 Hz, HArO), 6.65 (1H, d, J = 7.5 Hz, NH), 6.47 (1H, d, J = 8.0 Hz, NH), 6.04 
(1H, app ddt, J = 17.0, 10.5, 5.25 and 5.25 Hz, OCH2CHCH2), 5.62-5.71 (1H, m, 
CHCH2CHCH2), 5.39 (1H, dd, J = 17.5 and 1.5 Hz, OCH2CHCHtransH), 5.26 (1H, dd, J = 
10.5 and 1.5 Hz, OCH2CHCHHcis), 5.03-5.12 (2H, m, OCH2CHCH2), 4.99 (1H, d, J = 7.5 Hz, 
NH), 4.58 (1H, dd, J = 13.5 and 6.5 Hz, CHCH2CH(CH3)2), 4.49 (2H, app d, J = 5.0 Hz, 
OCH2CHCH2), 4.40-4.45 (1H, m, CHCO2CH3), 4.25-4.34 (1H, m, CHCH2ArO), 3.73 (3H, s, 
OCH3), 2.96-3.05 (2H, m, CHCH2ArO), 2.45-2.61 (2H, m, CHCH2CHCH2), 1.52-1.68 (2H, 
m, CHCHCH2(CH3)2), 1.43-1.50 (1H, m, CHCHCH2(CH3)2) 1.39 (9H, s, C(CH3)3), 0.90 (3H, 
d, J = 6.5 Hz, CH3), 0.89 (3H, d, J = 6.5 Hz, CH3); 13C NMR (75 MHz, CDCl3): _ 171.8, 
171.5, 171.3, 157.5, 155.4, 133.2, 132.2, 132.0, 130.3, 130.1, 128.5, 119.2, 119.0, 117.6, 
114.8, 80.2, 68.7, 55.6, 52.3, 51.7, 40.9, 40.7, 37.0, 36.2, 28.2, 24.4, 22.8, 22.0; HRMS (ES) 
546.3180 (MH+); C29H43N3O7 requires 546.3179. 
 
(S)-2-{(S)-2-[(S)-3-(4-But-3-enyloxyphenyl)-2-tertbutoxycarbonyl aminopropionyl 
amino]-4-methylpentan-oylamino}-pent-4-enoic acid methyl ester (2.7).1  
 
 
Carboxylic acid 2.19 (1.2 g, 2.6 mmol) was coupled with allyl-Gly-OMe (General 
Procedure A1). The crude product was purified by flash chromatography on silica gel and 
elution with ethyl acetate/petroleum ether (2:3) to give 2.7 as a white solid (1.23 g, 82%). 
Mp 86-88 ºC. 1H NMR (500 MHz, CDCl3): δ 7.07 (2H, d, J = 8.6 Hz, HArO), 6.79 (2H, 
app d, J = 8.5 Hz, HArO), 6.71 (1H, d, J = 7.7 Hz, NH), 6.52 (1H, d, J = 8.0 Hz, NH), 
5.85-5.88 (1H, dddd, J = 17.0, 10.0, 7.5 and 3.7 Hz, OCH2CH2CHCH2), 5.85-5.88 (1H, 
m, CHCH2CHCH2), 5.03-5.16 (4H, m, OCH2CH2CHCH2 and CHCH2CHCH2), 4.56-4.60 
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(1H, m, CHCO2CH3), 4.50 (1H, m, CHCH2CH(CH3)2), 4.31 (1H, m, CHCH2ArO), 3.96 
(2H, t, J = 6.6 and 6.8 Hz,OCH2CH2CHCH2), 3.72 (3H, s, OCH3), 2.98 (2H, m, 
CHCH2ArO), 2.45-2.56 (4H, m, CHCH2CHCH2 and OCH2CH2CHCH2, 1.54-1.66 (2H, 
m, CHCH2CH(CH3)2), 1.43-1.48 (1H, m, CHCH2CH(CH3)2), 1.38 (9H, s, C(CH3)3), 0.89 
(6H, m, CHCH2CH(CH3)2). 13C NMR (75 MHz, CDCl3): δ 172.0, 171.7, 171.5, 158.2, 
155.4, 134.4, 132.3, 130.5, 130.2, 128.6, 118.9, 116.9, 114.5, 79.8, 67.0, 55.6, 52.2, 51.8, 
51.5, 41.2, 37.2, 36.5, 33.8, 28.5, 24.7, 23.1, 22.3. MS (ES) 560.33 (MH+); C30H45N3O7 
requires 560.33. 
Lit cit: 1Abell, A. D.; Jones, M. A.; Coxon, J. M.; Morton, J. D.; Aitken, S. G.; McNabb, 
S. B.; Lee, H. Y. Y.; Mehrtens, J. M.; Alexander, N. A.; Stuart, B. G.; Neffe, A. T.; 
Bickerstaffe, R. Molecular Angew. Chem. Int. Ed., 2009, 48, 1455 –1458.  
mp 88-90 ºC; 1H NMR (500 MHz, CDCl3): 7.09 (2H, app d, J = 8.5 Hz, HArO), 6.93 (1H, d, 
J = 7.5 Hz, NH), 6.80 (2H, app d, J = 8.5 Hz, HArO), 6.71 (1H, d, J = 7.3 Hz, NH), 5.86 (1H, 
dddd, J = 17.0, 10.0, 7.5 and 3.5 Hz, OCH2CH2CHCH2), 5.61-5.70 (1H, m, CHCH2CHCH2), 
5.09-5.22 (4H, m, OCH2CH2CHCH2 and CHCH2CHCH2), 4.54-4.60 (1H, m, CHCO2CH3), 
4.50 (1H, dd, J = 13.5 and 6.5 Hz, CHCH2CH(CH3)2), 4.36-4.38 (1H, dd, J = 8.5 and 6.5 Hz, 
CHCH2ArO), 3.96 (2H, app t, J = 6.75 and 6.75 Hz, OCH2CH2CHCH2), 3.73 (3H, s, OCH3), 
2.91 (2H, m, CHCH2ArO), 2.45-2.58 (4H, m, CHCH2CHCH2 and OCH2CH2CHCH2, 1.54-
1.66 (2H, m, CHCH2CH(CH3)2), 1.43-1.48 (1H, m, CHCH2CH(CH3)2), 1.39 (9H, s, C(CH3)3), 
0.86 (3H, d, J = 6.5 Hz, CH3), 0.86 (3H, d, J = 6.5 Hz, CH3); 13C NMR (75 MHz,CDCl3): 
171.8, 171.6, 171.5, 157.8, 155.4, 134.4, 132.2, 130.3, 130.2, 128.6, 118.9, 116.9, 114.5, 79.8, 
67.0, 55.6, 52.2, 51.8, 51.5, 41.1, 37.2, 36.3, 36.2, 33.6, 28.2, 24.4, 22.8, 22.2; HRMS (ES) 
560.3346 (MH+); C30H45N3O7 requires 560.3336. 
 
(S)-2-{(S)-2-[(S)-3-(4-Allyloxy-phenyl)-2-tert-butoxycarbonylamino-propionyl 
amino]-4-methyl-pentanoylamino}-hex-5-enoic acid methyl ester (2.8) 
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Carboxylic acid 2.12 (5.83 g, 13.4 mmol) was coupled homoallyl-Gly-OMe 2.22 
(General procedure A1). The crude product was purified by flash chromatography on 
silica using a gradient of ethyl acetate/petroleum ether (1:1) gave 2.8 as a white solid 
(5.75g, 77%). Mp 125-127 ºC. 1H NMR (500 MHz, CDCl3): δ 7.05 (2H, app d, J = 8.6 
Hz, HArO), 6.82 (1H, br s, NH),  6.76 (2H, app d, J = 8.6 Hz,  HArO), 6.03 (1H, dddd, J 
= 17.3, 10.4, 5.2 and 5.2 Hz, OCH2CHCH2), 5.73 (1H, dddd, J = 17.0, 10.3, 6.6 and 6.6 
Hz, CαHCH2CH2CHCH2), 5.38 (1H, dd, J = 17.3, 1.5, Hz, OCH2CHCHtransH), 5.30 (1H, 
d, J = 7.9Hz, NH), 5.23 (1H, dd, J = 10.4, 1.3 Hz, OCH2CHCHHcis), 4.99 (1H, dd, J = 
17.0, 1.6, Hz CαHCH2CH2CHCHtransH), 4.95 (1H, dd, J = 10.3, 1.0 Hz 
CαHCH2CH2CHCHHcis), 4.52 (2H, m, CHCO2CH3 and CHCH2CH(CH3)2), 4.45 (2H, d, J 
= 5.2 Hz, OCH2CHCH2), 4.38 (1H, br s, CHCH2ArO), 3.68 (3H, s, OCH3), 2.92 (2H, m, 
CHCH2ArO), 2.04 (2H, m, CαHCH2CH2CHCH2), 1.87 (1H, m, CHCH2CH2CHCH2), 
1.73 (1H, m, CHCHHCH2CHCH2), 1.61 (1H, m, CHCHHCH(CH3)2), 1.56 (1H, m, 
CHCH2CH(CH3)2), 1.45 (1H, m, CHCHHCH(CH3)2), 1.33 (9H, s, C(CH3)3), 0.85 (6H, m, 
2 x CH3). 13C NMR (75 MHz, CDCl3) δ 172.7, 171.9, 171.8, 157.7, 155.8, 136.9, 133.5, 
130.5, 130.4, 128.9, 117.7, 116.1, 114.9, 80.2, 68.9, 55.9, 52.4, 51.9, 51.8, 41.3, 37.3, 
35.3, 31.4, 29.7, 28.4, 24.7, 23.0, 22.9, 22.4, 18.2. HRMS (ES) 560.3326 (MH+); 
C30H46N3O7 requires 560.3336. 
 
(S)-2-[(S)-3-(4-Allyloxy-phenyl)-2-tert-butoxycarbonylamino-propionylamino]-4-
methyl-pentanoic acid methyl ester (2.11 ).1 
 
 
N-Boc-Tyr(O-allyl)-H 2.9 (17 g, 55 mmol) was coupled with Leu-OMe·HCl 2.10 
(General Procedure A1). The crude product was purified by flash chromatography on 
silica using a gradient of ethyl acetate and petroleum ether to give  as a glassy white solid 
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2.11 (19.5 g, 79 %). Mp 78-80 ºC. 1H NMR (500 MHz, CDCl3): δ 7.10 (2H, m, HArO), 
6.82 (2H, m, HArO), 6.30 (1H, d, J = 7.9 Hz, NH), 6.01 (1H, m, OCH2CHCH2), 5.41 
(1H, dd, J = 14.2 and 1.5 Hz, OCH2CHCHtransH), 5.27 (1H, dd, J = 10.3 and 1.2 Hz, 
OCH2CHCHHcis), 5.09 (1H, app d, NH), 4.54-4.56 (1H, m, CHCH2CH(CH3)2), 4.49 (2H, 
m, OCH2CHCH2), 4.30 (1H, m, CHCH2ArO), 3.68 (3H, s, OCH3), 2.98-3.01 (2H, m, 
CHCH2ArO), 1.54-1.57 (2H, m, CHCH2CH(CH3)2), 1.44-1.48 (1H, m, 
CHCH2CH(CH3)2) 1.41 (9H, s, (CH3)3), 0.87 (3H, d, J = 6.5 Hz, CH3), 0.86 (3H, d, J = 
6.5 Hz, CH3). MS (ES) 449.2655 (MH+); C24H37N2O6 requires 449.2651. 
Lit cit: 1Abell, A. D.; Jones, M. A.; Coxon, J. M.; Morton, J. D.; Aitken, S. G.; McNabb, 
S. B.; Lee, H. Y. Y.; Mehrtens, J. M.; Alexander, N. A.; Stuart, B. G.; Neffe, A. T.; 
Bickerstaffe, R. Molecular Angew. Chem. Int. Ed., 2009, 48, 1455 –1458.  
1H NMR (500 MHz, CDCl3): 7.08 (2H, m, HArO), 6.79 (2H, m, HArO), 6.43 (1H, d, J = 7.5 
Hz, NH), 6.01 (1H, app ddt, J = 17.5, 10.5, 5.75 and 5.75 Hz, OCH2CHCH2), 5.37 (1H, dd, J 
= 17.0 and 1.5 Hz, OCH2CHCHtransH), 5.24 (1H, dd, J = 10.5 and 1.5 Hz, OCH2CHCHHcis), 
5.09 (1H, d, J = 7.0 Hz, NH), 4.54-4.57 (1H, m, CHCH2CH(CH3)2), 4.47 (2H, app d, J = 5.5 
Hz, OCH2CHCH2), 4.30-4.36 (1H, m, CHCH2ArO), 3.66 (3H, s, OCH3), 2.88-3.02 (2H, app 
d, J = 7.0 Hz, CHCH2ArO), 1.51-1.59 (2H, m, CHCH2CH(CH3)2), 1.41-1.48 (1H, m, 
CHCH2CH(CH3)2) 1.38 (9H, s, (CH3)3), 0.87 (3H, d, J = 6.5 Hz, CH3), 0.86 (3H, d, J = 6.5 
Hz, CH3); 13C NMR (75 MHz CDCl3): 174.1, 172.8, 171.4, 157.5, 155.5, 133.2, 130.4, 130.3, 
128.7, 117.4, 114.7, 80.0, 68.7, 54.3, 52.1, 50.7, 41.3, 37.3, 28.2, 24.6, 22.7, 21.8; HRMS 
(ES) 449.2662 (MH+); C24H37N2O6 requires 449.2651. 
 
(S)-2-[(S)-3-(4-Allyloxy-phenyl)-2-tert-butoxycarbonylamino-propionylamino]-4-
methyl-pentanoic acid (2.12 ).1 
 
 
Methyl ester 2.11 (19 g, 42.4 mmol) was hydrolyzed (General procedure B) to give 2.12 
as a white solid (18.5 g, 98%). 1H NMR (500 MHz in CDCl3): 7.11 (2H, d, J = 7.0 Hz, 
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HArO), 6.82 (2H, d, J = 7.0 Hz, HArO), 6.99 (1H, app d, NH), 6.03 (1H, m, 
OCH2CHCH2), 5.28-5.37 (2H, m, OCH2CHCH2), 5.23 (1H, br s, NH), 4.54-4.56 (1H, m, 
CHCH2CH(CH3)2), 4.42-4.49 (2H, m, OCH2CHCH2 and CHCH2ArO), 2.95-3.01 (2H, m, 
CHCH2ArO), 1.53-1.68 (2H, m, CHCHCH2(CH3)2), 1.52-1.56 (1H, m, 
CHCHCH2(CH3)2), 1.39 (9H, s, C(CH3)3), 0.85-0.93 (6H, m, 2 x CH3). 13C NMR (75 
MHz CDCl3): 176.1, 172.0, 157.8, 155.2, 133.5, 130.6, 128.8, 117.8, 115.1, 80.2, 69.0, 
55.9, 51.1, 41.4, 37.3, 28.4, 24.9, 23.0, 20.1. 
Lit cit: 1Abell, A. D.; Jones, M. A.; Coxon, J. M.; Morton, J. D.; Aitken, S. G.; McNabb, 
S. B.; Lee, H. Y. Y.; Mehrtens, J. M.; Alexander, N. A.; Stuart, B. G.; Neffe, A. T.; 
Bickerstaffe, R. Molecular Angew. Chem. Int. Ed., 2009, 48, 1455 –1458.  
mp 72-75 ºC; 1H-NMR (500 MHz in CDCl3): 7.10 (2H, app d, J = 8.5 Hz, HArO), 6.82 (2H, 
app d, J = 8.5 Hz, HArO), 6.58 (1H, d, J = 8.0 Hz, NH), 6.03 (1H, app ddt, J = 16.0, 10.5, 
5.75 and 5.75 Hz, OCH2CHCH2), 5.39 (1H, dd, J = 17.0 and 1.5 Hz, OCH2CHCHtransH), 5.26 
(1H, dd, J = 10.5 and 1.5 Hz, OCH2CHCHHcis), 5.22 (1H, br s, NH), 4.54-4.58 (1H, m, 
CHCH2CH(CH3)2), 4.48 (2H, app d, J = 5.5 Hz, OCH2CHCH2), 4.34-4.40 (1H, m, 
CHCH2ArO), 2.96-3.02 (2H, m, CHCH2ArO), 1.58-1.70 (2H, m, CHCHCH2(CH3)2), 1.50-
1.56 (1H, m, CHCHCH2(CH3)2), 1.39 (9H, s, C(CH3)3), 0.91 (3H, d, J = 6.0 Hz, CH3), 0.91 
(3H, d, J = 6.0 Hz, CH3); 13C NMR (75 MHz CDCl3): _ 176.1, 172.1, 157.8, 155.2, 133.6, 
130.7, 128.9, 117.9, 115.1, 80.3, 69.0, 55.9, 51.1, 41.5, 37.3, 28.5, 25.0, 23.1, 20.1; HRMS 
(ES) 435.2515 (MH+); C23H35N2O6 requires 435.2495. 
 
(S)-2-tert-Butoxy carbonylamino -hex-5-enoic acid (2.21).  
 
 
To a suspension of N-Boc-Lys-OH 2.20 (31.8 g, 129.3 mmol) was treated with sodium 
nitroprusside (58.8 g, 197.3 mmol) (General Procedure I1) and the crude product was 
purified by flash chromatography on silica gel and elution with ethyl acetate/petroleum 
ether (1:2) to give 2.21 as yellow oil (9.8 g, 30%). 1H NMR (CDCl3, 300 MHz): δ 5.75-
5.81 (1H, m, CHCH2CH2CHCH2), 5.01-5.10 (2H, m, CHCH2CH2CHCH2), 4.02 (1H, m, 
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CHCH2CH2CHCH2), 2.15-2.18 (2H, m, CHCH2CH2CHCH2), 1.65-1.80 (2H, m, 
CHCH2CH2CHCH2), 1.39 (9H, m, (CH3)3). 13C NMR ((CD3)2SO, 75 MHz): δ 174.8, 
156.2, 138.2, 116.1, 78.6, 53.5, 30.7, 30.4, 28.9, 28.6. LRMS (ES) 230.13 (MH+); 
C11H20NO4 requires 230.13. 
 
(S)-2-Amino-hex-5-enoic acid methyl ester (2.22) 
 
 
Carboxylic acid 2.21 (2.23 g, 9.7 mmol) was treated with thionyl chloride in methanol 
(General Procedure E2) to give 2.22 as a yellow solid (1.85 g, 95%). 1H NMR ((CD3)2SO, 
300 MHz): δ 5.77 (1H, m, CHCH2CH2CHCH2), 5.02-5.06 (2H, m, CHCH2CH2CHCH2), 
3.92 (1H, m, CHCH2CH2CHCH2), 3.71 (1H, s, OCH3), 2.10-2.15 (2H, m, 
CHCH2CH2CHCH2), 1.82-1.89 (2H, m, CHCH2CH2CHCH2). 13C NMR ((CD3)2SO, 75 
MHz): δ 170.4, 136.9, 117.2, 56.6, 52.7, 39.8, 29.6.  
 
(8S,11S,14S)-14-tert-Butoxycarbonyl amino-11-isobutyl-10,13-dioxo-2-oxa -9,12-
diaza - bicyclo[14.2.2]icosa-1(19),16(20),17-triene-8-carboxylic acid methyl ester 
(2.28). 
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Alkene 2.4 (76 mg) prepared by RCM under thermal reflux condition (general procedure 
C1) was subjected to hydrogenation (General procedure D) to give a mixture of 17- and 
18-membered macrocyclic products (30mg). 
 
Alkene 2.4 (196 mg) prepared by RCM under thermal reflux with chlorodicyclohexyl 
borane (General procedure C2) was subjected to hydrogenation (General procedure D) to 
give a mixture of 16-, 17- and 18-membered macrocyclic products (147mg). 
 
Alkene 2.4 (153 mg) prepared by RCM under microwave (General procedure C3) was 
subjected to hydrogenation (General procedure D) to give a mixture of 17- and 18-
membered macrocyclic products (105 mg). 
 
Alkene 2.4 (180 mg) prepared by RCM under microwave irradiation with 
chlorodicyclohexyl borane (General procedure C4) was subjected to hydrogenation 
(General procedure D) to give a mixture of 16-, 17- and 18-membered macrocyclic 
products (95mg). 1H NMR of the major 18-memered macrocycle 2.28 (500 MHz, 
CDCl3): δ 7.06 (2H, d, J = 8.2 Hz, HArO), 6.75 (2H, d, J = 8.5 Hz, HArO), 6.02 (1H, d, J 
= 7.1 Hz, NH), 5.84 (1H d, J = 8.0 Hz, NH), 5.20 (1H d, J = 8.8 Hz, NH), 4.37 (1H, m, 
CHCO2CH3), 4.15 (CHCH2CH(CH3)2), 4.09-4.11 (2H, m, ArOCHHCH2CH2 and 
CHCH2ArO), 4.01 (1H, m, ArOCHHCH2CH2), 3.71 (3H, s, OCH3), 3.04 (1H, dd, J = 
12.8 and 4.9 Hz, CHCHHArO), 2.72 (1H, t, J = 12.5 and 12.0 Hz, CHCHHArO), 1.63-
1.74 (3H, m, ArOCH2CH2CH2 and CHHCHCO2CH3), 1.51-1.60 (3H, m, 
CHCH2CH(CH3)2 and CHCH2CH(CH3)2), 1.43 (9H, s, C(CH3)3), 1.21-1.37 (5H, m, 
ArOCH2CH2CH2, CH2CH2CHCO2CH3 and CHHCHCO2CH3), 0.86 (6H, m, 2 x CH3). 
MS (ES) 534.30 (18-membered macrocycle [M+H]+); 520.30 (17-membered macrocycle 
[M+H]+); 506.28 (16-membered macrocycle [M+H]+). 
 
(7S,10S,13S)-13-tert-Butoxycarbonylamino-10-isobutyl-9,12-dioxo-2-oxa-8,11-diaza-
bicyclo[13.2.2]-nonadeca-1(18),15(19),16-triene-7-carboxylic acid methyl ester 
(2.29).1 
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Alkene 2.2 (3.65 g, 7.1 mmol) was hydrogenated (General Procedure D) and the crude 
product was purified by flash chromatography on silica gel and elution with a gradient of 
ethyl acetate and petroleum ether to give 2.29 as a white solid (3.48 g, 95%).1H NMR 
(500 MHz in CDCl3): δ 7.06 (2H, m, HArO), 6.79 (2H, m, HArO), 6.05 (1H, d, J = 7.5 
Hz, NH), 5.78 (1H, d, J = 8.5 Hz, NH), 5.21 (1H, d, J = 8.5 Hz, NH), 4.55 (1H, m, 
CHCO2CH3), 4.27 (1H, m, ArOCHHCH2), 4.20 (1H, m, CHCH2ArO), 4.12 (1H, m, 
ArOCHHCH2), 3.98 (1H, m, CHCH2CH(CH3)2), 3.76 (3H, s, OCH3), 3.08-3.10 (1H, m, 
CHCHHArO), 2.60-2.64 (1H, m, CHCHHArO), 1.85-1.93 (1H, m, 
ArOCH2CH2CH2CHH), 1.65-1.70 (2H, m, ArOCH2CH2), 1.52-1.60 (4H, m, 
ArOCH2CH2CH2CHH, CHCH2CH(CH3)2 and CHCH2CH(CH3)2), 1.43 (9H, s, (CH3)3), 
1.25-1.36 (2H, m, ArOCH2CH2CH2), 0.84-1.90 (6H, m, 2 xCH3). 
Lit cit: 1Abell, A. D.; Jones, M. A.; Coxon, J. M.; Morton, J. D.; Aitken, S. G.; McNabb, 
S. B.; Lee, H. Y. Y.; Mehrtens, J. M.; Alexander, N. A.; Stuart, B. G.; Neffe, A. T.; 
Bickerstaffe, R. Molecular Angew. Chem. Int. Ed., 2009, 48, 1455 –1458.  
mp 235-236 ºC; 1H-NMR (500 MHz, CDCl3): 7.05 (2H, m, HArO), 6.79 (2H, m, HArO), 
6.08 (1H, d, J = 6.0 Hz, NH), 5.74 (1H, d, J = 8.5 Hz, NH), 5.22 (1H, d, J = 8.5 Hz, NH), 
4.38-4.42 (1H, ddd, J = 8.5, 8.5 and 4.0 Hz, CHCO2CH3), 4.25-4.30 (1H, m, ArOCHHCH2), 
4.17-4.22 (1H, m, CHCH2ArO), 4.10-4.14 (1H, m, ArOCHHCH2), 3.96-4.06 (1H, dd, J = 
13.5 and 6.5 Hz, CHCH2CH(CH3)2), 3.73 (3H, s, OCH3), 3.11 (1H, dd, J = 12.5 and 5.5 Hz, 
CHCHHArO), 2.65 (1H, app t, J = 12.0 and 12.0 Hz CHCHHArO), 1.68-1.74 (2H, m, 
ArOCH2CH2), 1.49-1.63 (5H, m, CHCH2CH(CH3)2, CHCH2CH(CH3)2 and 
CH2CH2CHCO2CH3), 1.45 (9H, s, C(CH3)3), 1.20-1.40 (2H, m, CH2CHCO2CH3), 0.82-0.85 
(6H, m, 2 x CH3); 13C NMR (75 MHz, CDCl3): 172.6, 170.8, 170.1, 157.0, 155.6, 155.1, 
130.3, 130.1, 128.4, 115.9, 115.7, 79.7, 66.7, 56.8, 52.5, 51.6, 51.22, 43.1, 38.7, 31.5, 28.2, 
28.2, 24.4, 22.7, 22.5, 21.4; HRMS (ES) 520.3031 (MH+); C27H42N3O7 requires 520.3023. 
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7.3: Experimental work described in chapter 3  
 
((7S,10S,13S)-7-Formyl-10-isobutyl-9,12-dioxo-2-oxa-8,11-diaza-bicyclo [13.2.2] 
nonadeca-1(18),15(19),16-trien-13-yl)-carbamic acid benzyl ester (CAT811).  
 
 
The macrocyclic alcohol 3.12 (2.0 g, 3.80 mmol) was oxidised (General procedure H1) 
and the crude product was recrystallised from ethyl acetate to give CAT811 as a white 
solid (1.49 g, 75 %). Mp 236-238 ºC. 1H NMR (500 MHz in (CD3)2SO): δ 9.33 (1H, s, 
CHO), 8.05 (1H, d, J = 8.0 Hz, NH),  7.55 (1H, d, J = 7.0 Hz, NH), 7.30-7.37 (5H, m, 
Ph), 7.16 (1H, m, NH), 7.02 (2H, m, HArO), 6.77 (2H, d, J = 7.5 Hz, HArO), 5.04 (1H, d, 
J = 12.5 Hz, PhCHH), 5.00 (1H, d, J = 12.5 Hz, PhCHH), 4.31-4.36 (3H, m, CHCH2ArO 
and ArOCH2), 4.18-4.25 (1H, m, CHCH2CH(CH3)2), 4.00-4.07 (2H, m, CHCHO and 
CHHCHCHO), 2.86 (1H, dd, J = 12.0 and 5.0 Hz, CHCHHArO), 2.63 (1H, app t, J = 
12.5 and 11.5 Hz, CHCHHArO), 1.70-1.77 (2H, m, CHHCHCHO), 1.46-1.52 (1H, m, 
CHCH2CH(CH3)2), 1.22-1.39 (6H, m, CHCH2CH(CH3)2, ArOCH2CH2 and 
CH2CH2CHCHO), 0.80-0.83 (6H, m, 2 x CH3). 13C NMR (75 MHz (CD3)2SO): δ 201.8, 
172.1, 170.3, 156.6, 156.1, 137.9, 130.1, 129.0, 128.4, 116.2, 66.8, 65.9 57.2, 56.8, 51.4, 
44.1, 31.0, 27.6, 27.1, 24.6, 23.6, 22.2. HRMS (ES) 524.2762 (MH+); C29H37N3O6 
requires 524.2760. 
 
(S)-2-[(S)-2-Benzyloxycarbonylamino-3-(4-hydroxy-phenyl)-propionylamino]-4-
methyl-pentanoic acid methyl ester (3.4). 
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Cbz-L-Tyrosine 3.2 (3.50 g, 11.1 mmol) was coupled with L-Leucine methyl ester 3.3 
(General procedure A1) to give 3.4 as a yellow oil which was not purified further (4.28 g, 
87%). 1H NMR (500 MHz, CDCl3): δ 7.25-7.35 (5H, m, Ph), 6.94 (2H, d, J = 8.5 Hz 
HArO), 6.65-6.70 (3H, m, NH and HArO), 5.62 (1H, d, J = 7.9 Hz, NH) 5.03 (2H, s, 
PhCH2), 4.51-4.56 (1H, m, CHCH2ArO), 4.42-4.46 (1H, m, CHCH2CH(CH3)2), 3.65 (3H, 
s, OCH3), 2.90-2.98 (2H, m, CHCH2ArO), 1.50-1.59 (2H, m, CHCH2CH(CH3)2 and 
CHCHHCH(CH3)2), 1.43-1.46 (1H, m, CHCHHCH(CH3)2), 0.82-0.95 (6H, m, 2 x CH3).  
 
(S)-2-[(S)-2-Benzyloxycarbonylamino-3-(4-hydroxy-phenyl)-propionylamino]-4-
methyl-pentanoic acid (3.5).  
 
 
Methyl ester 3.4 (4.20 g, 9.4 mmol) was hydrolysed under aqueous basic conditions 
(General procedure B). The crude product was recrystallized from ethyl acetate to give 
3.5 as a white solid (3.75 g, 92 %). 1H NMR (500 MHz in (CD3)2SO): δ 9.31 (1H, br s, 
COOH), 8.22 (1H, d, J = 7.9 Hz, NH), 7.35-7.41 (5H, m, Ph), 7.10-7.13 (2H, m, HArO), 
6.67-6.69 (2H, m, HArO), 4.93-4.97 (2H, s, PhCH2), 4.21–4.31 (2H, m, CHCH2ArO and 
CHCH2CH(CH3)2), 3.61 (1H, br s, ArOH), 2.90-2.96 (1H, m, CHCHHArO), 2.63-2.67 
(1H, m, CHCHHArO), 1.68–1.71 (1H, m, CHCH2CH(CH3)2), 1.54-1.60 (2H, m, 
CHCH2CH(CH3)2), 0.88 (3H, d, J= 6.3 Hz, CH3), 0.84 (3H, d, J= 6.5 Hz, CH3). 
 163 Chapter 7: Experimental 
 
(2S)-tert-Butoxycarbonylamino-6-hydroxyhexanoic acid (3.7).2  
 
 
Diazotization of N-Boc-lysine 3.6 (31.8 g, 129.3 mmol) (General procedure I1) gave the 
crude product that was purified by flash column chromatography on silica gel and elution 
with ethyl acetate, petroleum spirit, HOAc (70:29:1) to give 3.7 (10.5 g, 33%) as a white 
solid. 1H NMR (CD3OD, 500 MHz): 4.90 (1H, br s, ), 4.06 (1H, dd, J = 4.8, 9.0 Hz, 
CHCH2CH2CH2CH2OH), 3.55 (2H, t, J = 6.4 Hz, CHCH2CH2CH2CH2OH), 1.79-1.82 
(1H, m, CHCHHCH2CH2CH2OH), 1.64-1.68 (1H, m, CHCHHCH2CH2CH2OH), 1.51-
1.58 (2H, m, CHCH2CH2CH2CH2OH), 1.44-1.49 (11H, m, C(CH3)3 and CHCH2CH2 
CH2CH2OH).  
Lit cit: 2Glenn, M. P.; Pattenden, L. K.; Reid, R. C.; Tyssen, D. P.; Tyndall, J. D. A.; 
Birch, C. J.; Fairlie, D. P. J. Med. Chem., 2002, 45, 371-381. 
1H NMR (CDCl3, 300 MHz): 5.21 (br d, 1H); 4.28 (m, 1H); 3.66 (t, 2H); 1.41 (s, 9H); 
1.90 to 1.37 (m, 6H). 13C NMR (CDCl3, 75 MHz): 175.3, 156.5, 80.3, 62.1, 53.7, 32.4, 
32.3, 28.5, 22.0. 
 
(S)-2-{(S)-2-[(S)-2-Benzyloxycarbonylamino-3-(4-hydroxy-phenyl)-propionylamino] 
-4-methyl-pentanoylamino}-6-hydroxy-hexanoic acid methyl ester (3.9).  
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Carboxylic acid 3.5 (5.02 g, 11.6 mmol) was coupled with Amine hydrochloride salt 3.8 
and (General procedure A1). The crude product was recrystallized from ethyl acetate to 
give .3.9 as a white solid (5.73 g, 87 %). 1H NMR (500 MHz, CD3OD): δ 7.24-7.37 (5H, 
m, Ph), 7.03 (2H, app d, J = 8.5 Hz, HArO), 6.67 (2H, app d, J = 8.5 Hz, HAr), 4.97-5.06 
(2H, m, OCH2Ar), 4.41-4.46 (1H, m, CHCH2CH(CH3)2), 4.32-4.38 (2H, m, CHCH2ArO 
and CHCO2CH3), 3.69 (3H, s, OCH3), 3.50-3.55 (2H, m, CH2OH), 2.98-3.03 (1H, m 
CHCHHAr), 2.73-2.77 (1H, m CHCHHAr),  1.77-1.87 (1H, m, CHCH2CH(CH3)2), 1.66-
1.75 (1H, m, OCH2CHHCH2CH2), 1.60-1.64 (1H, m, OCH2CHHCH2CH2), 1.51-1.58 
(4H, m, CHCH2CH(CH3)2 and OCH2CH2CH2CH2), 1.38-1.48 (2H, m, 
OCH2CH2CH2CH2), 0.93 (3H, d, J = 6.5 Hz, CH3), 0.90 (3H, d, J = 6.5 Hz, CH3). 13C 
NMR (75 MHz CD3OD): δ 173.5, 173.0, 157.1, 156.1, 137.0, 130.4, 128.4, 128.0, 127.8, 
127.5, 115.2, 66.5, 62.4, 61.5, 56.7, 52.7, 40.9, 31.9, 31.1, 24.6, 22.4, 22.1, 21.3. HRMS 
(ES) 572.2984 (MH+); C30H42N3O8 requires 572.2972. 
 
(7S,10S,13S)-13-Benzyloxycarbonylamino-10-isobutyl-9,12-dioxo-2-oxa-8, 11-diaza 
bicyclo[13.2.2]nonadeca-1(18),15(19),16-triene-7-carboxylic acid methyl ester (3.11).  
 
 
Intramolecular nucleophilic substitution of 3.10 (7.0 g, 0.01 mol) was conducted (General 
procedure P). Recrystallisation of the product from ethyl acetate and pentane gave 3.11 as 
a white solid (3.87 g, 70%). Mp 274-276 ºC. 1H NMR (500 MHz, C5D5N): δ 9.44 (1H, d, 
J = 9.0 Hz, NH), 8.88 (1H, d, J = 8.0 Hz, NH), 8.52 (1H, d, J = 8.0 Hz, NH), 7.33 (2H, m, 
Ph), 7.18-7.23 (5H, m, Ph and HArO), 6.86 (2H, app d, J = 8.5 Hz, HArO), 5.25 (2H, br s, 
PhCH2), 5.06-5.12 (1H, m CHCH2ArO), 4.83-4.88 (1H, m, CHCH2CH(CH3)2), 3.95 (1H, 
dd, J = 14.0 and 7.0 Hz,  CHCO2CH3), 4.22-4.26 (1H, m, ArOCHH), 3.41-3.99 (1H, m, 
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ArOCHH),  3.54 (3H, s, OCH3), 3.22 (1H, dd, J = 13.0 and 6.0 Hz, CHCHHArO), 3.14 
(1H, app t, J = 12.0 and 12.0 Hz, CHCHHArO), 1.76-1.82 (4H, m, CHCH2CH(CH3)2, 
CHCHHCH(CH3)2, ArOCH2CHH and CHHCHCO2CH3), 1.60-1.67 (2H, m, 
CH2CHCO2CH3 and CHCH2CH(CH3)2), 1.41-1.52 (1H, m, CH2CHHCHCO2CH3), 1.21-
1.32 (2H, m, ArOCH2CHH and CH2CHHCHCO2CH3), 0.72 (3H, d, J = 6.5 Hz, CH3), 
0.68 (3H, d, J = 6.5 Hz, CH3). 13C NMR (75 MHz in CDCl3): δ 172.5, 170.8, 169.7, 
157.1, 155.5, 136.3, 130.1, 128.5, 128.2, 128.1, 127.9, 115.7, 66.8, 66.7, 57.1, 52.5, 51.7, 
51.2, 43.3, 39.0, 31.5, 28.0, 24.5, 22.9, 22.4, 21.2. HRMS (ES) 554.2859 (MH+); 
C30H40N3O7 requires 554.2866. 
 
 ((7S,10S,13S)-7-Hydroxymethyl-10-isobutyl-9,12-dioxo-2-oxa-8,11-diaza bicycle 
[13.2.2] nonadeca-1(18),15(19),16-trien-13-yl)-carbamic acid benzyl ester (3.12).  
 
 
The macrocyclic methyl ester 3.11 (1.50 g, 2.7 mmol) was reduced (General procedure 
G2) and the crude product was recrystallisation from ethyl acetate to give 3.12 as a white 
solid (1.38 g, 97%). 1H NMR (500 MHz, (CD3OD): δ 7.26–7.36 (3H, m, Ph), 7.05 (2H, 
m, HArO), 6.79 (2H, m, HArO), 5.05-5.13 (1H, m, PhCH2), 4.29–4.34 (2H, m, 
CHCH2ArO and ArOCHH), 4.05–4.10 (1H, m, ArOCHH), 3.96–4.02 (1H, m, 
CHCH2CH(CH3)2), 3.79 (1H, m, CHCH2OH), 3.32 (2H, m, CH2OH), 2.98 (1H, m, 
CHCHHArO), 2.69 (1H, m, CHCHHArO), 1.75–1.84 (2H, m, CH2CHCH2OH), 1.51–
1.56 (3H, m, CHCH2CH(CH3)2 and CHCH2CH(CH3)2), 1.22–1.42 (4H, m, ArOCH2CH2 
and CH2CH2CHCH2OH), 0.83-0.87 (6H, m, 2 x CH3). 
 
(S)-2-Amino-3-hydroxy-propionic acid tert-butyl ester (3.14). 
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N-Cbz-Ser-OtBu 3.13 (3 g, 10.2 mmol) was hydrogenated (General procedure D) to give 
product 3.14 (1.6 g, 97%). 1H NMR (CDCl3, 300 MHz): δ 3.78-3.82 (1H, dd, J = 3.9 and 
10.8 Hz, CHCHHOH), 3.64-3.68 (1H, dd, J = 5.9 and 10.7 Hz, CHCHHOH), 3.43-3.48 
(1H, m, CHCH2OH), 1.49 (9H, s, OC(CH3)3). 13C NMR (CDCl3, 75 MHz): δ 173.3, 81.9, 
64.4, 56.6, 28.2. MS (ES) 162.11 (MH+); C7H16NO3 requires 162.11.  
 
(S)-2-{(S)-2-[(S)-2-Benzyloxycarbonylamino-3-(4-hydroxy-phenyl)-propionylamino] 
-4-methyl-pentanoylamino}-3-hydroxy-propionic acid tert-butyl ester (3.16). 
 
 
Ser-OtBu 3.14 (1.60 g, 9.9 mmol) was coupled with carboxylic acid 3.5 (General 
procedure A1) to give the crude product. The crude product was purified by flash 
chromatography on silica gel and elution with ethyl acetate/petroleum ether (3:2) as 
eluent to give 3.16 as a white solid (4.58 g, 78%). 1H NMR (CDCl3, 500 MHz): δ 7.64 
(1H, d, J = 9.0 Hz, NH), 7.26-7.29 (5H, m, Ph), 7.23 (1H, d, J = 7.1 Hz, NH), 6.89 (2H, 
m, J = 7.9 Hz, ArH), 6.64 (2H, m, J = 8.1Hz, ArH), 6.03 (1H, d, J = 7.2 Hz, NH), 5.04 
(1H, d, J = 12.5 Hz, PhCHH), 5.00 (1H, d, J = 12.5 Hz, PhCHH), 4.55-4.58 (2H, m, 
CHCH2CH(CH3)2 and CHCH2OH), 4.45 (1H, m, CHCH2ArO), 3.82 (2H, s, CHCH2OH), 
2.85-2.94 (2H, m, CHCH2ArO), 1.48-1.61 (3H, m, CHCH2CH(CH3)2 and 
CHCH2CH(CH3)2). 1.43 (9H, s, C(CH3)3), 0.82-0.87 (6H, m, CHCH2CH(CH3)2). 13C 
NMR (75 MHz CD3OD): δ 172.5, 172.3, 169.5, 156.4, 155.5, 136.3, 130.6, 128.7, 128.4, 
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128.2, 115.9, 83.0, 67.3, 63.1, 57.0, 55.6, 52.3, 41.2, 28.3, 24.8, 22.9, 22.4. HRMS (ES) 
594.2779 (MNa+); C30H41N3NaO8 requires 594.2786. 
 
(S)-2-((S)-2-{(S)-2-Benzyloxycarbonylamino-3-[4-(4-bromo-butoxy)-phenyl] 
propionyl amino}-4-methyl-pentanoylamino)-3-hydroxy-propionic acid tert-butyl 
ester (3.18). 
 
 
Tripeptide 3.16 (200 mg, 0.35mmol), potassium carbonate (72.5 mg, 0.52 mmol) and 
cesium carbonate (11.4 mg, 0.035 mmol) were dissolved in MeCN (10 ml). To this 
solution was added dibromobutane 3.17 (418 µl) and solution was stirred under reflux 
condition overnight. The reaction solution was concentrated and residue was partitioned 
between ethyl acetate and 1M HCl. The organic layer was washed by 1M HCl, distilled 
water, brine and dried over MgSO4 before concentrated in vacuo to give the crude 
product 3.18 as a white crystal (252 mg) The crude product was purified by flash 
chromatography on silica gel and elution with ethyl acetate/petroleum ether (1:1) to give 
3.18 as a yellow oil (131 mg, 53%). 1H NMR (CDCl3, 500 MHz): δ 7.30-7.38 (5H, m, 
Ph), 7.11 (2H, d, J= 8.5Hz, HArO), 6.83 (2H, d, J= 8.5Hz, HArO), 6.63 (1H, d, J = 7.8 
Hz, NH), 5.56 (1H, d, J = 7.1 Hz, NH), 5.09 (2H, m, OCH2Ar), 4.53-4.56 (2H, m, 
CHCH2CH(CH3)2 and CHCH2OH), 4.45-4.48 (1H, m, CHCH2ArO), 3.91 (2H, m, 
ArOCH2CH2CH2CH2Br), 3.85 (CHCH2OH), 3.45 (2H, ArOCH2CH2-CH2CH2Br), 3.01 
(2H, m, CHCH2Ar), 2.07 (2H, m, ArOCH2CH2CH2CH2Br), 1.92 (2H, m, 
ArOCH2CH2CH2CH2Br), 1.52-1.70 (3H, m, CHCH2CH(CH3)2 and CHCH2CH(CH3)2), 
1.47 (9H, s, OC(CH3)3), 086-0.88 (6H, m, CHCH2CH(CH3)2).13C NMR (75 MHz 
CD3OD): δ 172.0, 169.5, 158.2, 157.0, 136.2, 130.6, 130.4, 128.8, 128.5, 128.3, 128.2, 
114.9, 82.9, 67.5, 67.0, 63.3, 56.6, 55.7, 52.2, 40.7, 36.9, 33.7, 29.7, 28.2, 24.9, 23.1, 22.2. 
HRMS (ES) 728.2540 (MNa+); C34H48BrN3NaO8 requires 728.2517.  
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(S)-2-((S)-2-{(S)-2-Benzyloxycarbonylamino-3-[4-(4-iodo-butoxy)-phenyl]-propionyl 
amino}-4-methyl-pentanoylamino)-3-hydroxy-propionic acid tert-butyl ester (3.20). 
 
 
To a solution of alkyl bromide 3.18 (250 mg, 0.35 mmol) in acetone (4 ml) was added 
sodium iodide (80 mg, 0.53 mmol). The resulting solution was stirred overnight and 
concentrated in vacuo. The residue was partitioned between ethyl acetate and 1M HCl 
and the organic layer was washed by 1M HCl, distilled water, brine and dired over 
MgSO4 and the solvent removed  in vacuo to give 3.20 as a yellow oil (260 mg, 98%). 1H 
NMR (CDCl3, 500 MHz): δ 7.30-7.37 (5H, m, Ph), 7.12 (2H, d, J= 8.6 Hz, HArO), 6.83 
(2H, d, J= 8.6 Hz, HArO), 6.53 (1H, d, J = 7.8 Hz, NH), 5.51 (1H, d, J = 7.0 Hz, NH), 
5.09 (2H, m, OCH2Ar), 4.52-4.55 (2H, m, CHCH2CH(CH3)2 and CHCH2OH), 4.41 (1H, 
m, CHCH2ArO), 3.97 (2H, m, ArOCH2CH2CH2CH2Br), 3.90 (CHCH2OH), 3.31 (2H, 
ArOCH2CH2CH2CH2Br), 3.03 (2H, m, CHCH2Ar), 2.03 (2H, m, 
ArOCH2CH2CH2CH2Br), 1.89-1.94 (4H, m, ArOCH2CH2CH2CH2Br and 
CHCH2CH(CH3)2), 1.69 (1H, m, CHCH2CH(CH3)2) and 1.52 (9H, s, OC(CH3)3), 0.92-
0.94 (6H, m, CHCH2CH(CH3)2). HRMS (ES) 776.2361 (MNa+); C34H48IN3NaO8  
requires 776.2378.  
 
7.4: Experimental work described in chapter 4  
 
(6S,9S,12S)-12-Benzyloxycarbonylamino-9-isobutyl-8,11-dioxo-1,7,10,15-tetraaza-
bicyclo[12.2.1] heptadeca-14(17),15-diene-6-carboxylic acid methyl ester (4.1a) 
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Intramolecular lactamization of macrocyclic precursor 4.15 (1.22 g, 2.24 mmol) (General 
procedure O2) gave the macrocycle and the crude product was purified by 
chromatography on silica gel and elution with methanol/dichloromethane (1:20) to give 
the 4.1a as a white solid (620 mg, 52%). 1H NMR (CD3OD, 500 MHz): δ 8.56 (1H, s, 2-
ArH), 7.35-7.37 (5H, m, Ph), 7.17 (1H, s, 5-ArH), 5.16 (1H, d, J = 12.2, OCHHAr), 5.08 
(1H, d, J = 12.5 Hz, OCHHAr), 4.63-4.65 (1H, m, CHCH2CH(CH3)2), 4.53-4.55 (1H, m, 
CHCH2Ar), 4.34-4.37 (1H, m, CHCH2CH2CH2CH2Ar), 4.23-4.26 (1H, m, 
CHCH2CH2CH2CHHAr), 4.10-4.13 (1H, m, CHCH2CH2CH2CHHAr), 3.71 (3H, s, 
OCH3), 3.12 (2H, m, CHCH2Ar), 2.12-2.15 (1H, m, CHCH2CH2CHHCH2Ar), 1.95-1.99 
(1H, m, CHCH2CH2CHHCH2Ar), 1.63-1.73 (3H, m, CHCH2CH(CH3)2 and 
CHCH2CH(CH3)2), 1.51-1.54 (2H, m, CHCH2CH2CH2CH2Ar), 1.21-1.26 (1H, m, 
CHCH2CHHCH2CH2Ar), 1.08-1.12 (1H, m, CHCH2CHHCH2CH2Ar), 0.94 (3H, d, J = 
6.4 Hz, CH(CH3)2),  0.89 (3H, d, J = 6.4 Hz, CH(CH3)2). 13C NMR (CDCl3, 75 MHz): 
173.0, 172.4, 170.1, 156.1, 137.8, 137.7, 137.0, 129.0, 128.5, 128.4, 116.7, 66.1, 54.0, 
52.6, 51.5, 49.4, 46.3, 41.7, 41.0, 31.0, 30.6, 28.1, 24.7, 23.2, 23.0, 21.3. HRMS (ES) 
528.2830 (MH+); C27H38N5O6 requires 528.2822. 
  
((6S,9S,12S)-6-Hydroxymethyl-9-isobutyl-8,11-dioxo-1,7,10,15-tetraaza-bicyclo 
[12.2.1] heptadeca-14(17), 15-dien-12-yl)-carbamic acid benzyl ester (4.1b). 
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The macrocyclic methyl ester 4.1a (200 mg, 0.378 mmol) was reduced (General 
procedure G2) and the crude product was recrystallised from ethanol to give 4.1b as a 
white solid (185 mg, 98%). 1H NMR (DMSO, 500 MHz): δ 8.15 (1H, s, 2-ArH), 7.95 
(1H, d, J = 8.6 Hz, NH), 7.78 (1H, d, J = 9.0 Hz, NH), 7.50 (1H, d, J = 7.1 Hz, NH), 
7.29-7.35  (5H, m, Ph), 7.13 (1H, s, 5-ArH), 4.97-5.02 (2H, m, OCH2Ar), 4.59 (1H, m, 
CH2OH), 4.55-4.58 (CHCH2Ar), 4.27-4.29 (1H, m, CHCH2CH(CH3)2), 3.94 (2H, m, 
CHCH2CH2CH2CH2Ar), 3.78 (1H, m, CHCH2CH2CH2CH2Ar), 3.21-3.25 (1H, m, 
CHHOH), 3.14-3.18 (1H, m, CHHOH), 3.07-3.10 (1H, m, CHCHHAr), 2.65-2.67 (1H, m, 
CHCHHAr), 1.85-1.97 (2H, m, CHCH2CH2CH2CH2Ar), 1.53-1.55 (1H, m, 
CHCHHCH2CH2CH2Ar), 1.30-1.45 (3H, m, CHCH2CH(CH3)2 and CHCH2CH(CH3)2), 
1.15-1.18 (1H, m, CHCHHCH2CH2CH2Ar),  1.05-1.09 (1H, m, CHCH2CHHCH2CH2Ar), 
0.94-0.96 (1H, m, CHCH2CHHCH2CH2Ar), 0.80-0.86 (6H, m, CH(CH3)2). 13C NMR 
(CDCl3, 75 MHz): δ 171.7, 160.6, 156.1, 137.9, 137.8, 134.0, 129.0, 128.4, 128.3, 118.9, 
66.0, 64.8, 51.7, 53.1, 51.7, 48.0, 42.3, 41.0, 30.5, 28.7, 27.1, 24.8, 23.2. HRMS (ES) 
500.2870 (MH+); C26H38N5O5 requires 500.2873. 
  
((6S,9S,11S)-6-Formyl-9-isobutyl-8,11-dioxo-1,7,10,15-tetraaza-bicyclo [12.2.1] 
heptadeca-14(17),15-dien-12-yl)-carbamic acid benzyl ester (4.1c).1 
 
The macrocyclic alcohol 4.1b (30 mg, 0.06 mmol) was oxidised (General procedure H3) 
and the crude product was purified by chromatography on silica gel and elution with 
methanol/dichloromethane (1:99) to give 4.3c as a white solid (20 mg, 67%). 1H NMR 
(300 MHz, CDCl3) δ 9.54 (s, 1H), 7.47 – 7.29 (m, 6H), 6.64 (s, 1H), 6.38 (d, J = 8.7 Hz, 
1H), 6.23 (d, J = 8.0 Hz, 1H), 6.17 (d, J = 7.3 Hz, 1H), 5.12 (q, J = 12.2 Hz, 2H), 4.63 
                                                
1 Oxidation of 4.1b to 4.1c was carried out by Ashok Pehere at the University of Adelaide using 
commercially available Dess-Martin periodinane. 
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(dd, J = 21.2, 11.1 Hz, 2H), 4.30 (dd, J = 12.6, 5.3 Hz, 1H), 4.09 – 3.92 (m, 1H), 3.92 – 
3.77 (m, 1H), 3.08 – 2.91 (m, 2H), 2.16 – 1.86 (m, 3H), 1.85 – 1.50 (m, 4H), 1.18 – 1.00 
(m, 2H), 0.93 (d, J = 4.2 Hz, 3H), 0.88 (d, J = 3.7 Hz, 3H).13C NMR (151 MHz, 
(CD3)2SO) δ 200.96, 172.19, 171.62, 157.73, 136.82, 135.08, 128.31, 127.85, 127.74, 
118.65, 65.59, 55.68, 54.32, 52.71, 51.04, 41.03, 35.07, 28.97, 24.10, 22.71, 22.21, 13.91. 
HRMS (ES) 498.2711 (MH+); C27H38N5O6 requires 498.2716. 
 
(7S,10S,13S)-13-Benzyloxycarbonylamino-10-isobutyl-9,12-dioxo-1,8,11,16-tetraaza-
bicyclo[13.2.1] octadeca-15(18),16-diene-7-carboxylic acid methyl ester (4.2a). 
 
 
Intramolecular lactamization of macrocyclic precursor 4.36 (335 mg, 0.6 mmol) (General 
procedure O2) gave the macrocycle and the crude product was purified by 
chromatography on silica gel and elution with methanol/dichloromethane (1:10) to give 
4.2a as a white solid (160 mg, 50%) 1H NMR (CD3OD, 500 MHz): δ 7.53 (1H, s, 2-ArH), 
7.33-7.35 (5H, m, Ph), 6.79 (1H, s, 5-ArH), 5.10 (1H, m, OCH2Ar), 4.50-4.52 (1H, m, 
CHCH2Ar), 4.42-4.45 (2H, m, CHCH2CH(CH3)2 and CHCH2CH2CH2CH2 CH2Ar), 4.01 
(1H, m, CHCH2CH2CH2CHHAr), 3.85 (1H, m, CHCH2CH2CH2CHHAr), 3.68 (3H, s, 
OCH3), 2.98 (2H, m, CHCH2Ar), 1.82-1.94 (2H, CHCH2CH2CH2CHHCH2Ar and 
CHCH2CH2CH2CH2CH2Ar), 1.60-1.75 (4H, CHCH2CH2CH2CHHCH2Ar, 
CHCH2CH2CH2CH2CH2Ar and CHCH2CH(CH3)2), 1.51 (2H, m, CHCH2CH(CH3)2), 
1.35-1.40 (2H, m, CHCH2CH2CHHCH2CH2Ar), 1.21 (1H, m, 
CHCH2CH2CHHCH2CH2Ar), 0.90-0.94 (6H, m, CHCH2CH(CH3)2). 13C NMR (CD3OD, 
75 MHz): 173.1, 173.0, 171.4, 156.8, 137.3, 137.0, 136.1, 128.3, 127.8, 127.7, 117.5, 
66.4, 54.5, 51.8, 51.5, 51.1, 50.4, 46.3, 41.8, 30.4, 30.3, 29.9, 24.9, 24.4, 24.3, 22.2, 21.3. 
HRMS (ES) 542.2979 (MH+); C27H38N5O6 requires 542.2979. 
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(6S,9S,12S)-6-Benzyloxycarbonylamino-9-isobutyl-7,10-dioxo-1,8,11,15-tetraaza 
bicycle [12.2.1] heptadeca-14(17),15-diene-12-carboxylic acid methyl ester (4.3a) 
 
 
Acidolysis of pseudo-tripeptide 4.39 (430 mg, 0.62 mmol) in the presence of 
trifloroacetic acid (General procedure N) followed by intramolecular lactamization of 
macrocyclic precursor 4.38 (General procedure O2) gave the macrocycle. The crude 
product was purified by chromatography on silica gel and elution with  methanol/ 
dichloromethane (1:20) to give 4.3a as a white solid (167 mg, 51%). 1H NMR (CD3OD, 
500 MHz): δ 7.57 (1H, s, 2-ArH), 7.29-7.33 (5H, m, Ph), 6.81 (1H, s, 5-ArH), 5.06 (2H, s, 
OCH2Ph), 4.84-4.86 (1H, m, CHCH2Ar), 4.52 (1H, m, CHCH2CH2CH2CH2Ar), 4.05-
4.07 (1H, dd, J = 4.2 and 9.7 Hz, CHCH2CH(CH3)2), 3.97 (2H, m, 
CHCH2CH2CH2CH2Ar), 3.76 (3H, s, OCH3), 3.17-3.20 (1H, dd, J = 2.6 and 15.0Hz, 
CHCHHAr), 2.80 (1H, m, CHCHHAr), 1.78-1.81 (1H, m, CHCH2CH2CHHCH2Ar), 
1.55-1.70 (5H, m, CHCH2CH2CHHCH2Ar, CHCH2CH2CH2CH2Ar, CHCH2CH(CH3)2 
and CHCHHCH(CH3)2), 1.50-1.55 (1H, m, CHCHHCH(CH3)2),  1.09-1.11 (1H, m, 
CHCHHCH(CH3)2), 0.96 (3H, d, J = 6.4Hz, CHCH2CH(CH3)2), 0.89 (3H, d, J = 6.4Hz, 
CHCH2CH(CH3)2). 13C NMR (CDCl3, 75 MHz): δ 172.7, 172.3, 171.8, 156.7, 137.0, 
136.8, 136.2, 128.3, 127.8, 127.7, 117.5, 66.4, 54.1, 51.8, 51.4, 51.2, 45.8, 41.1, 31.3, 
30.3, 28.3, 24.5, 21.8, 21.6, 21.3. HRMS (ES) 528.2799 (MH+); C27H38N5O6 requires 
528.2822. 
 
((6S,9S,12S)-12-Hydroxymethyl-9-isobutyl-7,10-dioxo -1,8,11,15-tetraaza-bicyclo 
[12.2.1] heptadeca-14(17), 15-dien-6-yl)-carbamic acid benzyl ester (4.3b). 
 173 Chapter 7: Experimental 
 
 
The macrocyclic methyl ester 4.1a (160 mg, 0.30 mmol) was reduced (General procedure 
G2) and crude product was purified by chromatography on silica gel and elution with 
methanol/dichloromethane (1:10) to give 4.3b as a white solid (116 mg,72%). 1H NMR 
(CD3OD, 500 MHz): δ 8.44 (1H, s, 2-ArH), 7.29-7.34 (5H, m, Ph), 7.08 (1H, s, 5-ArH), 
5.06 (2H, s, OCH2Ar), 4.40 (1H, m, CHCH2CH2CH2CH2Ar), 4.21 (1H, m, CHCH2Ar), 
4.14 (2H, m, CHCH2CH2CH2CH2Ar), 4.06 (1H, dd, J = 4.7 and 10.2Hz, 
CHCH2CH(CH3)2), 3.58 (2H, m, CH2OH), 2.98 (1H, d, J = 14.1 Hz, CHCHHAr), 2.65 
(1H, m, CHCHHAr), 1.85 (1H, m, CHCH2CH2CHHCH2Ar), 1.71-1.73 (2H, m, 
CHCH2CH2CHHCH2Ar and CHCH2CHHCH2CH2Ar), 1.60-1.70 (3H, CHCH2CHH 
CH2CH2Ar, CHCH2CH(CH3)2 and CHCHHCH(CH3)2), 1.54 (1H, m, 
CHCHHCH2CH2CH2Ar), 1.48 (1H, m, CHCHHCH2CH2CH2Ar), 1.18 (1H, m, CHCHH 
CH(CH3)2), 0.89-0.93 (6H, m, CHCH2CH(CH3)2). 13C NMR (CDCl3, 75 MHz): δ 171.9, 
171.2, 160.6, 156.0, 138.8, 137.8, 129.0, 128.5, 128.4, 123.1, 116.6, 65.9, 64.7, 51.3, 49.7, 
47.7, 42.6, 40.8, 30.7, 24.8, 23.3, 23.1, 22.2. HRMS (ES) 500.2850 (MH+). C26H38N5O5 
requires 500.2867. 
 
((7S,9S,12S)-12-Formyl-9-isobutyl-7,10-dioxo-1,8,11,15-tetraaza-bicycl o[12.2.1] 
heptadeca-14(17),15-dien-6-yl)-carbamic acid benzyl ester (4.3c).2  
                                                
2 Oxidation of 4.3b to 4.3c was carried out by Ashok Pehere at the University of Adelaide using 
commercially available Dess-Martin periodinane. 
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The macrocyclic alcohol 4.3b (20 mg, 0.04 mmol) was oxidised (General procedure H3) 
and the crude product was purified by chromatography on silica gel and elution with 
methanol/dichloromethane (1:99) to give 4.3c as a white solid (10 mg, 50%). 1H NMR 
(600 MHz, CDCl3): δ 9.71 (s, 1H), 7.34 (m, J = 23.4, 4.8 Hz, 6H), 6.83 (d, J = 6.0 Hz, 
1H), 6.67 (s, 1H), 6.30 (d, J = 7.2 Hz, 1H), 5.53 (d, J = 7.2 Hz, 1H), 5.10 (d, J = 23.5 Hz, 
2H), 4.80 (dd, J = 11.9, 8.0 Hz, 1H), 4.46 (dd, J = 14.8, 8.3 Hz, 1H), 4.09 (dd, J = 11.3, 
7.7 Hz, 1H), 3.89 (m, 2H), 3.39 (dd, J = 15.2, 4.1 Hz, 1H), 2.81 (dd, J = 14.9, 8.9 Hz, 
1H), 2.17 – 1.93 (m, 2H), 1.90 – 1.42 (m, 4H), 1.40 – 1.03 (m, 3H), 0.96 – 0.77 (m, 
6H).13C NMR (151 MHz, CDCl3) δ 198.25, 171.90, 170.37, 155.58, 136.96, 136.60, 
135.93, 128.54, 128.22, 128.02, 116.86, 66.99, 58.52, 54.32, 51.56, 46.25, 41.55, 31.97, 
29.70, 24.67, 22.69, 22.11, 14.12. HRMS (ES) 498.2716 (MH+); C26H36N5O5 requires 
498.2711. 
 
(S)-2-Amino-6-{4-[(S)-2-benzyloxycarbonylamino-2-((S)-1-carboxy-3-methyl-butyl 
carbamoyl)-ethyl]-imidazol-1-yl}-hexanoic acid methyl ester (4.15). 
 
4.15 
 
Acidolysis of pseudo-tripeptide 4.21 (1.6 g, 2.3 mmol) in the presence of trifloroacetic 
acid (General procedure N) to give 4.15 (1.22 g, 99%) as a colourless oil which was used 
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without purification. 1H NMR for major product from mixture (CD3OD, 500 MHz): δ 
8.78 (1H, s, 2-ArH), 7.40 (1H, s, 5-ArH), 7.34-7.36 (5H, m, Ph), 5.08 (2H, m, OCH2Ar), 
4.49-4.52 (1H, m, CHCH2Ar), 4.40-4.43 (1H, m, CHCH2CH(CH3)2), 4.15-4.18 (2H, m, 
CHCH2CH2CH2CH2Ar), 4.03-4.06 (1H, m, CHCH2CH2CH2CH2 Ar), 3.83 (3H, s, OCH3), 
3.29-3.31 (1H, dd, , J =  6.8 and 15.4 Hz, CHCHHAr), 3.03-3.06 (1H, dd, J = 7.2 and 
15.6 Hz, CHCHHAr), 1.85-2.00 (4H, CHCH2CH2CH2CH2Ar and 
CHCH2CH2CH2CH2Ar), 1.62-1.75 (3H, m, CHCH2CH(CH3)2 and CHCH2CH(CH3)2), 
1.41-1.49 (2H, m, CHCH2CH2CH2CH2Ar), 0.95 (3H, d, J = 6.3Hz, CHCH2CH(CH3)2), 
0.91 (3H, d, J = 6.1Hz, CHCH2CH(CH3)2). 13C NMR (CD3OD, 75 MHz): δ 174.8, 171.1, 
169.6, 158.5, 136.9, 134.5, 130.4, 127.8, 125.1, 120.2, 114.1, 66.7, 53.8, 52.5, 51.0, 45.8, 
40.1, 29.7, 29.2, 27.6, 24.8, 22.2, 21.7, 20.5, 20.3. HRMS (ES) 546.2914 (MH+). 
C27H40N5O7 requires 546.2928. 
 
(S)-2-tert-Butoxycarbonylamino-6-iodo-hexanoic acid methyl ester (4.17) 
 
 
Primary alcohol 4.18 (3.2 g, 12.2 mol) was converted to the iodide (General procedure 
L1). The crude product was purified by chromatography on silica gel and elution with 
ethyl acetate/petroleum ether (1:5) to give 4.17 (2.94 g, 66%): 1H NMR (CDCl3, 500 
MHz): δ 5.03 (1H, d, J = 14.1 Hz, NH), 4.29-4.30 (1H, m, CHCH2CH2CH2CH2I), 3.75 
(3H, s, OCH3), 3.16-3.18 (2H, m, CHCH2CH2CH2CH2I), 1.81-1.84 (3H, 
CHCH2CH2CH2CH2I and CHCHHCH2CH2CH2I), 1.60-1.63 (CHCHHCH2CH2CH2I), 
1.44-1.47 (11H, m, CHCH2CH2CH2CH2I and C(CH3)3) 13C NMR (CDCl3, 75 MHz): δ 
173.4, 155.5, 80.2, 53.3, 52.6, 32.9, 31.9, 28.5, 26.4, 6.4. HRMS (ES) 372.0687 (MH+). 
C12H23NO4I requires 372.0672.  
 
(S)-2-tert-Butoxycarbonylamino-6-hydroxy-hexanoic acid methyl ester (4.18). 
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Carboxylic acid 4.12 (2.3 g, 9.3 mmol) was esterified with methyl iodide (General 
procedure J1) and the crude product purified by chromatography on silica gel and elution 
with cyclohexane/ethyl acetate (8:2) to give 4.18 as a yellow oil (1.58 g, 65%): 1H NMR 
(CDCl3, 500 MHz): δ 5.15 (1H, NH) 4.22-4.26 (1H, m, CHCH2CH2CH2CH2OH), 3.69 
(3H, s, OCH3), 3.56-3.59 (2H, m, CHCH2CH2CH2CH2OH), 1.74-1.79 (1H, m, 
CHCHHCH2CH2CH2OH), 1.62-1.65 (H, CHCHHCH2CH2CH2OH), 1.50-1.55 (2H, m, 
CHCH2CH2CH2CH2OH), 1.38-1.42 (1H, m, CHCH2CH2CH2CH2OH and OC(CH3)3). 13C 
NMR (CDCl3, 75 MHz): δ 173.6, 162.8, 80.1, 62.5, 53.5, 52.5, 36.7, 32.7, 32.3, 31.7, 
28.5, 21.8. HRMS (ES) 262.1658 (MH+). C12H24NO5  requires 262.1654.  
 
6-{4-[(S)-2-Benzyloxycarbonylamino-2-((S)-1-tert-butoxycarbonyl-3-methyl-butyl 
carba moyl)-ethyl]-imidazol-1-yl}-2-tert-butoxycarbonylamino-hexanoic acid methyl 
ester (4.21) 
 
4.21 
 
The imidazole ring of dipeptide 4.22 (3.5 g, 7.6 mmol) was alkylated with alkyl halide 
4.17 (General procedure M2) and the crude product was purified by column 
chromatography on silica gel by elution with ethyl acetate/petroleum ether (6:1) to give 
4.21 as a yellow oil (2.66 g, 50%). 1H NMR (CD3OD, 500 MHz): δ 7.58 (1H, s, 2-ArH), 
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7.29-7.32 (5H, m, Ph), 6.91 (1H, s, 5-ArH), 5.04 (2H, m, OCH2Ar), 4.38-4.41 (1H, m, 
CHCH2Ar), 4.31-4.32 (1H, m, CHCH2CH(CH3)2), 4.08-4.12 (1H, m, 
CHCH2CH2CH2CH2Ar), 3.90-3.93 (2H, m, CHCH2CH2CH2CH2Ar), 3.68 (3H, s, OCH3), 
3.02-3.05 (1H, dd, J = 4.8 and 14.9 Hz, CHCHHAr) 2.82-2.85 (1H, dd, J = 9.2 and 14.9 
Hz, CHCHHAr), 1.72-1.80 (3H, m, CHCH2CH2CH2CH2Ar and CHCH2CH(CH3)2), 1.62-
1.65 (2H, m, CHCH2CH(CH3)2), 1.57-1.62 (2H, m, CHCH2CH2CH2CH2Ar), 0.94 (3H, d, 
J = 6.4Hz, CH3), 0.89 (3H, d, J = 6.4Hz, CH3). 13C NMR (CDCl3, 75 MHz): δ 173.6, 
172.8, 172.0, 156.9, 137.0, 136.8, 136.7, 128.3, 127.8, 127.7, 117.4, 110.4, 81.4, 79.4, 
66.4, 55.0, 53.6, 51.7, 51.4, 46.7, 40.4, 30.9, 30.5, 30.2, 27.5, 27.1, 24.7, 22.6, 22.1, 20.7. 
HRMS (ES) 702.4080 (MH+). C36H56N5O9 requires 702.4078.  
 
(S)-2-[(S)-2-Benzyloxycarbonylamino-3-(1H-imidazol-4-yl)-propionylamino]-4-
methyl-pentanoic acid tert-butyl ester (4.22)   
 
 
Cbz-Histidine 4.7 (10 g, 1 equiv) was coupled with leucine tert-butyl 4.20 (General 
procedure A1) and the crude product was purified by chromatography on silica gel and 
elution with methanol/dichloromethane (1:10) to give 4.22 as a white solid (14.1 g, 89%). 
1H NMR (CDCl3, 500 MHz): δ 7.50 (1H, app d, J = 5.8Hz, NH), 7.43 (1H, s, 2-ArH), 
7.25 (5H, m, Ph), 6.74 (1H, s, 5-ArH), 5.08 (2H, m, OCH2Ar), 4.49 (1H, m, CHCH2Ar), 
4.34-4.37 (1H, m, CHCH2CH(CH3)2), 3.08-3.12 (1H, dd, J = 4.2 and 14.5 Hz, 
CHCHHAr), 2.99-3.03 (1H, dd, J = 6.1 and 14.8 Hz, CHCHHAr), 1.45-1.54 (3H, m, 
CHCH2CH(CH3)2 and CHCH2CH(CH3)2) 1.43 (9H, s, OC(CH3)3), 0.82-0.85 (6H, m, 
CHCH2CH(CH3)2). 13C NMR (CDCl3, 75 MHz): δ 172.6, 171.5, 156.7, 136.4, 135.3, 
128.7, 128.4, 128.2, 104.9, 82.3, 67.2, 54.8, 52.0, 41.2, 28.2, 24.9, 23.0, 22.0. HRMS (ES) 
459.2600 (MH+); C24H35N4O5 requires 459.2607. 
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(S)-2-tert-Butoxycarbonylamino-7-iodo-heptanoic acid methyl ester (4.27). 
 
 
Primary alcohol 4.33 (1.3 g, 4.7 mmol) was converted to the iodide 4.27 (General 
procedure L1). The crude product was purified by chromatography on silica gel and 
elution with ethyl acetate/petroleum ether (1:10) to give 4.27 as a light yellow oil (1.2 g, 
66%). 1H NMR (CDCl3, 500 MHz): 5.02 (1H, app d, NH),  4.28 (1H, m, 
CHCH2CH2CH2CH2CH2I), 3.74 (3H, s, OCH3), 3.16-3.19 (2H, m, 
CHCH2CH2CH2CH2CH2I), 1.79-1.83 (3H, m, CHCHHCH2CH2CH2CH2I and 
CHCH2CH2CH2CH2CH2I), 1.61-1.64 (1H, CHCHHCH2CH2CH2CH2I), 1.44  (9H, s, 
(CH3)3), 1.35-1.42 (4H, m, CHCH2CH2CH2CH2CH2I and CHCH2CH2CH2CH2CH2I). 13C 
NMR (CDCl3, 75 MHz): 173.5, 155.5, 80.1, 53.5, 52.5, 33.4, 32.8, 30.2, 28.5, 24.5, 6.9. 
HRMS (ES) 386.0829 (MH+). C13H25NO4 I requires 386.0828. 
 
(S)-2-tert-Butoxycarbonylamino-hex-5-enoic acid methyl ester (4.29). 
 
 
Carboxylic acid 4.28 (15 g, 65.4 mmol) was esterified with methyl iodide (General 
procedure J1) and the crude product purified by chromatography on silica gel and elution 
with ethyl acetate/petroleum ether (1:6) to give 4.29 as a colorless oil (11 g, 68%). 1H 
NMR (CDCl3, 500 MHz): 5.75-5.79 (1H, m, CHCH2CH2CHCH2), 4.98-5.01 (2H, m, 
CHCH2CH2CHCH2), 4.32 (1H, m, CHCH2CH2CHCH2), 3.73 (3H, s, OCH3), 2.10-2.12 
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(2H, m, CHCH2CH2CHCH2)), 1.70-1.73 (1H, m, CHCHHCH2CHCH2), 1.65-1.67 (1H, 
m, , CHCHHCH2 CHCH2), 1.43 (9H, m, C(CH3)3). 13C NMR (CDCl3, 75 MHz): 173.5, 
155.5, 137.1, 115.9, 80.1, 53.2, 52.5, 32.2, 29.7, 28.5. HRMS (ES) 244.1547 (MH+). 
C12H22NO4 requires 244.1549.  
 
(E)-(S)-2-tert-Butoxycarbonyloxy-7-chlorohept-5-enoic acid  methyl ester (4.30).3  
 
 
To a solution of (S)-2-tert-butoxycarbonyloxyhex-5-enoic acid methyl ester 4.29 (325 mg, 
1.33 mmol) and allyl chloride (4 equiv) in dichloromethane (22 ml) was added Grubbs 
catalyst second generation (0.1 equiv). The reaction mixture was heated under reflux for 
14 h and the solvent was evaporated under reduced pressure, The residue was 
chromatographed on silica gel and elution with ethyl acetate/petroleum ether (1:10) to 
give 4.30 (227 mg, 60%). 1H NMR (500 MHz, CDCl3) δ 5.70-5.73 (1H, dt, J = 15.1 and 
6.6 Hz), 5.64-5.66 (1H, dt, J = 15.1, 6.6 Hz), 5.02 (1H, app d, J = 8.0 Hz, NH), 4.28 (1H, 
m, CHCH2CH2CHCH), 3.99 (2 H, d, J = 6.6 Hz, CHCHCH2Cl), 3.70 (3H, s, OCH3), 
2.07-2.12 (2 H, m, CHCH2CH2CHCH), 1.84-1.88 (1H, m, CHCHHCH2CHCH), 1.64-
1.69 (1H, m, CHCHHCH2CHCH), 1.40 (9 H, s, OCH3). 13C NMR (75 MHz, CDCl3) δ 
173.3, 155.5, 134.1, 127.4, 80.2, 53.1, 52.6, 45.2, 32.2, 28.5, 28.1. MS (ES) 292.13 
(MH+). C13H23ClNO4 requires 292.13. 
Lit cit: 3Eustache, J.; Weghe, P. V. D.; Nouen, D. L.; Uyehara, H.; Kabuto, C.; 
Yamamoto, Y. J. Org. Chem., 2005, 70, 4043-4053. 
1H NMR (400 MHz, CDCl3) δ 1.44 (9 H, s), 1.66-1.77 (1 H, m), 1.96 (1 H, m), 2.09-2.20 
(2 H, m), 3.74 (3 H, s), 4.02 (2 H, d, J = 6.6 Hz), 4.26-4.35 (1 H, m), 4.96-5.08 (1 H, m), 
5.65 (1H, dt, J = 15.1, 6.6 Hz), 5.75 (1H, dt, J = 15.1, 6.6 Hz); 13C NMR (100 MHz, 
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CDCl3) δ 27.9, 28.4, 32.1, 45.1, 52.4, 53.0, 80.0, 127.2, 133.8, 161.6, 173.0; HRMS (ESI, 
positive mode) calcd for C13H22ClNO4 + Na 314.1135, found 314.1130. 
 
(E)-(S)-7-Acetoxy-2-tert-butoxycarbonyloxyhept-5-enoic acid methyl ester (4.31).3  
 
 
A mixture of allylic chloride 4.30 (560 mg, 1.92 mmol) and NaOAc (156 mg, 10 equiv) 
in DMF (10 ml), was heated at 100 °C for 23 h. Additional NaOAc (50 mg) was added 
and stirring continued for 3 h. The reaction mixture was cooled to rt, diluted with ether, 
and washed with saturated NH4Cl. The organic layer was dried and concentrated under 
reduced pressure. The residue was purified by chromatography on silica gel and elution 
with ethyl acetate/petroleum ether (1:4) to give 4.31 (409 mg, 68%): 1H NMR (500 MHz, 
CDCl3) δ 5.71-5.74 (1H, dt, J = 15.1 and 6.6 Hz),  5.57-5.61 (1H, dt, J = 15.1, 6.6 Hz), 
5.03 (1H, d, J = 8.0 Hz, NH), 4.48 (2 H, d, J = 6.6 Hz, CHCHCH2OCOCH3), 4.29 (1H, m, 
CHCH2CH2CHCH), 3.72 (3H, s, OCH3), 2.11-2.14 (2 H, m, CHCH2CH2CHCH), 2.04 (3 
H, m, CHCHCH2OCOCH3), 1.88-1.91 (1H, m, CHCHHCH2CHCH), 1.68-1.72 (1H, m, 
CHCHHCH2CHCH), 1.42 (9 H, s, OCH3). 13C NMR (75 MHz, CDCl3) δ 173.4, 17.0, 
155.5, 134.4, 128.6, 80.2, 65.1, 53.2,  52.5, 32.2, 28.5, 28.2, 21.2. MS (ES) 338.15 
(MNa+). C15H25NNaO6  requires 338.15. 
Lit cit: 3Eustache, J.; Weghe, P. V. D.; Nouen, D. L.; Uyehara, H.; Kabuto, C.; 
Yamamoto, Y. J. Org. Chem., 2005, 70, 4043-4053.  
1H NMR (400 MHz, CDCl3) δ 1.43 (9 H, s), 1.66-1.77 (1 H, m), 1.86-1.97 (1 H, m), 2.06 
(3 H, m), 2.08-2.23 (2 H, m), 3.74 (3 H, s), 4.25-4.36 (1H, m), 4.50 (2 H, d, J = 6.3 Hz), 
4.99-5.10 (1 H, m), 5.55-5.69 (1 H, m), 5.74 (1H, dt, J = 15.3, 6.6 Hz); 13C NMR (100 
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MHz, CDCl3) δ 21.2, 28.1, 28.4, 32.1, 52.3 53.0, 64.9, 80.0, 125.1, 134.0, 155.2, 170.6, 
172.9; HRMS (ESI, positive mode) calcd for C15H25NO6 + Na 338.1580, found 338.1574. 
 
(E)-(S)-2-tert-Butoxycarbonyloxy-7-hydroxyhept-5-enoic acid methyl ester (4.32).3 
 
The acetate 4.31 (400 mg, 1.27 mmol) was dissolved in a solution of NaOMe in methanol 
(0.1 M). The mixture was stirred for 2.5 h, and aqueous HCl (1 N, 4 ml) was added, 
followed by ether. The organic layer was washed with H2O and brine and dried over 
MgSO4, and the solvent removed under reduced pressure to give allylic alcohol 4.32 as 
an oil which was not further purified (298 mg, 86%). 1H NMR (500 MHz, CDCl3) δ 5.59-
5.65 (2H, m, CHCHCH2OH), 5.09 (1H, d, J = 8.1 Hz, NH), 4.25 (1H, m, 
CHCH2CH2CHCH),  4.04 (2H, m, CHCHCH2OH), 3.69 (3H, s, OCH3), 2.05-2.08 (2H, m, 
CHCH2CH2CHCH), 1.83-1.88 (1H, m, CHCHHCH2CHCH), 1.62-1.70 (1H, m, 
CHCHHCH2CHCH), 1.39 (9H, s, C(CH3)3). MS (ES) 274.1 (MH+). C13H24NO5  requires 
274.1. 
Lit cit: 3Eustache, J.; Weghe, P. V. D.; Nouen, D. L.; Uyehara, H.; Kabuto, C.; 
Yamamoto, Y. J. Org. Chem., 2005, 70, 4043-4053.  
1H NMR (400 MHz, CDCl3) δ 1.45 (9 H, s), 1.65-1.77 (1 H, m), 1.85-1.97 (1 H, m), 
2.09-2.19 (2 H, m), 3.74 (3 H, s), 4.08 (2 H, t, J = 4.1 Hz), 4.27-4.37 (1 H, m), 4.95-5.03 
(1 H, m), 5.72-5.60 (2 H, m); 13C NMR (100 MHz, CDCl3) δ 28.0, 28.4, 32.1, 52.3, 52.8, 
63.4, 80.0, 130.5, 130.7, 155.2, 173.2; HRMS (ESI, positive mode) calcd for C13H23NO5 
+ Na 296.1474, found 296.1468. 
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(S)-2-tert-Butoxycarbonylamino-7-hydroxy-heptanoic acid methyl ester (4.33). 
 
 
The allylic alcohol 4.32 (298 mg, 1.08 mmol) was hydrogenated in a hydrogen 
atmosphere over platinum oxide (30 mg, 10 mol% w/w) in ethyl acetate for 16 hours. The 
mixture was filtered and solution was concentrated in vacuo. The crude product was 
purified by silica gel column chromatography and elution with ethyl acetate/petroleum 
ether (1:2) to give 4.33 (280 mg, 94%) as a thick oil. 1H NMR (CDCl3, 500 MHz): 5.01 
(1H, d, J = 5.3 Hz, NH), 4.3 (1H, m, CHCH2CH2CH2CH2CH2OH), 3.74 (3H, s, OCH3), 
3.62-3.65 (2H, m, CHCH2CH2CH2CH2CH2OH), 1.79-1.81 (1H, m, 
CHCHHCH2CH2CH2CH2OH), 1.59-1.63 (1H, m, CHCHHCH2CH2CH2CH2OH),  1.57-
1.59 (2H, m, CHCH2CH2CH2CH2CH2OH), 1.45 (9H, s, C(CH3)3), 1.37-1.40 (4H, 
CHCH2CH2CH2CH2CH2OH  and CHCH2CH2CH2CH2CH2OH). 13C NMR (CDCl3, 75 
MHz): 173.8, 155.3, 80.1, 62.6, 53.6, 52.4, 33.0, 32.9, 28.5, 25.1, 22.6. HRMS (ES) 
276.1814 (MH+). C13H26NO5  requires 276.1811.   
  
7-{[(E)-(S)-4-Benzyloxycarbonylamino-4-((S)-1-tert-butoxycarbonyl-3-methyl-butyl 
carbamoyl)-2-methyl-but-1-enyl]-vinyl-amino}-2-tert-butoxycarbonylamino-
heptanoic acid methyl ester (4.35). 
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Alkylation of N-Cbz-His-OtBu 4.22 (488 mg, 1.06 mmol) with alkyl iodide 4.27 (General 
procedure M2) gave the crude product that was purified by column chromatography on 
silica gel by elution with ethyl acetate/petroleum ether (6:1) to give gave 4.35 as a yellow 
oil (430 mg, 56%). 1H NMR (CD3OD, 500 MHz): 7.88 (1H, s, 2-ArH), 7.29-7.33 (5H, m, 
Ph), 7.03 (1H, s, 5-ArH), 6.95 (1H, d, J= 8.3 Hz, NH),  5.05 (2H, m, OCH2Ar), 4.40-4.43 
(1H, m, CHCH2Ar), 4.30-4.33 (1H, m, CHCH2CH(CH3)2), 4.06-4.10 (1H, m, 
CHCH2CH2CH2CH2CH2Ar), 3.95-3.98 (2H, m, CHCH2CH2CH2CH2CH2Ar), 3.69 (3H, s, 
OCH3), 3.06-3.09 (1H, dd, J = 5.3 and 14.8 Hz, CHCHHAr), 2.86-2.89 (1H, dd, J = 8.4 
and 14.4 Hz, CHCHHAr), 1.74-1.78 (5H, m, CHCH2CH2CH2CH2CH2Ar, 
CHCH2CH(CH3)2 and CHCH2CH(CH3)2), 1.43-1.61 (4H, m, CHCH2CH2CH2CH2CH2Ar 
and CHCH2CH2CH2CH2CH2Ar). 1.45 (9H, s, OC(CH3)3), 1.43 (9H, s, OC(CH3)3), 1.28-
1.38 (2H, m, CHCH2CH2CH2CH2CH2Ar), 0.95 (3H, d, J = 6.6 Hz, CH3), 0.89 (3H, d, J = 
6.4 Hz, CH3). 13C NMR (CDCl3, 75 MHz): 173.8, 172.4, 172.1, 156.9, 137.0, 136.1, 
128.3, 127.9, 127.7, 118.1, 81.5, 79.4, 66.4, 54.7, 53.7, 51.8, 51.4, 46.6, 40.3, 31.3, 30.3, 
27.5, 27.1, 25.7, 25.2, 24.8, 22.1, 20.7. HRMS (ES) 716.4239 (MH+); C37H58N5O9 
requires 716.4235. 
 
(S)-2-(2-Benzyloxycarbonylamino-acetylamino)-4-methyl-pentanoate1-methoxy 
carbonyl -6-(4-methyl-imidazol-1-yl)-hexyl-ammonium (4.36) 
 
 
Acidolysis of pseudo-tripeptide 4.35 (430 mg, 0.6 mmol) in the presence of 
trifluoroacetic acid (General procedure N) afforded 4.36 as a thick oil (99%).1H NMR for 
major product from mixture (CD3OD, 500 MHz): 8.80 (1H, s, 2-ArH), 8.37 (1H, d , J = 
7.7 Hz, NH), 7.38 (1H, s, 5-ArH), 7.31-7.36 (5H, m, Ph), 5.07 (2H, m, OCH2Ar), 4.48-
4.51 (1H, m, CHCH2Ar), 4.41-4.43 (1H, m, CHCH2CH(CH3)2), 4.13-4.16 (2H, m, 
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CHCH2CH2CH2CH2CH2Ar), 4.02-4.04 (1H, m, CHCH2CH2CH2CH2CH2Ar), 3.82 (3H, s, 
OCH3), 3.21-3.25 (1H, dd, J = 6.4 and 15.4 Hz, CHCHHAr), 3.03-3.07 (1H, dd, J = 7.4 
and 15.2 Hz, CHCHHAr), 1.83-1.96 (4H, CHCH2CH2CH2CH2CH2Ar and 
CHCH2CH2CH2CH2CH2Ar), 1.63-1.72 (3H, m, CHCH2CH(CH3)2 and CHCH2CH(CH3)2), 
1.34-1.52 (4H, m, CHCH2CH2CH2CH2CH2Ar and CHCH2CH2CH2CH2CH2Ar), 0.94 (3H, 
d, J = 6.4 Hz, CHCH2CH(CH3)2), 0.90 (3H, d, J = 6.1 Hz, CHCH2CH(CH3)2). 13C NMR 
(CD3OD, 75 MHz): 174.8, 171.1, 169.9, 156.8, 136.9, 134.5, 130.3, 128.4, 128.0, 127.8, 
120.2, 66.7, 53.9, 52.6, 52.5, 49.2, 44.1, 40.1, 30.1, 29.4, 27.5, 25.5, 24.8, 24.2, 22.2, 20.5. 
HRMS (ES) 560.3077 (MH+); C28H42N5O7 requires 560.3084. 
 
(S)-2-Benzyloxycarbonylamino-6-{4-[(S)-2-((S)-2-tert-butoxycarbonylamino-4-
methyl pentanoylamino)-2-methoxycarbonyl-ethyl]-imidazol-1-yl}-hexanoic acid 
tert-butyl ester (4.39). 
 
 
Alkylation of N-Boc-Leu-His-OMe 4.40 (1.14 g, 2.98 mmol) with alkyl iodide 4.41 
(General procedure M2) gave the crude material. The crude product was purified by 
chromatography on silica gel and elution with methanol/dichloromethane (1:20) to give 
4.39 as a yellow oil (860 mg, 41%). 1H NMR (CD3OD, 500 MHz): 7.52 (1H, s, 2-ArH), 
7.32-7.37 (5H, m, Ph), 6.93 (1H, s, 5-ArH), 5.09 (2H, m, OCH2Ar), 4.85 (1H, m, 
CHCH2Ar), 4.07 (1H, m,CHCH2CH(CH3)2), 4.01 (1H, m, CHCH2CH2CH2 CH2Ar), 3.92-
3.95 (2H, m, CHCH2CH2CH2CH2Ar), 3.67 (3H, s, OCH3), 3.03-3.07 ((1H, dd, J = 4.9 
and 14.8 Hz, CHCHHAr) 2.82-2.85 (1H, m, CHCHHAr), 1.74-1.80 (3H, m, 
CHCH2CH2CH2CH2N and CHCHHCH2CH2 CH2N), 1.63-1.69 (2H, m, 
CHCHHCH2CH2CH2N and CHCH2CH(CH3)2), 1.45-1.50 (2H, m, CHCH2CH (CH3)2), 
1.43 (9H, s, OC(CH3)3), 1.42 (9H, s, OC(CH3)3), 1.32-1.39 (2H, m, 
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CHCH2CH2CH2CH2N), 0.91-0.95 (6H, m, CHCH2CH(CH3)2). 13C NMR (CD3OD, 126 
MHz): 174.4, 172.1, 171.9, 157.4, 156.5, 137.0, 136.7, 128.3, 127.8, 127.7, 117.2, 81.5, 
79.3, 66.4, 54.8, 53.2, 52.6, 51.5, 46.6, 40.9, 31.0, 30.3, 29.8, 27.6, 27.0, 24.6, 22.6, 22.3, 
20.7. HRMS (ES) 702.4044 (MH+); C36H56N5O9 requires 702.4078. 
 
(Z)-(S)-2-((S)-2-tert-Butoxycarbonylamino-4-methyl-pentanoylamino)-5-methyl 
amino-4-methyleneamino-pent-4-enoic acid methyl ester (4.40). 
 
Histidine methyl ester 4.49 (10.7 g, 44.5 mmol) was coupled with Boc-Leucine 4.50 
(General procedure A1) and the crude product was purified by chromatography on silica 
gel and elution with methanol/dichloromethane (1:10) to give 4.40 as a white solid (14.4 
g, 85%). 1H NMR (CDCl3, 500Hz): δ 7.48 (1H, s, 2-ArH), 7.36 (1H, appr s, NH), 6.71 
(1H, s, 5-ArH), 5.26 (1H, d, J = 7.2 Hz, NH), 4.72-4.76 (1H, m, CHCH2Ar), 4.04-4.05 
(1H, m, CHCH2CH(CH3)2), 3.65 (3H, s, OCH3), 3.07-3.10 (2H, m, CHCH2Ar), 1.61-1.67 
(1H, m, CHCH2CH(CH3)2), 1.53-1.60 (1H, m, CHCHHCH(CH3)2), 1.41-1.48 (1H, m, 
CHCHHCH(CH3)2), 1.38 (9H, s, C(CH3)3), 0.86-0.89 (6H, m, CHCH2CH(CH3)2). 13C 
NMR (CDCl3, 75 MHz): δ 173.2, 171.6, 156.3, 135.6, 130.7, 120.0, 80.4, 53.7, 52.9, 52.6, 
41.4, 28.5, 24.8, 23.2, 23.0, 22.2. HRMS (ES) 383.2279 (MH+); C18H31N4O5 requires 
383.2294. 
 
(S)-2-Benzyloxycarbonylamino-6-iodo-hexanoic acid tert-butyl ester (4.41).4  
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Primary alcohol 4.46 (5.9 g, 17.5 mmol) was converted to the iodide 4.41 (General 
procedure L1). The crude product was purified by chromatography on silica gel and 
elution with ethyl acetate/petroleum ether (1:10) to give 4.41 as a light yellow oil (4.86 g, 
62%). 1H NMR (CDCl3): δ 7.34-7.36 (5H, m, Ph), 5.37 (1H, d, J = 6.7, NH), 5.10 (2H, s, 
OCH2Ph), 4.25 (1H, m, CHCH2CH2CH2CH2I), 3.16 (2H, m, CHCH2CH2CH2CH2I), 1.79-
1.85 (2H, m, CHCH2CH2CH2CH2I and CHCHHCH2CH2CH2I), 1.64 (1H, m, 
CHCHHCH2CH2CH2I), 1.44-1.47 (2H, m, CHCH2CH2CH2CH2I), 1.45 (9H, s, C(CH3)3). 
HRMS (ES) 448.0975 (MH+); C18H27NO4I requires 448.0985. 
Lit cit: 4Allevi, P.; Galligani, M.; Anastasia, M. Tetrahedron: Asymm., 2002, 13, 1901–
1910. 
1H NMR (CDCl3): 7.40–7.28 (5H, aromatics-H), 5.33 (1H, d, J = 7.4, NH), 5.11–5.05 
(2H, AB system, OCH2Ph), 4.23 (1H, m, 2-H), 3.14 (2H, t, J = 6.7, 6-H2), 1.87–1.75 (3H, 
overlapping), 1.64 (1H, m), 1.48–1.40 (2H, overlapping), 1.45 [9H, s, C(CH3)3]. Anal. 
calcd for C18H26INO4: C, 48.33; H, 5.86; N, 3.13. Found: C, 48.25; H, 5.88; N, 3.23%. 
 
(S)-2-Benzyloxycarbonylamino-6-(9H-fluoren-9-ylmethoxycarbonylamino)-hexanoic 
acid (4.43).5  
 
 
Cbz-Lys-OH 4.42 (2.8 g, 10.6 mmol) was allowed to react with Fmoc-Cl (General 
procedure Q). to give 4.43 (5.119 g, 92%) without purification. 1H NMR (CD3OD, 500 
MHz): 7.77 (2H, d, J = 7.3Hz, ArH), 7.62 (2H, d, J = 7.5Hz, ArH),  7.23-7.38 (9H, m, 
ArH), 5.05 (2H, m, ArCH2), 4.30 (2H, m, ArCH2OCONH), 4.17 (1H, t, J = 6.8Hz, 
FmocH), 4.04 (1H, m, CHCH2CH2CH2CH2NH), 3.08 (2H, m, CHCH2CH2CH2CH2NH), 
1.81-1.84 (1H, m, CHCHHCH2CH2CH2NH),  1.64-1.68 (1H, m, CHCHHCH2CH2 
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CH2NH), 1.44-1.51 (2H, m, CHCH2CH2CH2CH2NH), 1.37-1.41 (2H, m, 
CHCH2CH2CH2CH2NH). 13C NMR (CD3OD, 126 MHz): 178.1, 157.7, 157.1, 144.1, 
141.4, 137.1, 128.2, 127.7, 127.6, 127.5, 126.9, 125.0, 119.7, 66.4, 66.2, 56.2, 47.3, 40.3, 
32.4, 29.4, 22.8. HRMS (ES) 525.1999 (MNa+); C29H30N2NaO6  requires 525.1996. 
Lit cit: 5Marrano, C.; Mace´do, P.; Gagnon, P.; Lapierre, D.; Gravel, C.; Keillor, J. W. 
Bioorganic & Medicinal Chemistry, 2001, 9, 3231–3241. 
1H NMR(CDCl3, 400 MHz) δ 7.75 (d, 2H, J = 7.5 Hz), 7.56 (d, 2H, J = 7.4 Hz), 7.43–
7.28 (m, 9H), 6.43 (s, 1H), 5.61 (s, 1H), 5.10 (s, 2H), 4.44–4.36 (m, 3H), 4.18 (t, 1H, J = 
6.5 Hz), 3.18 (t, 2H, J = 4.6 Hz), 1.54–1.24 (m, 6H). 13C NMR (CDCl3, 100 MHz) δ 
175.95, 156.97, 156.58, 143.98, 141.33, 136.28, 128.57, 128.21, 128.13, 127.15, 125.15, 
125.01, 120.06, 67.09, 66.69, 53.76, 47.24, 40.56, 31.78, 29.26, 22.41. MS (FAB+) 503.4 
(MH+). Mp 139 oC. 
 
(S)-2-Benzyloxycarbonylamino-6-(9H-fluoren-9-ylmethoxycarbonylamino)-hexanoic 
acid tert-butyl ester (4.44)  
 
 
DCC mediated esterification of carboxylic acid 4.43 (1.1 g, 2.18 mmol) with tert-butyl 
alcohol (General procedure K1) gave the ester. The crude product was purified by 
chromatograghy on silica gel and elution with ethyl acetate/petroleum ether (1:3) to give 
4.44 as a white solid (548 mg, 45%).  
 
EDCI mediated esterification of carboxylic acid 4.43 (500 mg, 1 mmol) with tert-butyl 
alcohol (General procedure K2) gave the ester. The crude product was purified by 
chromatography on silica gel and elution with ethyl acetate/petroleum ether (1:3) to give 
4.44 as a white solid (363 mg, 65%). 1H NMR(CDCl3, 500 MHz): 7.75 (2H, d, J=7.5 Hz), 
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7.58 (2H, d, J = 7.4 Hz), 7.26-7.41 (9H, m, ArH), 5.34 (1H, NH, d, J = 7.9Hz), 5.10 (2H, 
s, ArCH2), 4.85 (1H, app s, NH), 4.38-4.40 (2H, ArHCH2), 4.22 (1H, CHCH2 
CH2CH2CH2NH), 4.20 (1H, ArHCH2), 3.18 (2H, m, CHCH2CH2CH2CH2NH), 1.82 (1H, 
m, CHCHHCH2CH2CH2NH), 1.66 (1H, m, CHCHHCH2CH2CH2NH), 1.52-1.55 (2H, m, 
CHCH2CH2CH2CH2NH), 1.46 (9H, s, C(CH3)3), 1.33-1.42 (2H, overlapping, CH 
CH2CH2CH2CH2NH). 13C NMR (CD3OD, 75 MHz): 171.7, 156.7, 156.2, 144.2, 141.5, 
128.7, 128.4, 128.3, 127.9, 127.3, 125.3, 120.2, 82.4, 67.1, 66.8, 54.3, 47.5, 40.9, 32.8, 
29.7, 28.2, 22.4. HRMS (ES) 559.2808 (MH+); C33H39N2O6 requires 559.2808. 
 
(S)-6-Amino-2-benzyloxycarbonylamino-hexanoic acid tert-butyl ester (4.45). 
 
 
Fmoc protecting group of 4.44 (1.2 g, 2.15 mmol) was removed on treatment with 
diethylamine (General procedure R) to give 4.45 (652 mg, 90%). 1H NMR (CDCl3): δ 
7.31-7.36 (5H, m, Ph), 5.34 (1H, d, J = 8.0 Hz, NH), 5.12 (2H, s, OCH2Ph), 4.25 (1H, m, 
CHCH2CH2CH2CH2NH2), 2.64-2.67 (2H, m, CHCH2CH2CH2CH2NH2), 1.74-1.83 (2H, 
m, CHCH2CH2CH2CH2NH2), 1.63-1.68 (4H, m, CHCH2CH2CH2CH2NH2 and  
CHCH2CH2CH2CH2NH2), 1.45 (9H, s, C(CH3)3). MS (ES) 337.2 (MH+); C18H29N2O4 
requires 337.2. 
 
(S)-2-Benzyloxycarbonylamino-6-hydroxy-hexanoic acid tert-butyl ester (4.46).4  
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Diazotization of lysine derivative 4.45 (3.1 g, 9.2 mmol) (General procedure I2) gave the 
crude product that was purified by flash column chromatography on silica gel and elution 
with ethyl acetate/petroleum ether (1:1) to give 4.46 as a white solid (1.31 g, 42%).1H 
NMR (CDCl3): δ 7.30-7.36 (5H, m, Ph), 5.36 (1H, d, J = 6.7 Hz, NH), 5.11 (2H, s, 
OCH2Ph), 4.25 (1H, m, CHCH2CH2CH2CH2OH), 3.62 (2H, m, CHCH2CH2CH2CH2OH), 
1.80-1.85 (2H, m, CHCH2CH2CH2CH2OH), 1.58-1.72 (4H, m, CHCH2CH2CH2CH2OH 
and  CHCH2CH2CH2CH2OH), 1.45 (9H, s, C(CH3)3). 13C NMR (CDCl3, 126 MHz): 
171.5, 156.1, 136.3, 127.9, 127.2, 125.2, 82.3, 67.3, 60.6, 53.2, 31.9, 31.1, 29.5, 21.3. 
HRMS (ES) 338.1953 (MH+); C18H28NO5 requires 338.1967. 
Lit cit: 4Allevi, P.; Galligani, M.; Anastasia, M. Tetrahedron: Asymm., 2002, 13, 1901–
1910. 
1H NMR (CDCl3): 7.33–7.26 (5H, aromatics-H), 5.35 (1H, d, J = 7.5, NH), 5.07 (2H, s, 
OCH2Ph), 4.22 (1H, m, 2-H), 3.58 (2H, t, J=6.1, 6-H2), 1.78 (1H, m), 1.63 (1H, m), 1.54 
(2H, m), 1.43 [9H, s, C(CH3)3] 1.41–1.36 (2H, overlapping). Anal. calcd for C18H27NO5: 
C, 64.07; H, 8.07; N, 4.15. Found: C, 64.13; H, 8.00; N, 4.13%. 
 
(S)-2-Benzyloxycarbonylamino-6-hydroxy-hexanoic acid (4.48). 
 
 
Diazotization of Cbz-Lysine 4.42 (40 g, 143 mmol) (General procedure I1) gave crude 
product that was purified by flash column chromatography on silica gel and elution with 
ethyl acetate/petroleum ether (2:1) to give 4.48 as an oil (18.1 g, 45%). 1H NMR (CD3OD, 
500 MHz): 7.28-7.35 (5H, m, Ph), 5.09 (2H, m, PhCH2), 4.14-4.17 (1H, CHCH2CH2CH2 
CH2OH), 3.54 (2H, m, CHCH2CH2CH2CH2OH), 1.83-1.87 (1H, m, 
CHCHHCH2CH2CH2OH),  1.66-1.71 (1H, m, CHCHHCH2CH2CH2OH), 1.51-1.57 (2H, 
m, CHCH2CH2CH2CH2OH), 1.43-1.50 (2H, m, CHCH2CH2CH2CH2OH) 13C NMR 
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(CD3OH, 126 MHz): 174.8, 157.5, 137.0, 128.2, 127.8, 127.6, 66.4, 61.4, 54.1, 31.9, 31.3, 
22.1. HRMS (ES) 282.1332 (MH+); C14H20NO5 requires 282.1341. 
 
7.5: Experimental work described in chapter 5  
 
Cyclopent-3-ene-1,1-dicarboxylic acid diethyl ester (5.29) 
 
The diene 5.28 (28 mg) was subjected to RCM (General procedure C6). Conversion to 
5.29 was determined by analysis of the 1H NMR spectrum of the crude product. Data for 
5.29 (from mixture): 1H NMR (CDCl3, 500 MHz) δ 5.62 (m, 2H), 4.18 (m, 4H), 2.62 (m, 
4H), 1.22 (m, 6H). 
Lit cit: Yao, Q. J. Am. Chem. Soc. 2004, 126, 74–75. 
H NMR (CDCl3, 500 MHz): δ 5.62 (s, 2H), 4.21 (q, 4H, J = 7.2 Hz), 3.02 (s, 4H), 1.26 (t, 
6 H, J = 7.1 Hz) 
 
1-(Toluene-4-sulfonyl)-2,5-dihydro-1H-pyrrole (5.31) 
 
The diene 5.30 (15.8 mg) was subjected to RCM (General procedure C6). Conversion to 
5.31was determined by analysis of the 1H NMR spectrum of the crude product. Data for 
5.31 (from mixture):  1H NMR (CDCl3, 500 MHz) δ 7.70 (m, 2H), 7.29 (m, 2H), 5.61 (s, 
2H), 4.08 (s, 4H), 2.39 (s, 3H).  
Lit cit: Varray, S; Organometallics , 2003, 22, 2426 
 
1H NMR (CDCl3, Me4Si) δ 2.45 (s, 3 H), 4.10 (s, 4 H), 5.65 (s, 2 H), 7.30 (d, J = 8.5 Hz, 
2 H), 7.75 (d, J = 8.5 Hz, 2H); MS (electrospray) m/z 224 (M+ H)+. 
 
3-Methyl-1-(toluene-4-sulfonyl)-2,5-dihydro-1H-pyrrole (5.33) 
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The diene 5.32 (36 mg) was subjected to RCM (General procedure C6) to give 5.33. 
Conversion to 5.33 was determined by analysis of the 1H NMR spectrum of the crude 
product. Data for 5.33 (from mixture): 1H NMR (CDCl3, 500 MHz) δ 7.72 (m, 2H), 7.26 
(m, 2H), 5.25 (m, 1H), 4.07 (m, 2H), 3.96 (m, 2H), 2.42 (s, 3H), 1.65 (s, 3H). 
Lit cit: Yao, Q. J. Am. Chem. Soc. 2004, 126, 74–75. 
1H NMR (CDCl3, 500 MHz): 7.72 (d, 2 H, J = 8.2 Hz), 7.32 (d, 2 H, J = 8.1 Hz), 5.25 (m, 
1 H), 4.06-4.08 (m, 2 H), 3.97 (bs, 2 H), 2.43 (s, 3 H), 1.66 (s, 3 H). 
 
1-(Toluene-4-sulfonyl)-1,2,3,6-tetrahydro-pyridine (5.35) 
 
The diene 5.34 (31.8 mg) was subjected to RCM (General procedure C6). Conversion to 
5.35 was determined by analysis of the 1H NMR spectrum of the crude product. Data for 
5.35 (from mixture): 1H NMR (CDCl3, 500 MHz) δ 7.69 (m, 2H), 7.31 (m, 2H), 5.76 (m, 
1H), 5.61 (m, 1H), 3.64 (m, 2H), 3.38 (m, 2H), 2.43 (m, 3H), 2.21 (m, 2H); 
Lit cit: Lipshutz, B. H.; Ghorai, S.; Abela, A. R.; Moser, R.; Nishikata, T.; Duplais, C.;  
Krasovskiy, A.  J. Org. Chem. 2011, 76, 4379–4391. 
1H NMR (400 MHz, CDCl3) δ 7.67 (d, J = 8.0 Hz, 2H), 7.32 (d, J = 8.0 Hz, 2H), 5.77-
5.72 (m, 1H), 5.63-5.58 (m, 1H), 3.58-3.55 (m, 2H), 3.16 (t, J = 6.0 Hz, 2H), 2.42 (s, 3H), 
2.24-2.18 (m, 2H). 
 
5-Methyl-1-(toluene-4-sulfonyl)-1,2,3,6-tetrahydro-pyridine (5.37) 
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The diene 5.36 (33.5 mg) was subjected to RCM (General procedure C6). Conversion to 
5.37 was determined by analysis of the 1H NMR spectrum of the crude product.Data for 
5.37 (from mixture), 1H NMR (CDCl3, 500 MHz) δ 7.70 (m, 2H), 7.31 (m, 2H), 5.42 (m, 
2H), 3.70 (m, 2H), 3.15 (m, 2H), 2.42 (m, 3H), 2.21 (m, 2H), 1.71 (m, 3H). 
Lit cit: Tamaru, Y.; Hojo, M.; Yoshida, Z.-i. J. Org. Chem. 1988, 53, 5731–5741. 
1H NMR (CDCl,) δ 1.65 (br s, 3 H), 2.10 (m, 2 H), 2.43 (5, 3 H), 3.16 (t, J = 5.8 Hz, 2 H), 
3.52 (m, 2 H), 5.29 (m, 1 H); 13C NMR (CDC13) 6 21.2, 22.6, 30.0, 
42.7,44.6,116.7,127.6, 129.4, 134.4, 143.1.  
 
1-(Toluene-4-sulfonyl)-2,3,4,7-tetrahydro-1H-azepine (5.39) 
 
The diene 5.38 (33.5 mg) was subjected to RCM (General procedure C6). Conversion to 
5.39 was determined by analysis of the 1H NMR spectrum of the crude product. Data for 
5.39 (from mixture): 1H NMR (CDCl3, 500 MHz) δ 7.69 (m, 2H), 7.29 (m, 2H), 5.74 (m, 
1H), 5.61 (m, 1H), 3.79 (m, 2H), 3.12 (m, 2H), 2.41 (m, 3H), 2.02 (m, 2H), 1.62 (m, 2H). 
MS (ES) 252.10 (MH+); C13H18NO2S  requires: 252.10. 
Lit cit: Yao, Q. J. Am. Chem. Soc. 2004, 126, 74–75. 
1H NMR (CDCl3, 500 MHz): 7.69 (d, 2 H, J = 8.2 Hz), 7.29 (d, 2 H, J = 8.1 Hz), 5.76-
5.80 (m, 1 H), 5.64-5.68 (m, 1 H), 3.84 (dd, 2 H, J = 0.9, 4.8 Hz), 3.40 (t, 2 H, J = 6.1 
Hz), 2.43 (s, 3 H), 2.17-2.21 (m, 2 H), 1.81 (quint, 2 H, J = 6.0 Hz). 
 
(S)-3-1H-Azepine-1,3-dicarboxylic acid, 2,3,4,7-tetrahydro-, 3-methyl 1-(phenyl 
methyl) ester (5.41). 
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Ring closing metathesis in aqueous media: The diene 5.40 (31 mg) was subjected to 
RCM (General procedure C6) to give 5.41 as a mixture of rotamers as a colourless oil. 1H 
NMR (CDCl3, 500 MHz) δ H 7.29–7.36 (m, 5H), 5.62–5.79 (m, 2H), 5.09–5.19 (m, 2H), 
4.17–4.26 (m, 1H), 3.84 - 4.18 (m, 1H), 3.61-3.74 (m, 4H), 2.91-2.98 (m, 1H), 2.44–2.48 
(m, 2H). HRMS (ES) 290.1404 (MH+); C16H20NO4 requires: 290.1392. 
 
2-tert-Butoxycarbonylamino-cyclopent-3-enecarboxylic acid methyl ester (5.43) 
 
 
The diene 5.42 (31 mg) was subjected to RCM (General procedure C6) to give 5.43. 
Conversion to 5.43 was determined by analysis of the 1H NMR spectrum of the crude 
product. Data for 5.43 (from mixture): 1H NMR (CDCl3, 500 MHz) δ 5.76 (m, 2H), 5.41 
(app d, 1H), 4.38 (m, 1H), 3.64 (s, 3H), 2.67 (m, 1H), 2.42 (m, 2H), 1.43 (s, 9H); MS (ES) 
242.13 (MH+).  
Lit cit: Gardiner, J.; Anderson, K. H.; Downard, A.; Abell, A. D. J. Org. Chem. 2004, 69, 
3375–3382. 
 
7.6: Experimental work described in chapter 6 
 
2-[(Phenylsulfonyl)amino]-3-methyl butyric acid methyl ester 6.4. 
 
 
Benzenesulfonyl chloride 6.3 (500 mg, 2.8 mmol) and valine-OMe 6.2 (470 mg, 1 equiv) 
were suspended in dried dichloromethane (10 ml) under a nitrogen atmosphere. DIPEA 
(1.1 ml, 2 equiv) was added dropwise and the mixture stirred overnight. The reaction 
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solution was diluted by ethyl acetate, washed by brine, dried over MgSO4 and 
concentrated in vacuo. The crude product was purified by column chromatography on 
silica gel and the product eluted with EtOAc/Petroleum ether (1:3) to give the 6.4 (622 
mg, 82%) as a white solid. M.p.80-82oC. 1H NMR (CDCl3, 500 MHz): 7.84 (2H, m, 
ArH), 7.56 (1H, m, ArH), 7.49 (2H, m, ArH), 5.12 (1H, d, J = 10.1 Hz, NH), 3.75 (1H, 
dd, J = 5.1 and 10.1 Hz, CHCH(CH3)2), 3.42 (3H, s, OCH3), 2.03 (1H, m, CHCH(CH3)2), 
0.95 (3H, d, J = 6.8 Hz, CHCH(CH3)2), 0.87 (3H, d, J = 6.8 Hz, CHCH(CH3)2). 13C NMR 
(CDCl3, 75 MHz): 171.9, 139.8, 133.0, 129.2, 127.5, 61.3, 52.4, 31.8, 19.2, 17.7. HRMS 
(ES) 294.0773 (MNa+); C12H17NNaO4S requires 294.0770.  
 
2-Benzenesulfonylamino-3-methyl-butyric acid 6.5. 
 
 
To a solution of methyl ether 6.4 (600 mg, 2.2 mmol) in water and THF (1:1, 20ml) was 
added KOH (4 equiv) and the mixture heated at 40oC for 4 hours, cooled to room 
temperature and washed with EtOAc (20 ml). The aqueous solution was acidified to pH 1 
by the drop wise addition of concentrated HCl. The product was extracted into EtOAc 
(3x20ml), dried over MgSO4 and concentrated in vacuo to give 6.5 as a white solid (537 
mg, 95%). Mp. 141-143oC. 1H NMR (CDCl3, 500 MHz): 7.94 (2H, m, ArH), 7.57 (1H, m, 
ArH), 7.48 (2H, m, ArH), 5.46 (1H, d, J = 10.1Hz, NH), 3.80 (1H, dd, J = 4.7 and 9.9 Hz, 
CHCH(CH3)2), 2.09 (1H, m, CHCH(CH3)2), 0.96 (3H, d, J = 6.8 Hz,CHCH(CH3)2), 0.87 
(3H, d, J = 7.0 Hz, CHCH(CH3)2). 13C NMR (CDCl3, 75 MHz): 176.6, 139.7, 133.2, 
129.5, 127.4, 60.9, 31.5, 19.2, 17.3. HRMS (ES) 280.0621 (MNa+); C11H15NNaO4S 
requires 280.0614.   
 
2-(2-Benzenesulfonylamino-3-methyl-butyrylamino)-4-methyl-pentanoic acid 
methyl ester 6.7. 
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To a stirred solution of 6.5 (100 mg) was coupled with Leu-OMe 6.6 (General procedure 
A1). The crude product was purified by column chromatography on silica gel and elution 
with EtOAc/Petroleum ether (1:3) to give the 6.7 (130 mg, 87%) as a white solid. m.p 
112-114 oC. 1H NMR (CDCl3, 500 MHz): 7.81 (2H, m, ArH), 7.51 (1H, m, ArH), 7.49 
(2H, m, ArH), 6.47 (1H, d, J = 8.3Hz, NH), 5.82 (1H, d, J = 8.8Hz, NH), 4.32 (1H, m, 
CHCH2CH(CH3)2), 3.69 (3H, s, OCH3), 3.62 (1H, dd, J = 5.2 and 8.6Hz, CHCH(CH3)2), 
2.01 (1H, m, CHCH(CH3)2), 1.42 (1H, m, CHCHHCH(CH3)2), 1.25-1.29 (2H, m, 
CHCHHCH(CH3)2 and CHCH2CH(CH3)2), 0.88 (3H, d, J = 6.8Hz, CHCH(CH3)2), 0.81 
(3H, d, J = 6.8Hz, CHCH(CH3)2), 0.78 (3H, d, J = 6.4Hz, CHCH2CH(CH3)2), 0.74 (3H, d, 
J = 6.4Hz, CHCH2CH (CH3)2). 13C NMR (CDCl3, 75 MHz): 173.1, 170.5, 140.0, 132.8, 
129.1, 127.4, 61.7, 52.5, 50.9, 41.2, 32.0, 24.6, 22.8, 21.9, 19.2, 17.3. HRMS (ES) 
407.1627 (MNa+); C18H28N2NaO5S requires 407.1611.   
 
2-Benzenesulfonylamino-N-(1-hydroxymethyl-3-methyl-butyl)-3-methyl-butyramide 
6.8. 
 
 
Methyl ester 6.7 (120 mg, 0.31 mmol) was reduced (General procedure G2) and the crude 
product was recrystallized from EtOAc to give the 6.8 as a white solid (87 mg, 79%). 
M.p 152-154 oC. 1H NMR (CDCl3, 500 MHz): 7.86 (2H, m, ArH), 7.61 (1H, m, ArH), 
7.52 (2H, m, ArH), 6.12 (1H, d, J = 9.0Hz, NH), 5.16 (1H, d, J = 6.4Hz, NH), 3.97 (1H, 
m, CHCH2CH(CH3)2), 3.69 (1H, dd, J = 3.2 and 10.6Hz, CHCHHOH), 3.42-3.46 (2H, 
CHCH(CH3)2 and CHCHHOH), 2.15 (1H, m, CHCH(CH3)2), 1.42 (1H, m, CHCH2CH 
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(CH3)2), 1.33 (1H, m, CHCHHCH(CH3)2),  1.31 (1H, m, CHCHHCH(CH3)2), 0.89 (3H, d, 
J = 6.6Hz, CHCH2CH(CH3)2), 0.86 (3H, d, J = 6.7Hz, CH CH2CH(CH3)2). 0.84 (3H, d, J 
= 7.0Hz, CHCH(CH3)2), 0.78 (3H, d, J = 7.0Hz, CHCH(CH3)2) 13C NMR (CDCl3, 75 
MHz): 170.7 (CONH), 139.0, 133.3, 129.4, 127.6, 65.6 , 62.6, 50.1, 41.2, 40.0, 31.3, 24.9, 
23.3, 22.3, 19.2, 17.3. HRMS (ES) 379.1679 (MNa+); C17H28N2NaO4S requires 379.1662. 
 
2-Benzenesulfonylamino-N-(1-formyl-3-methyl-butyl)-3-methyl-butyramide 6.9. 
 
 
 
The alcohol 6.8 (50 mg, 0.13 mmol) was oxidized (General procedure H3) and the crude 
was purified by chromatography on silica gel and elution with ethyl acetate/petroleum 
ether gave 6.9 as an white solid (36 mg, 72%).1H NMR (CDCl3, 500 MHz): 9.46 (1H, s, 
CHO), 7.86 (2H, m, ArH), 7.57 (1H, m, ArH), 7.49 (2H, m, ArH), 6.15 (1H, d, J = 7.0Hz, 
NH), 5.37 (1H, d, J = 8.5Hz, NH), 4.38 (1H, m, CHCH2CH(CH3)2), 3.59 (1H, dd, J = 5.2 
and 8.6Hz, CHCH(CH3)2), 2.10 (1H, m, CHCH(CH3)2), 1.55 (1H, m, CH 
CHHCH(CH3)2), 1.41 (CHCH2CH(CH3)2), 1.26-1.29 (1H, m, CHCHHCH(CH3)2), 0.84-
0.92 (12H, m, CHCH(CH3)2 and CHCH2CH(CH3)2). 13C NMR (CDCl3, 75 MHz): 199.0 
(CHO), 170.7 (CONH), 133.1 , 129.3, 127.5, 62.0, 57.6, 50.9, 38.0, 31.9, 24.7, 23.2, 22.0, 
19.3, 17.2. HRMS (ES) 377.1509 (MNa+); C17H26N2NaO4S requires 377.1505. 
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Appendix  
 
Appendix 1: Assay of Ovine Calpain 2 Activity 
 
Fluorometric assays (excitation: 485 nm, emission: 520 nm) with ovine calpain 2 were 
carried out with a (BMG Labtech) Fluostar Optima plate reader at 37.0 ± 0.2 °C in 96-
well black (Greiner Bio-one) microassay plates. Calpain 2 partially purified from sheep 
lung by hydrophobic interaction and ion-exchange chromatography were diluted in 20 
mM MOPS, pH 7.5, containing 2 mM EGTA, 2 mM EDTA and 0.035% v/v 2-
mercaptoethanol to give a linear response over the course of the assay. The substrate 
BODIPY-Fl casein was prepared as reported.1 A 0.0005% solution of the substrate in 10 
mM MOPS, pH 7.5, 10 mM CaCl2, 0.1 mM NaN3, 0.1% v/v 2-mercaptoethanol was 
prepared freshly before each experiment. Stock solutions of inhibitors (5 mM) were 
freshly prepared in DMSO and diluted in DMSO/water mixtures to obtain a total DMSO 
concentration of 4% v/v. 
 
Inhibition studies were performed in the presence of seven different inhibitor 
concentrations and 1% v/v DMSO in a volume of 200 µL: 50 µl of inhibitor solution was 
added to a microassay well followed by 50 µl of calpain-containing solution. The 
reaction was initiated by adding 100 µl of BODIPY-Fl casein solution to each well and 
progress curves were monitored every 30 s over 570 s. Uninhibited enzyme activity was 
determined by adding 4% v/v DMSO in water instead of inhibitor solution. Every 
experiment included two blanks, a Ca2+ blank and an EDTA blank. The Ca2+ blank 
contained 50 µl water and 50 µl 20 mM MOPS, pH 7.5, 2 mM EGTA, 2 mM EDTA and 
0.035% v/v 2-mercaptoethanol instead of inhibitor and enzyme solution, respectively. For 
the EDTA blank, 50 µl 50 mM EDTA/NaOH, pH 7.5, was added instead of inhibitor 
solution to the well. 
 
The rate of enzyme-catalyzed substrate hydrolysis was obtained by linear regression of 
the progress curves over the time course. If slow-binding inhibition occurred2 only those 
data points representing the steady state of enzyme-inhibitor interaction were taken into 
account, i.e. data points between 390 s and 570 s. The rate of the enzymatic reaction was 
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corrected by the average value of the rates obtained for the two blanks, and the rate in the 
absence of inhibitor was set to 100%. 
 
The average value of rates obtained in two separate experiments, each in triplicate, was 
plotted versus the inhibitor concentration and IC50 values were calculated with the 
following equation: 
 
 
 
where [I] is the inhibitor concentration, and v0 and v are the enzyme activities in the 
absence and presence of inhibitor. All analysis was done with the program GraphPad 
Prism version 5.02 for Windows, GraphPad Software, San Diego California USA, 
www.graphpad.com. 
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                            4.1a                                                                            4.2a 
 
No inhibition of calpain 2 was observed by either esters-15m 4.1a and ester-16m 4.2a. 
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                                 4.1b                                                         4.2b 
 
No inhibition observed for alcohol-16m 4.2b at 5µM. Higher concentrations were tried 
but compound did not dissolve at higher concentrations. 
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                         4.1b 
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                                      4.1b 
 
Compound 4.1b has an IC50 of 29.39 µM. 
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Assay 102-104 refers to compound 4.1c 
Compound 4.1c has an IC50 of 238nm ± 44nm 
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Assay 110-111 refers to compound 4.3b  
 
Compound 4.3b is inactive with an IC50 greater than 50 µm 
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Assay 118-119 refers to compound 4.3c 
Compound 4.3c has an IC50 of 1 µm ± 0.1 µm. 
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Appendix 2: Molecular modeling of histidine containing macrocycles 4.1-4.3 
 
A conformational search has been carried out by Wanting Jiao on the following nine 
macrocycles 4.1a-c, 4.2a-c and 4.3a-c and docking studies were carried out with a 
calpain 1 construct model (see Figure A1-A9). The modelling studied showed that:  
i. All nine compounds have low energy Glide scores  
ii. Macrocyclic alcohols 4.1b and 4.2b and aldehydes 4.1c and 4.2c form the three 
essential hydrogen bonds with Gly208 and Gly271 (denoted as A, B and C) that 
are important for stabilizing a β-strand conformation of the peptide chain,  
iii. The warhead distance defined as carbonyl carbon to the active cysteine sulfur for 
macrocyclic aldehydes 4.1c and 4.2c is less than 4.5 Å.  
iv. Compounds 4.3a-c do not fit at the P1 pocket of the binding site and poses of 4.3c 
do not show it bound in a β-strand conformation. 
 
Table A1: Molecular modelling results for histidine-based macrocycles 4.1a-c, 4.2a-c 
and 4.3a-c studies carried out with Wanting Jiao. 
 Glide Emodel Essential WHD b Internal contacts 
compound Score Score H bondsa Å Good Bad Ugly 
IC50 
calpain2 
4.1a -6.05 -65.5 A,C +2 3.51 303 14 3 >50 µM 
4.1b -7.48 -58.5 A,B,C +1 3.69 240 14 2 29 µM 
4.1c -6.05 -64.1 A,B,C +1 3.33 286 13 2 238 nM 
4.2a -4.38 -61.2 A,B +1 4.35 293 13 0 >50µM 
4.2b -6.24 -60.8 A,B,C +3 3.41 245 12 2  
4.2c -5.72 -59.0 A,B,C +1 3.51 245 13 1  
4.3a -5.42 -60.2 A,B +1 5.51 253 11 1 >50 µM 
4.3b -6.17 -56.0 A +1 3.79 249 9 2 >50 µM 
4.3c -5.93 -50.8 3 10.7 255 13 0 1 µM 
a Hydrogen bonds from the carbonyl group of Gly208, the NH group of Gly208, and the carbonyl group of 
Gly271 of the o-CAPN1 homology model are labeled A, B and C respectively. b War head distance (WHD) 
is the distance between the warhead carbon and the active site cysteine sulfur in Å. 
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Figure A1: Bonding mode of compound 4.1a 
 
            
Figure A2: Bonding mode of compound 4.1b 
 
               
Figure A3: Bonding mode of compound 4.1c 
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Figure A4: Bonding mode of compound 4.2a  
 
  
Figure A5: Bonding mode of compound 4.2b  
 
  
Figure A6: Bonding mode of compound 4.2c  
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Figure A7: Bonding mode of compound 4.3a 
 
 
Figure A8: Bonding mode of compound 4.3b 
 
  
Figure A9: Bonding mode of compound 4.3c 
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Appendix 3: X-ray structural analysis of (E)-2.2 
 
Analysis on a single crystal was carried out by Dr Matthew Polson at rt. Graphite-
monochromated Cu Kα radiation was used for cell parameter determinations and data 
collection. The intensities of two standard reflections were monitored during data 
collection to check the stability of the crystals: no loss of intensities was recognized. The 
integrated intensities, measured using the θ/2θ scan mode, were corrected for Lorentz and 
polarization effects. The non-hydrogen atoms were refined anisotropically, whereas 
hydrogen atoms were refined as isotropic. The structures were solved by direct methods 
of SIR97 and refined using the full-matrix least squares on F2 provided by SHELXL97.  
 
Aromatic and methyl hydrogens were assigned in calculated positions, the others were 
found in the Fourier difference synthesis. 
 
Compound (E)-2.2: C27H39N3O7, M=517.61, Orthorhombic, space group P 21 21 21, 
a=9.5967(7), b=13.576(3), c=22.201(6) Å, α=90, β=90, γ=90 deg, V=2892.5(11) Å3, 
Z=4 Dc=1.189, µ=0.086 mm-1, F(000)=1112. The reflections collected were 37305 with 
a 1.76<θ< 25.10 range; 2923 were independent and the final R index was 0.0729 for 
reflections having I>2σI, and 0.0529 for all data. 
 
 
Crystal data and structure refinement for (E)-2.2. 
 
Table A1.  Crystal data and structure refinement for (E)-2.2. 
Identification code   (E)-2.2 
Empirical formula  C27 H39 N3 O7 
Formula weight  517.61 
Temperature  93(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P 21 21 21 
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Unit cell dimensions a = 9.5967(17) Å α= 90°. 
 b = 13.576(3) Å β= 90°. 
 c = 22.201(6) Å ϒ = 90°. 
Volume 2892.5(11) Å3 
Z 4 
Density (calculated) 1.189 Mg/m3 
Absorption coefficient 0.086 mm-1 
F(000) 1112 
Crystal size 0.75 x 0.23 x 0.07 mm3 
Theta range for data collection 1.76 to 25.10°. 
Index ranges -11<=h<=11, -16<=k<=16, -26<=l<=26 
Reflections collected 37305 
Independent reflections 2923 [R(int) = 0.0729] 
Completeness to theta = 25.10° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1 and 0.838033 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2923 / 0 / 349 
Goodness-of-fit on F2 1.220 
Final R indices [I>2sigma(I)] R1 = 0.0422, wR2 = 0.0976 
R indices (all data) R1 = 0.0529, wR2 = 0.1153 
Absolute structure parameter 10(10) 
Extinction coefficient 0.0216(19) 
Largest diff. peak and hole 0.499 and -0.501 e.Å-3 
 
Table A2:  Atomic coordinates (x 104) and equivalent isotropic displacement parameters 
(Å2x 103) for (E)-2.2. U(eq) is defined as one third of  the trace of the orthogonalized Uij 
tensor. 
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________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________ 
C(1) 4529(2) 1344(2) 87(1) 19(1) 
C(2) 5195(2) 2355(2) -10(1) 18(1) 
C(3) 4854(3) 4129(2) -90(1) 18(1) 
C(4) 4071(2) 4849(2) 308(1) 18(1) 
C(5) 4211(3) 6201(2) 1020(1) 25(1) 
C(6) 4607(3) 7203(2) 760(1) 28(1) 
C(7) 4551(3) 6213(2) 1695(1) 29(1) 
C(8) 4195(3) 5284(2) 2020(1) 29(1) 
C(9) 4804(3) 5020(2) 2531(1) 31(1) 
C(10) 4481(4) 4136(2) 2904(1) 37(1) 
C(11) 3950(3) 2912(2) 2157(1) 29(1) 
C(12) 2909(3) 2405(2) 1852(1) 30(1) 
C(13) 3248(3) 1774(2) 1386(1) 28(1) 
C(14) 4620(3) 1627(2) 1215(1) 23(1) 
C(15) 5643(3) 2161(2) 1513(1) 27(1) 
C(16) 5320(3) 2803(2) 1979(1) 30(1) 
C(17) 4976(3) 937(2) 704(1) 23(1) 
C(18) 4578(3) 4375(2) -757(1) 23(1) 
C(19) 4917(3) 5420(2) -961(1) 29(1) 
C(20) 4492(4) 5533(3) -1620(1) 44(1) 
C(21) 6430(3) 5691(2) -877(2) 38(1) 
C(22) 4121(3) 131(2) -717(1) 18(1) 
C(23) 4211(3) -1031(2) -1564(1) 27(1) 
C(24) 3391(3) -1857(2) -1276(1) 31(1) 
C(25) 5458(3) -1438(3) -1908(1) 36(1) 
C(26) 3330(3) -374(2) -1969(1) 34(1) 
C(27) 6037(5) 8083(2) 103(2) 53(1) 
N(21) 4985(2) 697(2) -394(1) 22(1) 
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N(2) 4352(2) 3130(2) 29(1) 18(1) 
N(4) 4834(2) 5385(2) 694(1) 22(1) 
O(2) 6456(2) 2427(1) -112(1) 24(1) 
O(4) 2803(2) 4950(2) 252(1) 27(1) 
O(6) 4143(3) 7958(2) 957(1) 49(1) 
O(10) 3493(2) 3491(2) 2624(1) 38(1) 
O(22) 2855(2) 122(2) -674(1) 26(1) 
O(23) 4886(2) -431(1) -1097(1) 23(1) 
O(27) 5530(2) 7152(2) 321(1) 36(1) 
________________________________________________________________________ 
 
Table A3:  Bond lengths [Å] and angles [°] for (E)-2.2. 
_____________________________________________________  
C(1)-N(21)  1.449(3) 
C(1)-C(2)  1.529(3) 
C(1)-C(17)  1.538(4) 
C(1)-H(1)  0.9800 
C(2)-O(2)  1.234(3) 
C(2)-N(2)  1.331(3) 
C(3)-N(2)  1.463(3) 
C(3)-C(4)  1.517(4) 
C(3)-C(18)  1.539(4) 
C(3)-H(3)  0.95(3) 
C(4)-O(4)  1.231(3) 
C(4)-N(4)  1.341(3) 
C(5)-N(4)  1.453(3) 
C(5)-C(6)  1.525(4) 
C(5)-C(7)  1.533(4) 
C(5)-H(5)  0.9800 
C(6)-O(6)  1.199(4) 
C(6)-O(27)  1.319(4) 
 217 Appendix 
C(7)-C(8)  1.493(4) 
C(7)-H(7A)  0.9700 
C(7)-H(7B)  0.9700 
C(8)-C(9)  1.325(4) 
C(8)-H(8)  0.9300 
C(9)-C(10)  1.490(4) 
C(9)-H(9)  0.9300 
C(10)-O(10)  1.433(4) 
C(10)-H(10A)  0.9700 
C(10)-H(10B)  0.9700 
C(11)-O(10)  1.372(3) 
C(11)-C(16)  1.382(4) 
C(11)-C(12)  1.389(4) 
C(12)-C(13)  1.382(4) 
C(12)-H(12)  0.9300 
C(13)-C(14)  1.384(4) 
C(13)-H(13)  0.9300 
C(14)-C(15)  1.389(4) 
C(14)-C(17)  1.511(4) 
C(15)-C(16)  1.386(4) 
C(15)-H(15)  0.9300 
C(16)-H(16)  0.9300 
C(17)-H(17A)  0.9700 
C(17)-H(17B)  0.9700 
C(18)-C(19)  1.526(4) 
C(18)-H(18A)  0.9700 
C(18)-H(18B)  0.9700 
C(19)-C(21)  1.509(4) 
C(19)-C(20)  1.527(4) 
C(19)-H(19)  0.9800 
C(20)-H(20A)  0.9600 
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C(20)-H(20B)  0.9600 
C(20)-H(20C)  0.9600 
C(21)-H(21A)  0.9600 
C(21)-H(21B)  0.9600 
C(21)-H(21C)  0.9600 
C(22)-O(22)  1.219(3) 
C(22)-N(21)  1.340(3) 
C(22)-O(23)  1.353(3) 
C(23)-O(23)  1.470(3) 
C(23)-C(24)  1.513(4) 
C(23)-C(26)  1.523(4) 
C(23)-C(25)  1.523(4) 
C(24)-H(24A)  0.9600 
C(24)-H(24B)  0.9600 
C(24)-H(24C)  0.9600 
C(25)-H(25A)  0.9600 
C(25)-H(25B)  0.9600 
C(25)-H(25C)  0.9600 
C(26)-H(26A)  0.9600 
C(26)-H(26B)  0.9600 
C(26)-H(26C)  0.9600 
C(27)-O(27)  1.438(4) 
C(27)-H(27A)  0.9600 
C(27)-H(27B)  0.9600 
C(27)-H(27C)  0.9600 
N(21)-H(21)  0.85(3) 
N(2)-H(2)  0.8600 
N(4)-H(4)  0.8600 
 
N(21)-C(1)-C(2) 108.2(2) 
N(21)-C(1)-C(17) 110.8(2) 
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C(2)-C(1)-C(17) 109.4(2) 
N(21)-C(1)-H(1) 109.5 
C(2)-C(1)-H(1) 109.5 
C(17)-C(1)-H(1) 109.5 
O(2)-C(2)-N(2) 123.0(2) 
O(2)-C(2)-C(1) 120.5(2) 
N(2)-C(2)-C(1) 116.5(2) 
N(2)-C(3)-C(4) 109.2(2) 
N(2)-C(3)-C(18) 108.5(2) 
C(4)-C(3)-C(18) 109.6(2) 
N(2)-C(3)-H(3) 110.6(17) 
C(4)-C(3)-H(3) 107.7(16) 
C(18)-C(3)-H(3) 111.2(16) 
O(4)-C(4)-N(4) 123.0(2) 
O(4)-C(4)-C(3) 120.2(2) 
N(4)-C(4)-C(3) 116.8(2) 
N(4)-C(5)-C(6) 112.9(2) 
N(4)-C(5)-C(7) 114.0(2) 
C(6)-C(5)-C(7) 107.9(2) 
N(4)-C(5)-H(5) 107.2 
C(6)-C(5)-H(5) 107.2 
C(7)-C(5)-H(5) 107.2 
O(6)-C(6)-O(27) 124.3(3) 
O(6)-C(6)-C(5) 122.1(3) 
O(27)-C(6)-C(5) 113.6(2) 
C(8)-C(7)-C(5) 114.5(2) 
C(8)-C(7)-H(7A) 108.6 
C(5)-C(7)-H(7A) 108.6 
C(8)-C(7)-H(7B) 108.6 
C(5)-C(7)-H(7B) 108.6 
H(7A)-C(7)-H(7B) 107.6 
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C(9)-C(8)-C(7) 122.8(3) 
C(9)-C(8)-H(8) 118.6 
C(7)-C(8)-H(8) 118.6 
C(8)-C(9)-C(10) 127.0(3) 
C(8)-C(9)-H(9) 116.5 
C(10)-C(9)-H(9) 116.5 
O(10)-C(10)-C(9) 112.9(2) 
O(10)-C(10)-H(10A) 109.0 
C(9)-C(10)-H(10A) 109.0 
O(10)-C(10)-H(10B) 109.0 
C(9)-C(10)-H(10B) 109.0 
H(10A)-C(10)-H(10B) 107.8 
O(10)-C(11)-C(16) 125.6(3) 
O(10)-C(11)-C(12) 115.0(3) 
C(16)-C(11)-C(12) 119.4(3) 
C(13)-C(12)-C(11) 120.2(3) 
C(13)-C(12)-H(12) 119.9 
C(11)-C(12)-H(12) 119.9 
C(12)-C(13)-C(14) 121.3(3) 
C(12)-C(13)-H(13) 119.4 
C(14)-C(13)-H(13) 119.4 
C(13)-C(14)-C(15) 117.7(3) 
C(13)-C(14)-C(17) 120.8(2) 
C(15)-C(14)-C(17) 121.5(2) 
C(16)-C(15)-C(14) 121.7(3) 
C(16)-C(15)-H(15) 119.1 
C(14)-C(15)-H(15) 119.1 
C(11)-C(16)-C(15) 119.6(3) 
C(11)-C(16)-H(16) 120.2 
C(15)-C(16)-H(16) 120.2 
C(14)-C(17)-C(1) 112.5(2) 
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C(14)-C(17)-H(17A) 109.1 
C(1)-C(17)-H(17A) 109.1 
C(14)-C(17)-H(17B) 109.1 
C(1)-C(17)-H(17B) 109.1 
H(17A)-C(17)-H(17B) 107.8 
C(19)-C(18)-C(3) 116.8(2) 
C(19)-C(18)-H(18A) 108.1 
C(3)-C(18)-H(18A) 108.1 
C(19)-C(18)-H(18B) 108.1 
C(3)-C(18)-H(18B) 108.1 
H(18A)-C(18)-H(18B) 107.3 
C(21)-C(19)-C(18) 113.3(2) 
C(21)-C(19)-C(20) 110.5(3) 
C(18)-C(19)-C(20) 108.7(3) 
C(21)-C(19)-H(19) 108.1 
C(18)-C(19)-H(19) 108.1 
C(20)-C(19)-H(19) 108.1 
C(19)-C(20)-H(20A) 109.5 
C(19)-C(20)-H(20B) 109.5 
H(20A)-C(20)-H(20B) 109.5 
C(19)-C(20)-H(20C) 109.5 
H(20A)-C(20)-H(20C) 109.5 
H(20B)-C(20)-H(20C) 109.5 
C(19)-C(21)-H(21A) 109.5 
C(19)-C(21)-H(21B) 109.5 
H(21A)-C(21)-H(21B) 109.5 
C(19)-C(21)-H(21C) 109.5 
H(21A)-C(21)-H(21C) 109.5 
H(21B)-C(21)-H(21C) 109.5 
O(22)-C(22)-N(21) 125.5(2) 
O(22)-C(22)-O(23) 125.8(2) 
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N(21)-C(22)-O(23) 108.8(2) 
O(23)-C(23)-C(24) 109.9(2) 
O(23)-C(23)-C(26) 109.7(2) 
C(24)-C(23)-C(26) 113.3(2) 
O(23)-C(23)-C(25) 102.0(2) 
C(24)-C(23)-C(25) 110.6(2) 
C(26)-C(23)-C(25) 110.6(2) 
C(23)-C(24)-H(24A) 109.5 
C(23)-C(24)-H(24B) 109.5 
H(24A)-C(24)-H(24B) 109.5 
C(23)-C(24)-H(24C) 109.5 
H(24A)-C(24)-H(24C) 109.5 
H(24B)-C(24)-H(24C) 109.5 
C(23)-C(25)-H(25A) 109.5 
C(23)-C(25)-H(25B) 109.5 
H(25A)-C(25)-H(25B) 109.5 
C(23)-C(25)-H(25C) 109.5 
H(25A)-C(25)-H(25C) 109.5 
H(25B)-C(25)-H(25C) 109.5 
C(23)-C(26)-H(26A) 109.5 
C(23)-C(26)-H(26B) 109.5 
H(26A)-C(26)-H(26B) 109.5 
C(23)-C(26)-H(26C) 109.5 
H(26A)-C(26)-H(26C) 109.5 
H(26B)-C(26)-H(26C) 109.5 
O(27)-C(27)-H(27A) 109.5 
O(27)-C(27)-H(27B) 109.5 
H(27A)-C(27)-H(27B) 109.5 
O(27)-C(27)-H(27C) 109.5 
H(27A)-C(27)-H(27C) 109.5 
H(27B)-C(27)-H(27C) 109.5 
 223 Appendix 
C(22)-N(21)-C(1) 123.8(2) 
C(22)-N(21)-H(21) 117(2) 
C(1)-N(21)-H(21) 118(2) 
C(2)-N(2)-C(3) 121.4(2) 
C(2)-N(2)-H(2) 119.3 
C(3)-N(2)-H(2) 119.3 
C(4)-N(4)-C(5) 120.5(2) 
C(4)-N(4)-H(4) 119.8 
C(5)-N(4)-H(4) 119.8 
C(11)-O(10)-C(10) 117.8(2) 
C(22)-O(23)-C(23) 120.89(19) 
C(6)-O(27)-C(27) 115.5(3) 
_____________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
  
Table A4: Anisotropic displacement parameters  (Å2x 103) for (E)-2.2.  The anisotropic 
displacement factor exponent takes the form:  -2π2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
________________________________________________________________________ 
 U11 U22  U33 U23 U13 U12 
________________________________________________________________________ 
C(1) 14(1)  17(1) 24(1)  -4(1) 0(1)  0(1) 
C(2) 14(1)  18(1) 20(1)  -2(1) -2(1)  0(1) 
C(3) 13(1)  15(1) 27(1)  0(1) -1(1)  -1(1) 
C(4) 16(1)  16(1) 23(1)  4(1) 1(1)  -2(1) 
C(5) 19(1)  26(1) 29(1)  -7(1) -1(1)  5(1) 
C(6) 26(1)  26(2) 31(1)  -7(1) -9(1)  6(1) 
C(7) 26(1)  31(2) 31(1)  -10(1) 1(1)  -1(1) 
C(8) 26(1)  33(2) 28(2)  -9(1) 5(1)  -4(1) 
C(9) 32(2)  32(2) 28(1)  -10(1) 5(1)  -3(1) 
C(10) 48(2)  43(2) 21(1)  -8(1) 5(1)  -5(2) 
C(11) 40(2)  27(2) 20(1)  4(1) 7(1)  -5(1) 
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C(12) 27(1)  35(2) 30(2)  3(1) 8(1)  -2(1) 
C(13) 25(1)  28(1) 29(1)  2(1) -1(1)  -6(1) 
C(14) 26(1)  22(1) 22(1)  7(1) -3(1)  1(1) 
C(15) 25(1)  28(1) 29(1)  4(1) -2(1)  -3(1) 
C(16) 35(2)  32(2) 25(1)  0(1) -3(1)  -8(1) 
C(17) 20(1)  19(1) 30(1)  4(1) -2(1)  0(1) 
C(18) 21(1)  21(1) 26(1)  -2(1) 1(1)  3(1) 
C(19) 35(2)  23(1) 28(1)  3(1) 5(1)  8(1) 
C(20) 60(2)  39(2) 32(2)  9(2) 4(2)  7(2) 
C(21) 41(2)  27(2) 47(2)  9(1) 9(2)  -5(1) 
C(22) 18(1)  17(1) 20(1)  1(1) -2(1)  1(1) 
C(23) 24(1)  30(2) 27(1)  -11(1) -3(1)  -2(1) 
C(24) 27(1)  26(2) 40(2)  -10(1) -3(1)  -2(1) 
C(25) 31(2)  42(2) 36(2)  -17(2) 4(1)  1(2) 
C(26) 32(2)  43(2) 27(2)  -4(1) -3(1)  -2(2) 
C(27) 78(3)  28(2) 51(2)  8(2) 8(2)  -8(2) 
N(21) 13(1)  20(1) 32(1)  -9(1) 0(1)  2(1) 
N(2) 12(1)  15(1) 27(1)  0(1) 2(1)  -1(1) 
N(4) 17(1)  22(1) 25(1)  -3(1) -2(1)  4(1) 
O(2) 13(1)  20(1) 38(1)  -1(1) 2(1)  0(1) 
O(4) 15(1)  26(1) 40(1)  -7(1) 2(1)  -1(1) 
O(6) 60(2)  28(1) 58(1)  -9(1) 5(1)  15(1) 
O(10) 48(1)  39(1) 27(1)  -5(1) 13(1)  -9(1) 
O(22) 14(1)  32(1) 32(1)  -8(1) 1(1)  -2(1) 
O(23) 18(1)  26(1) 26(1)  -8(1) -1(1)  -1(1) 
O(27) 46(1)  22(1) 38(1)  3(1) 7(1)  2(1) 
________________________________________________________________________ 
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Table A5: Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 
10 3) for (E)-2.2. 
________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________ 
H(1) 3512 1407 75 22 
H(5) 3198 6136 982 30 
H(7A) 5539 6340 1744 35 
H(7B) 4050 6753 1881 35 
H(8) 3518 4872 1857 35 
H(9) 5509 5430 2672 37 
H(10A) 5336 3776 2979 45 
H(10B) 4115 4350 3289 45 
H(12) 1982 2490 1962 36 
H(13) 2542 1442 1184 33 
H(15) 6568 2086 1398 32 
H(16) 6022 3158 2169 36 
H(17A) 4520 308 771 27 
H(17B) 5974 823 701 27 
H(18A) 5115 3921 -1002 27 
H(18B) 3601 4251 -839 27 
H(19) 4354 5877 -721 34 
H(20A) 4981 5057 -1860 65 
H(20B) 4720 6184 -1756 65 
H(20C) 3506 5428 -1658 65 
H(21A) 6570 6365 -994 58 
H(21B) 6999 5271 -1123 58 
H(21C) 6683 5609 -462 58 
H(24A) 2651 -1585 -1037 47 
H(24B) 3996 -2240 -1023 47 
H(24C) 3004 -2271 -1584 47 
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H(25A) 6038 -1809 -1639 54 
H(25B) 5985 -903 -2075 54 
H(25C) 5138 -1858 -2227 54 
H(26A) 3878 176 -2103 51 
H(26B) 2537 -139 -1749 51 
H(26C) 3020 -745 -2312 51 
H(27A) 6518 8420 421 79 
H(27B) 5266 8477 -31 79 
H(27C) 6665 7973 -227 79 
H(2) 3494 3043 127 22 
H(4) 5698 5244 749 26 
H(3) 5810(30) 4180(20) 3(11) 16(7) 
H(21) 5850(40) 580(20) -423(13) 27(8) 
________________________________________________________________________ 
 
 
Table A6:  Torsion angles [°] for (E)-2.2. 
________________________________________________________________  
N(21)-C(1)-C(2)-O(2) -48.6(3) 
C(17)-C(1)-C(2)-O(2) 72.1(3) 
N(21)-C(1)-C(2)-N(2) 132.2(2) 
C(17)-C(1)-C(2)-N(2) -107.0(2) 
N(2)-C(3)-C(4)-O(4) -63.1(3) 
C(18)-C(3)-C(4)-O(4) 55.7(3) 
N(2)-C(3)-C(4)-N(4) 119.7(2) 
C(18)-C(3)-C(4)-N(4) -121.5(2) 
N(4)-C(5)-C(6)-O(6) 176.8(3) 
C(7)-C(5)-C(6)-O(6) -56.2(4) 
N(4)-C(5)-C(6)-O(27) -5.3(3) 
C(7)-C(5)-C(6)-O(27) 121.6(2) 
N(4)-C(5)-C(7)-C(8) -54.8(3) 
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C(6)-C(5)-C(7)-C(8) 178.9(2) 
C(5)-C(7)-C(8)-C(9) 156.7(3) 
C(7)-C(8)-C(9)-C(10) 176.9(3) 
C(8)-C(9)-C(10)-O(10) 6.3(4) 
O(10)-C(11)-C(12)-C(13) -177.9(2) 
C(16)-C(11)-C(12)-C(13) 1.9(4) 
C(11)-C(12)-C(13)-C(14) 0.5(4) 
C(12)-C(13)-C(14)-C(15) -2.2(4) 
C(12)-C(13)-C(14)-C(17) -179.9(3) 
C(13)-C(14)-C(15)-C(16) 1.7(4) 
C(17)-C(14)-C(15)-C(16) 179.3(2) 
O(10)-C(11)-C(16)-C(15) 177.4(3) 
C(12)-C(11)-C(16)-C(15) -2.4(4) 
C(14)-C(15)-C(16)-C(11) 0.6(4) 
C(13)-C(14)-C(17)-C(1) 70.3(3) 
C(15)-C(14)-C(17)-C(1) -107.3(3) 
N(21)-C(1)-C(17)-C(14) 175.6(2) 
C(2)-C(1)-C(17)-C(14) 56.4(3) 
N(2)-C(3)-C(18)-C(19) 175.0(2) 
C(4)-C(3)-C(18)-C(19) 55.9(3) 
C(3)-C(18)-C(19)-C(21) 60.1(3) 
C(3)-C(18)-C(19)-C(20) -176.6(2) 
O(22)-C(22)-N(21)-C(1) 4.1(4) 
O(23)-C(22)-N(21)-C(1) -175.6(2) 
C(2)-C(1)-N(21)-C(22) -131.6(2) 
C(17)-C(1)-N(21)-C(22) 108.5(3) 
O(2)-C(2)-N(2)-C(3) 4.5(4) 
C(1)-C(2)-N(2)-C(3) -176.4(2) 
C(4)-C(3)-N(2)-C(2) -147.3(2) 
C(18)-C(3)-N(2)-C(2) 93.3(3) 
O(4)-C(4)-N(4)-C(5) -7.3(4) 
 228 Appendix 
C(3)-C(4)-N(4)-C(5) 169.9(2) 
C(6)-C(5)-N(4)-C(4) -103.1(3) 
C(7)-C(5)-N(4)-C(4) 133.3(3) 
C(16)-C(11)-O(10)-C(10) 8.6(4) 
C(12)-C(11)-O(10)-C(10) -171.7(2) 
C(9)-C(10)-O(10)-C(11) 75.3(3) 
O(22)-C(22)-O(23)-C(23) 8.5(4) 
N(21)-C(22)-O(23)-C(23) -171.8(2) 
C(24)-C(23)-O(23)-C(22) -67.9(3) 
C(26)-C(23)-O(23)-C(22) 57.3(3) 
C(25)-C(23)-O(23)-C(22) 174.6(2) 
O(6)-C(6)-O(27)-C(27) 3.7(4) 
C(5)-C(6)-O(27)-C(27) -174.1(3) 
________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
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